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1. Basic mechanisms of transcriptional regulation
1.1 Introduction
For cells to function properly within a certain tissue of an organism, they must be able 
to respond correctly to signals they receive from neighboring cells and, vice versa, 
to give the proper signals to them. This cell-cell communication is for a large part 
mediated by secreted growth factors and their receptors, which have to be expressed 
in the right amount and at the right time and place for transduction of the correct 
signals. Regulation of protein expression takes place at several levels (1). First, each 
gene contains regulatory sequences that control the cell specificity, amount and 
time of DNA transcription. These regulatory sequences include a promoter, which is 
located just 5’ of the coding region, and in addition so-called enhancer and silencer 
elements that can be located several kb away from the gene itself, either 5’ or 3’, or 
within intron sequences. Second, the full length mRNA must be processed by splicing, 
in order to remove the introns or to produce alternatively spiced mRNAs that encode 
protein variants. Third, the processed mRNA has to be transported correctly from 
the nucleus to the cytoplasm where the ribosomes are located. A fourth regulatory 
step is provided by mRNA stability; stable mRNAs can be translated multiple times, 
in contrast to mRNAs that are quickly degraded. A fifth control point is the efficiency 
by which mRNA is translated by ribosomes. Recently, a new regulating mechanism, 
which affects approximately one third of all human genes (2), has been identified that 
is based on short RNA fragments called microRNAs, which induce mRNA cleavage 
or inhibit its translation (3). Sixth, the protein must be transported to its proper site of 
action, including specific cell organelles, the cytoplasm, the plasma membrane or 
the extracellular space. A seventh step is regulation of protein activity by dimerization, 
phosphorylation, proteolytic processing from precursor forms etc., while finally the rate 
of protein degradation and recycling determines the amount of functional protein 
in a cell. All these processes together influence how a cell can function in its cellular 
environment (1). 
1.2 The core promoter and basal transcription machinery
The first regulatory step in protein expression, i.e. transcriptional control, is mediated 
by specific DNA sequences that function as promoter, enhancer or silencer elements. 
The promoter can be functionally divided into the core promoter and the upstream 
promoter region. The core promoter is able to drive basal transcription of the gene, 
whereas the upstream promoter region can further stimulate or repress transcription in 
a cell type specific manner.
The core promoter can be defined as the 5’ sequence of a gene that 
specifically binds RNA polymerase and thereby determines the transcription start 
site. Eukaryotic RNA polymerase II (polII), which transcribes protein-encoding genes, 
cannot initiate transcription by itself, but is dependent on a set of general transcription 
factors, named TFIIA to TFIIH, which guide polII to the proper position on the DNA, 
as shown in Figure 1. The complex of polII with these general transcription factors is 
called the basal transcriptional machinery or preinitation complex (PIC), and is able 
to perform transcription at a low rate. PIC formation starts by binding of TFIID to the 
core promoter. TFIID is a multi-protein complex consisting of TBP (TATA binding protein) 
and 14 TBP-associated factors (TAFs). The interaction of TFIID with the promoter is 
subsequently stabilized by TFIIA, although TFIIA binding is not required for transcription 
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from all promoters. Next TFIIB, which in contrast to all other PIC components consists of 
only a single protein, joins the complex. Binding of TFIIB as well as of TBP to the DNA is 
essential for basal transcription. TFIIB binding stabilizes the interaction of TBP with the 
DNA and allows the subsequent recruitment of polII, which is escorted by TFIIF. Next, 
the complex is joined by TFIIE which in turn recruits TFIIH. TFIIH contains helicase activity 
which is modulated by TFIIE, resulting in facilitated melting of the promoter DNA. Upon 
phosphorylation by THFIIH, polII is finally released from the complex together with TFIIF, 
which also contains helicase activity, and the actual transcription will start. This release 
of polII together with TFIIF is referred to as promoter clearance (4, 5).   
PIC recruitment is mediated by specific sequences in the DNA surrounding 
the transcription initiation site. Four of these binding sites are currently known, which 
are recognized by TFIID and TFIIB. TFIID can be recruited to promoters via a TATAAA 
sequence located 30-25 bp upstream of the transcription initiation site. This so-called 
TATA-box, which is present in many but not all promoters, is specifically recognized 
by TBP present in TFIID. Some promoters also use other motives to recruit TFIID, such 
as the initiator (Inr) sequence or the downstream core promoter element (DPE). Inr is 
found in both TATA-containing and TATA-less promoters. The mammalian Inr consensus 
sequence is Py-Py(C)-A+1-N-T/A-Py-Py, where the +1 designates the transcription 
start site and Py stands for a pyrimidine (C or T). The DPE is mainly found in TATA-less 
promoters and has the consensus sequence A/G+28-G-A/T-C/T-G/A/C. The DPE must 
be located precisely at position +28 to +32 relative to the +1 of the Inr in order for the 
two elements to cooperatively bind TFIID, and mutation of either motive or altering the 
space between them results in a loss of TFIID binding and a substantial decrease in 
transcriptional activity. Both the Inr and the DPE are not bound by TBP itself, but by one 
of the TAFs of TFIID. TFIIB can bind the core promoter at the TFIIB recognition element 
(BRE), which is located immediately 5’ of some TATA-boxes and has a consensus 
sequence of G/C-G/C-G/A-C-G-C-C. TFIIB is essential for TFIID-mediated transcription. 
No specific sequence requirements are known for the other general transcription 
factors (4, 5). 
Figure 1: PIC formation and Mediator function (from (7)). Transcription initiation starts by binding 
of TFIIB to the promoter, which is subsequently joined by TFIIA and TFIIB. Next, polII and TFIIF enter 
the complex, followed by TFIIE and TFIIH to start basal transcription. Transcription factors bound 
to upstream activator sequences (UAS) can interact with the Mediator coactivator complex. 
Mediator then facilitates entry of polII into the complex, thus stimulating basal transcription.
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1.3 Cis- and trans-acting factors
Each gene is flanked by and contains regulatory DNA sequences that are able to bind 
transcriptional activators and repressors, generally referred to as transcription factors, 
that are necessary for proper expression of the gene in a given cell type. Thus, the 
expression of a gene is dependent on regulatory DNA sequences (cis regulation) as 
well as the presence of diffusible proteins that bind these regulatory sequences (trans 
regulation). Most regulatory sequences necessary for proper expression are present in 
the upstream promoter region, i.e. the region 5’ of the transcription initiation site, but as 
stated earlier they may also be located in enhancers or silencers several kb upstream 
or downstream of the gene or even in introns. 
 Transcription factors typically contain a DNA binding domain and a 
transactivation domain. The surface of a DNA binding domain precisely complements 
the structure of the major groove of a specific DNA sequence. Therefore, transcription 
factors show very high DNA sequence specificity, generally recognizing a consensus 
sequence of 5-8 nucleotides that is characteristic for each family of transcription factors 
(6). Various types of DNA binding domains can be discriminated, such as helix-turn-helix 
motives, as in homeodomains proteins, and zinc-finger motives. Other motives that are 
often found in transcription factors are leucine zippers and helix-loop-helix motives, 
which are used not only for DNA binding, but also for protein-protein interaction in 
transcription factors that function in dimers. After DNA binding, the transactivation 
domain of a transcription factor communicates with the basal transcription machinery 
to influence the rate of transcription.
Interaction between activators and repressors with the PIC does not take 
place directly but occurs through coregulator complexes, i.e. protein complexes that 
are involved in transcriptional regulation but that do not interact themselves with DNA. 
Mediator is an example of such a complex that is essential for transcriptional regulation. 
It was first discovered in yeast, but appears to be highly conserved in all organisms. 
Mediator complexes can consist of approximately 30 subunits reaching a molecular 
mass of up to 2 MDa, depending on the species. The mechanism by which Mediator 
influences transcription is not entirely clear yet, but it is believed that DNA-bound 
activator proteins bind specific Mediator subunits, which can be gene specific, while 
other Mediator subunits subsequently interact with RNA pol II to facilitate its recruitment 
into the PIC, thereby stimulating transcription, as outlined in Figure 1 (7).  
1.4 Epigenetic: histone modifications and DNA methylation
Transcription is also regulated on the level of chromatin. DNA tightly packed in so-
called heterochromatin is inaccessible to transcription factors and can thus not be 
transcribed even if the proper transcriptional activators are present in the nucleus. On 
the other hand, the more loosely packaged euchromatin is readily accessible and 
can be transcribed if the proper transcription factors are available. The packaging 
of DNA into so-called nucleosomes is mediated by specific DNA binding proteins 
called histones. A nucleosomal particle consists of 147 bp of DNA that is wrapped 
around a histone core complex made up of a histone (H3/H4) tetramer and two 
histone (H2A/H2B) dimers, thereby creating an 11 nm euchromatin fiber, referred to as 
“beads on a string”. The chromatin structure can be further compacted into a 30 nm 
heterochomatin fiber by incorporation of the linker histone H1 into the complex (8). 
Control of nucleosomal architecture is a very dynamic process that is 
regulated by specific modifications of a number of residues in the protruding tails of 
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histone molecules. Of these modifications, acetylation (of Lys residues) and methylation 
(Lys and Arg) have been studied most, but histone phosphorylation (Ser and Thr), 
ubiquitination (Lys), sumoylation (Lys), ADP ribosylation, glycosylation, biotinylation 
and carbonylation also take place. In addition to histone modifications, methylation 
of the DNA strand itselfs is also involved in chromatin compaction and thereby affects 
the transcription process. Hypermethylation of promoter regions is generally found in 
inactive DNA, whereas promoter hypomethylation correlates with gene transcription. 
These DNA and histone marks are maintained throughout the cell cycle and are 
transferred to daughter cells, thereby forming an epigenetic level of gene expression 
control (figure 2) (8).
Acetylation of histone tails is generally associated with active transcription, 
whereas histone hypoacetylation is found particularly in heterochromatin regions. 
Histone acetylation takes place on lysine residues and is performed by enzymes known 
as histone acyltransferases (HATs). Histone acetylation is believed to have a positive 
Figure 2: Epigenetic regulation of gene expression (from (123)). A silenced allele (top) is 
characterized by DNA methylation that is performed by DNA methyltransferase (DNMT) and 
methylation of H3-K9 by histone methyltransferases (HMT). Methyl-CpG-binding-domain (MBD) 
proteins bind the methylated DNA and recruit histone deacetylases (HDAC) containing 
complexes that keep histone tails dacetylated. An active allele (bottom) is not metylated 
and displays histone acyltransferases (HAT) driven histone acetylation (Ac) and HMT directed 
methylation of H3-K4.
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influence on gene transcription in two ways. Firstly, the acetyl groups reduce the 
interaction between the negatively charged DNA and the positively charged histone 
tails, thus creating an open chromatin structure that allows transcription. Furthermore, 
acetylated histones recruit positive effectors for the transcription process, including 
certain TAFs. Deacetylation of histone tails is performed by histone deacetylases 
(HDACs), and their action results in transcriptional repression by reversing the 
acetylation effects (8).
Histone methylation is performed by histone methyltransferases and takes 
place on lysines, which can be mono-, di- and trimethylated, and on arginines, which 
can be monomethylated or (symmetrically or asymmetrically) dimethylated. At 
present, 24 sites are known to be methylation targets on histones, of which 17 are lysines 
and 7 arginines, thus in principle enabling 3 x 1011 distinct methylation states of histone 
proteins. Histone methylation was previously believed to be an irreversible process 
such that methylation marks could only be removed by histone replacement, but this 
view has changed recently by the discovery of two histone demethylating enzymes; 
a histone lysine demethylase (LSD1), and a peptidyl arginine deiminase (PAD4) which 
converts mono-methylated arginines to citrulline (8).
The effects of histone methylation on gene activity are not as straightforward 
as those of acetylation. Methylation of lysine 9 of histone H3 (H3-K9), as well as H3-
K27 and H3-K79 methylation are associated with gene repression, whereas H3-K4 
and H3-K36 methylation are specific for active genes (9). Furthermore, asymmetric 
dimethyl-arginine methylation is involved in gene activation, whereas symmetric 
dimethyl-arginine methylation has been associated with gene repression (10). There is 
also a strong interplay between the various types of histone modification in such a way 
that one modification can facilitate or inhibit other modifications. For instance, mono-
ubiquitination of H2B-K123 is required for subsequent di-methylation of H3-K4 or H3-K79 
(11), while phosphorylation of H3-S10 facilitates H3-K9 and H3-K14 acetylation, thereby 
inhibiting H3-K9 methylation (8).   
DNA methylation in mammals takes place on the cytosine residue of CpG 
dinucleotides. The nucleotide combination CpG is relatively underrepresented in the 
genome when regarding the overall occurrence of cytosines and guanidines, but 
they tend to cluster in so-called CpG islands in promoter regions. CpG methylation 
of promoters can repress transcription in two ways: (1) it can directly interfere with 
transcription factor binding, or (2) it can recruit methyl-CpG-binding-domain (MBD) 
proteins which subsequently recruit HDACs that cause the chromatin to condense. DNA 
can be methylated by DNA methyltransferases which catalyze de novo methylation 
of unmethylated DNA or methylate the newly synthesized strand complementary to 
an already methylated strand after DNA replication. DNA methylation is indispensable 
for development, as is indicated for example by the observation that mouse mutants 
of the de novo DNA methyltransferases genes Dnmt3a or Dnmt3b, which are both 
highly expressed in the embryo but downregulated in differentiated cells, die before 
or around birth (12). Also, mice deficient in methyl CpG-binding proteins display a 
variety of developmental defects (13), thus underlining the importance of proper DNA 
methylation for development. 
It is not known precisely what triggers de novo DNA methylation, but several 
factors have been proposed to be involved. First, information in the DNA itself, such 
as the nucleotide sequence, overall base composition and secondary DNA structure, 
may play a role. In certain fungi, TA-rich sequences of minimally 75 bp stimulate DNA 
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methylation, whereas G-C base pairs in this system tend to inhibit DNA methylation. 
Also certain regions of imprinted genes in the mouse can induce DNA methylation 
when placed in non-imprinted DNA regions (14). 
Second, histone modification can influence DNA methylation. Histone H3-K9 
methylation seems to control DNA methylation since murine embryonic stem cells 
lacking the H3-K9 histone methyltransferase Suv39h show decreased DNA methylation 
of major satellite DNA, and this specific transferase can be coprecipitated with 
the DNA methyltransferase Dnmt3b. This suggests that DNA methylating enzymes 
and histone modification enzymes work cooperatively (14). Moreover, the human 
methyl CpG-binding protein MBD1 has been found to interact with the H3-K9 histone 
methyltransferase SETDB1 such that H3-K9 methylation is lost in the absence of MBD1 
(15). Thus, there appears to be a reciprocal interaction between histone modification 
and DNA methylation during regulation of gene repression. 
Third, DNA methylation can be induced by so-called RNA-dependent DNA 
methylation, a process which involves the RNAi machinery. Small interfering RNA 
molecules have been found to target methylation of homologous DNA sequences 
mediated through Dnmt3b. Furthermore, mice that lack the RNAi processing molecule 
DICER are defective in DNA methylation and histone modification. This indicates that 
DNA methylation, histone modifications and RNAi are interconnected processes (16). 
It has recently been established that DNA demethylation can be actively 
performed by some DNA glycosylases, which can excise methylated cytosines (17-
20).
2. Regulatory polymorphisms, allele specific expression and 
disease susceptibility
2.1 Introduction
DNA polymorphisms are usually defined as sequence variations that occur in at least 
1% of the population. Polymorphisms include substitutions of one nucleotide, referred 
to as single nucleotide polymorphisms (SNPs), and insertions or deletions (ins/dels) of 
one or more nucleotides. Sequence variation also occurs as a result of nucleotide 
rearrangements and insertion of repeating sequences. The latter are known as 
microsatellites, if the repeat sequence is not more than six nucleotides, and as 
minisatellites if this sequence is longer (21). SNPs occur with an average frequency of 
approximately one in every thousand nucleotides (6). When a polymorphism is present 
in a coding sequence, its effect may be evident if it results in an amino acid substitution 
or introduction of a premature stopcodon. Variation in putative regulatory sequences, 
on the other hand, may influence the expression of nearby genes by altering the 
binding affinity of transcription regulating proteins or by introducing new transcription 
factor recognition sites, resulting in altered rate or specificity of gene transcription, 
as shown schematically in Figure 3. Therefore it is assumed that such regulatory 
polymorphisms form the genetic basis for not only the phenotypic variation between 
individuals but also for the susceptibility of individuals to diseases.
2.2 Identification of regulatory polymorphisms
The effect of a polymorphism on the DNA binding affinity of transcription factors 
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can relatively easy be studied by in vitro DNA-protein binding experiments, such as 
electrophoretic mobility shift assays (EMSAs) and DNA footprinting. An EMSA is a fast 
and sensitive method to study DNA-protein interactions, in which short radiolabeled 
DNA sequences are used to specifically bind transcription factors, usually out of a large 
pool of nuclear proteins, which are subsequently identified by gel electrophoresis. The 
disadvantage of this method is the small size of the oligonucleotides that can be used 
(typically 20-30 nt), which does not allow to study the effect of possible interactions 
of multiple polymorphisms. Furthermore, there is no straightforward method to identify 
the bound nuclear protein, unless specific antibodies are available against candidate 
proteins. DNA footprinting is based on the principle that DNA binding proteins protect 
otherwise naked DNA regions from cleavage by DNAseI. Differential protein binding 
thus results in different cleavage fragments, allowing specific protein binding regions 
in the DNA to be recognized. The advantage of the technique is that several hundred 
nucleotides can be studied at the same time, but protein concentrations must be 
high enough to ensure saturated DNA binding, while the resolution of this technique is 
limited because of the size of the DNAseI enzyme (6). 
 The most commonly used method to study the effects of regulatory 
polymorphisms on gene expression levels is transient transfection of promoter-reporter 
gene constructs into a cell line of interest. The amount of reporter gene protein 
produced thus reflects the corresponding promoter activity. Based on this technique, 
it has been shown on the basis of 170 randomly selected genes with polymorphisms in 
their proximal promoter region, that in 34% of the cases such polymorphisms modulate 
reporter gene expression by at least 1.5-fold in at least one of three human cell 
lines tested (22). Thus, promoter polymorphisms seem to have a direct effect on the 
expression level of a substantial number of genes. 
2.3 Endogenous allele specific expression
The above techniques can give valuable information in terms of the function 
of specific polymorphisms in transcription factor binding and gene expression levels, 
since it is easy to study the effect of mutations on promoter activity and/or transcription 
factor binding. In addition, many different cell types can be tested for the presence of 
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Figure 3: Regulatory variation and allele specific expression. A promoter SNP influences binding 
of a transcription factor and thus expression level of the two alleles, of which transcripts can be 
distinguished by a marker SNP in the coding region. 
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cell specific cis- and trans-acting factors. A disadvantage of these techniques is that 
they study protein binding to DNA outside its normal chromatin environment, and as 
a result the endogenous epigenetic regulation is likely to go unnoticed. Furthermore, 
these approaches focus only on a limited number or even a single polymorphism, 
whereas in vivo a combination of polymorphisms present in the promoter region may 
determine the effect on transcriptional regulation. Such a genetically transmittable 
DNA region with a specific combination of polymorphisms is generally referred to as a 
haplotype. 
 The effect of promoter polymorphisms and haplotype differences on 
endogenous gene expression can be studied by analyzing allele-specific expression 
levels in samples that are heterozygous for a promoter haplotype. In this way it is 
ensured that trans-acting factors are equally available for each allele and as a result 
that differences in allelic expression must result from sequence differences between 
the alleles themselves. However, this approach requires the presence of a linked, 
so-called marker polymorphism in the coding region, which enables transcripts from 
different promoter haplotypes to be distinguished (figure 3). In that case, mRNA 
from individual alleles can be discriminated and quantified by SNP-microarray or by 
RT-PCR based methods. The latter include restriction fragment length polymorphism 
(RFLP) analysis, which is a method to determine allelic abundance based on the 
introduction or disappearance of a restriction site by a polymorphism. Another method 
is single base primer extension analysis, which makes use of (fluorescently labeled) 
dideoxynucleotides as chain terminators of an extended primer in order to discriminate 
both alleles on the basis a polymorphism, either by mass spectrometry or by sequence 
analysis (6). 
Using the above techniques a number of studies have been carried out to 
investigate the effect of sequence variation on gene expression levels. Yan et al. 
(23) reported that six out of the 13 genes showed variation in allelic expression in 
lymphoblastoid cell lines with a maximum difference of 4.3 fold for the P73 gene. 
Furthermore, in a study based on 193 single-nucleotide polymorphisms (SNPs) from 129 
genes expressed in lymphoblastoid cell lines it has been shown that 23 genes (18%) 
display allele-specific expression with significant deviation from an equimolar ratio (24). 
Based on a SNP oligonucleotide array on RNA material from seven individuals, Lo et al. 
(25) demonstrated that from the 602 heterozygous genes analyzed  326 (54%) showed 
preferential expression of one allele in at least one individual. Although in these cases 
the evidence for regulatory variation is indirect, it does clearly illustrate that many 
genes display variation in their regulatory sequences that will significantly influence the 
endogenous mRNA levels of those genes.
A very elegant and sensitive method to measure allele-specific expression 
without the need of a marker SNP has been described by Knight et al. (26). This so-
called haplotype-specific chromatin immunoprecipitation (haplo-ChIP) method 
is based on the principle that the allele with the highest expression must also bind 
most phosphorylated RNA polII. In this assay, cells are treated with formaldehyde in 
order to fix protein-DNA interactions and subsequently the chromatin is sonicated to 
create short fragments. After immunoprecipitation with an antibody directed against 
phosphorylated RNA polII, the relative abundance of each allele is then measured 
by PCR, primer extension and mass spectrometry. Such haplo-ChIP analysis also 
allows the identification of polymorphism-dependent protein binding in vivo, by 
immunoprecipitating a candidate transcription factor instead of polII by a specific 
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antibody. Using this method the authors have demonstrated that the +80A/C SNP of the 
lymphotoxin-α (LTA) gene influences allelic expression in vivo as a result of differential 
binding of ABF-1 (transcriptional repressor activated B cell factor-1) (27). The limitation 
of the haplo-ChIP applied to polII method is that the polymorphism of interest must lie 
within approximately 800 bp of the transcription start site, which corresponds to the size 
of the DNA fragments after sonication.
2.4 Regulatory variation and disease susceptibility
Many examples have shown that regulatory polymorphisms may affect the 
susceptibility of individuals for common diseases. For instance, the G allele of a G/A 
SNP substitution in the promoter of the CCR5 gene, which encodes a chemokine co-
receptor necessary for the HIV1 virus to enter the cell, appears to correlate with low 
expression and low propagation of the HIV1 virus. Furthermore, minisatellites near the 
insulin-encoding gene INS have been shown to influence INS expression levels and 
differentially bind the transcription factor PUR1 in vitro, and furthermore have been 
associated with type I diabetes (21). Moreover, variation in the promoter region of 
the macrophage migration inhibitory factor gene MIF is associated with differences in 
MIF production and with risk of juvenile idiopathic arthritis and psoriasis (28, 29), while 
SNP dependent binding of OCT-1 to the TNF promoter appears to influence promoter 
activity and susceptibility to malaria (30) Finally, polymorphisms in the LTA gene have 
been associated with susceptibility to a.o. asthma and cancer (21). These examples 
show that nucleotide variation in regulatory sequences can influence gene expression 
and thereby disease susceptibility. It should well be realized that it often remains 
unclear whether a disease-associated polymorphism is really functional or only acts as 
a marker due to linkage with other polymorphisms. 
3. Platelet-derived growth factor alpha-receptor (PDGFRA)
3.1 Introduction
Platelet-derived growth factors (PDGFs) are dimeric polypeptide molecules that have 
initially been identified in platelets as mitogens for vascular smooth muscle cells. Thus 
far, four PDGF chains have been identified, called PDGF-A, PDGF-B, PDGF-C and 
PDGF-D, and two receptors, called the PDGF alpha-receptor and PDGF beta-receptor 
(PDGFRA and PDGFRB). The ligands and receptors are expressed in overlapping but 
also in distinct cell types. PDGFRA is mainly expressed in cells of mesodermal and neural 
origin and is involved in the regulation of cell migration, proliferation and differentiation. 
PDGFRA plays an important role in various biological processes such as embryonic 
development, wound healing and atherosclerosis, but also in tumorigenesis (31).
3.2 PDGFRA gene and protein structure
The human PDGFRA gene is located on chromosome 4q11-12, spans approximately 
65 kb of DNA and contains 23 exons. The gene structure is very similar to that of the 
related receptor tyrosine kinase family members PDGFRB, c-KIT and c-FMS. It has a non-
coding exon 1 followed by a large first intron of 23 kb, while the translation start codon 
is located in exon 2.  PDGFRA and c-KIT are located in a head to tail orientation on 
chromosome 4, whereas PDGFRB and c-FMS are similarly orientated on chromosome 
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5 (32). The PDGFRA gene encodes a full length protein of 140 kDa which consists of 
an extracellular ligand binding domain containing five immunoglobulin-like domains, 
a transmembrane domain and a cytoplasmic split tyrosine kinase domain. When fully 
glycosylated, the molecular mass of the protein increases to approximately 170 kDa 
(33).
The PDGFRA gene encodes at least four different transcripts, which are formed 
as a result of alternative splicing and promoter use. A promoter located upstream 
of exon 1, called P1, gives rise to the full length 6.4 kb transcript as well as a 3.0 kb 
alternatively spliced transcript that putatively encodes a truncated receptor protein. 
Similarly, a promoter located in intron 12, termed P2, drives the expression of a 5.0 and 
1.5 kb transcript and is particularly active in early embryonic human cells (34). The 1.5 
kb transcript has been shown to be a prognostic marker for testicular germ cell tumors 
in humans, but protein products for these transcripts have not been established yet 
(35). 
3.3 Ligands and downstream signaling
 The four PDGF ligands act mainly as homodimers, but heterodimers of PDGF-
A and PDGF–B are also known. Upon binding to their receptors they induce the 
formation of receptor homo- or heterodimers, depending on the ligand specificity 
and the relative abundance of receptor types expressed. PDGFRA can bind PDGF-
Figure 4: Interaction between PDGF receptor and ligand dimers (from (31)).
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A, PDGF-B and PDGF-C, whereas PDGFRB can only bind PDGF-B and PDGF-D (figure 
4). Receptor dimerization induces transphosphorylation of multiple tyrosine residues in 
the cytoplasmic region, after which a variety of intracellular signaling pathways are 
activated, depending on the type and concentration of the ligand (36) and the type 
of receptor dimer that is formed (31, 37). 
Signaling downstream of PDGFRA involves the activation of phospholipase Cγ 
(PLCγ), phosphatidylinositol kinase (PI3K) and RAS/mitogen-activated protein kinase 
(MAPK) pathways (reviewed by (38, 39)). PLCγ binds the autophosphorylated receptor 
at Tyr-988 and Tyr-993, and converts phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) 
into inositol(1,4,5)trisphosphate and diacylglycerol (DAG), resulting in an increase in 
the intracellular Ca2+ concentration and activation of members of the protein kinase 
C (PKC) family respectively. PLCγ is particularly involved in PDGF-stimulated cell growth 
and motility. 
PI3K binds the autophosphorylated receptor at Tyr-731 and Tyr-742, and 
phosphorylates PI(4,5)P2 to give phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3). 
Among the downstream targets of PI3K are protein kinase B/AKT, members of the Rho 
family of small GTPases and several PKC members, thereby mediating a variety of 
cellular responses which include actin reorganization, chemotaxis, cell growth, and 
anti-apoptosis (38, 39). 
Activation of the RAS/MAPK pathway takes place through the tyrosine 
phosphatase SHP2 and the adapter protein SHC. These two molecules subsequently 
bind GRB2/SOS which can induce RAS into the active GTP-bound form, thereby 
activating the MAPK cascade via the serine/threonine kinase RAF1. Besides MAPK 
activation, RAS can also activate PI3K. The RAS/MAPK pathway has been implicated in 
cell growth, migration and differentiation (38, 39).
 .
3.4 Developmental expression of Pdgfra and ligands 
In the mouse Pdgfra is expressed from the two cell stage onwards by all cells of the 
blastocyst, but later in development its expression becomes restricted to cells of 
mesodermal and neural origin. In early post-implantation embryos, at embryonic day 
E6-E7.5, Pdgfra mRNA can be found in extra-embryonic and embryonic endoderm, 
as well as in the embryonic mesoderm (40-42). At E8.0-8.5 expression in the embryo 
becomes more regionalized to the somites and mesenchyme, while somite expression 
subsequently becomes restricted to the sclerotome and dermatome at E9.5 (40, 41). 
In the developing neural tube, Pdgfra is expressed in neuroepithelial stem cells as early 
as E8.5 and continues to be expressed by developing neurons (43-45). Furthermore, 
Pdgfra expression is found in oligodendrocytes precursor cells (OPCs, also referred to 
as O2A cells), which arise in the mouse around E12.5 in the periventricular zone of the 
neuroepithelium. From E12.5-E15.5, these OPCs proliferate and migrate to populate 
the entire neural tube/spinal cord (46). Expression of Pdgfa during this period is found 
in the surface ectoderm, the myotome of the somites and the floor plate of the neural 
tube, resulting in alternating layers of ligand and receptor expression (47). Pdgfb is 
mainly expressed in vascular endothelial cells (48), while its protein Pdgfb has also been 
detected in various neurons of the embryonic and adult brain (49). Pdgfc is expressed 
in the myotome and sclerotome of the somites, the surface ectoderm and the 
notochord, as well as in the developing brain and the neural tube, where its expression 
becomes restricted to the ventral horn and the floorplate at E16.5 (50). 
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3.5 Pdgfra and ligand mouse mutants
The first Pdgfra mouse mutant described was the naturally occurring Patch (Ph) 
mouse (51). The Ph mutation involves a variable deletion on mouse chromosome 5 
that includes the entire Pdfgra gene (52, 53). While Ph/+ mice appear phenotypically 
normal apart from white patches in their fur (hence also its name), the Ph mutation is 
lethal in its homozygous form. Although Pdfgra is normally expressed from the two-cell 
stage onward, developmental defects in homozygous Ph mice are only observed 
from the primitive streak stage onward, indicating that Pdfgra function is dispensable 
until then. Ph/Ph mice survive until E10.5-E18, depending on their genetic background 
(C57/BL6/J, CBA or Balb/C), and display various developmental defects, mainly in 
mesodermal and neural crest-derived tissues and the neural tube. These include an 
overall smaller body size, spina bifida and a cleft face and/or palate, in addition to 
many axial skeletal defects such as malformed vertebrae and ribs (40, 54-56) (51). 
Targeted Pdfgra null mutants display more or less the same phenotype as 
homozygous Patch mice, also involving mesoderm, neural crest and neural tube 
malformations (57). Pdfgra (-/-) mice survive until E16, are also smaller than their wild-type 
littermates and display a.o. a cleft face, spina bifida (figure 5) and various additional 
vertebral and rib cage malformations. The defects seen in both Pdgfra (-/-) and Pdgfra 
(+/-) mice generally occur in tissues that show physiological Pdgfra expression. Notably, 
the development of surrounding tissues and cell types that lack Pdgfra expression, e.g. 
the myotome and neurons, can also be affected. This is probably due to an altered 
interaction between these receptor negative cell types and cell types that normally 
express Pdgfra (41, 55, 57). The few differences between Ph and Pdgfra mutant mice, 
including the absence of patches in Pdfgra (+/-) mice and the milder heart defects in 
Pdgfra (-/-) mice, can most likely be ascribed to the deletion of sequences in the Ph 
mutation that affect the expression of other genes. Introduction of a YAC transgene 
carrying the entire human PDGFRA gene almost completely rescued the Pdgfra (-/-) 
phenotype, while the survival of Ph/Ph mice was not affected by this YAC, indicating 
that the Ph mutation indeed involves more than Pdgfra alone (58). Also in Xenopus, 
disabling Pdgfra function results in aberrant mesoderm development and neural tube 
closure (59).
Since the Ph/Ph and Pdgfra (-/-) mutants are both embryonically lethal, Pdgfra 
function in these mice cannot be studied later in development. Knock-in mice in which 
the endogenous Pdgfra gene was replaced by a transgene encoding mutant receptors 
deficient in activating specific downstream signaling molecules, allowed a study of the 
function of Pdgfra at later time points, as well as the unraveling of the contributions 
of specific Pdgfra-activated signaling pathways (60). Transgenic mice expressing a 
Pdgfra mutant that lacks the ability to activate PI3K (αPI3K/αPI3K) displayed prolonged 
survival until birth compared to Pdgfra (-/-) mice, but died soon after probably as a 
result of respiratory failure. The developmental defects of these αPI3K/αPI3K mice are also 
much milder than those observed in the homozygous null mutants, but do include 
several skeletal malformations (a.o. spina bifida) and impaired oligodendrocyte 
development. Blocking only the receptor’s ability to activate Src family kinases 
resulted in an even less severe phenotype. In these αSrc/αSrc mice only oligodendrocyte 
development seemed to be affected, resulting in a severe hypomyelination of the 
central nervous system. Surprisingly, mice hemizygous for the so-called F7 allele (F7/-), 
a mutation that leads to a disruption of binding sites for PI3K, SRC family kinases, PLCγ 
and SHP2, do not show additional defects compared to the αPI3K/αPI3K mice, indicating 
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that PI3K is the main intracellular signaling molecule for Pdgfra during embryogenesis 
(61). The observation that the phenotype of both the PI3K and F7 mutant is milder than 
that of Pdgfra (-/-) mice, suggests that these mutant receptors are probably still able to 
activate PI3K at a low level by forming dimeric complexes with Pdgfrb. Disabling PI3K 
binding capacity in both Pdgfra and Pdgfrb indeed resulted in the same phenotype 
as observed for Pdgfra (-/-) mice (60). McKinnon et al. (36) confirmed the importance 
of Pdgfra signaling via PI3K and also through PLCγ for oligodendrocyte development. 
They demonstrated that PI3K is activated at relatively low ligand concentrations, is 
required for OPC migration and survival, and promotes proliferation, whereas PLCγ 
activation takes place at relatively high ligand concentration and promotes OPC 
proliferation but is not required for migration. 
 Mutations in the genes for the Pdgfra binding ligands Pdgfa, Pdgfb and Pdgfc 
are likely to display at least some of the defects seen in the receptor mutants. Pdgfa 
knockout mice die perinatally and show severe hypomyelination due to defective 
oligodendrocyte development, but lack the axial skeleton defects seen in the Ph/Ph 
and Pdgfra (-/-) mice (62). So although Pdgfa is expressed in neurons and appears 
to be the main Pdgfra ligand for proliferation and migration of OPCs in vivo, it does 
not seem necessary for proper bone formation. In contrast, the phenotype of Pdgfb 
deficient mice looks very similar to that of Pdgfrb knockout but not of Pdgfra knockout 
mice. Pdgfb (-/-) as well as Pdgfrb (-/-) mice die around birth, displaying defects in 
cardiovascular, hematological and renal development (48, 63-66). Also, the phenotype 
of Pdgfa/Pdgfb double mutant mice does not resemble that of Pdgfra (-/-) mice (67). 
Pdgfb therefore does not seem to play an important role as a Pdgfra ligand, at least 
not during embryonic development. In contrast, Pdgfc (-/-) mice resemble Pdgfa (-/-) 
Figure 5: Spina bifida in Pdgfra (-/-) mice (from (57)). Cross-section of wildtype (A) and mutant (B) 
E15.5 embryos. The arrow indicates the neural tube. Ninth thoracic (C) and first sacral vertebrae 
(D) from wildtype (top) and mutant (bottom) embyos are shown in detail. (a) represents neural 
arch, (vb) vertebral body.
A
B
C
D
Chapter 1
20
General Introduction
21
mice, in that they show some but not all of the characteristics of Pdgfra null mice; they 
die perinatally displaying a cleft palate and spina bifida. Pdgfa/Pdgfc double mutants 
on the other hand, fully recapitulate the Pdgfra (-/-) phenotype, indicating that a 
combination of these two ligands is required for proper activation of Pdgfra during 
development (67).     
3.6 PDGFRA expression regulation: cis- and trans-acting factors
The 2.1 kb 5’ flanking region of the human PDGFRA gene was first to characterized 
in our laboratory by Afink et al. (68). This region acts as a functional promoter since it 
can drive reporter gene expression in an orientation dependent manner in a variety 
of human and murine cell lines. Of the various deletion mutants tested, the -441/+118 
promoter region displayed the highest activity, indicating the presence of both 
positive and negative regulatory elements in the -2100/+118 promoter region tested. 
Moreover, all deletion mutants, including the -52/+118 promoter fragment, appeared 
to be inducible by retinoic acid (RA) and cAMP in undifferentiated human embryonal 
carcinoma cells, a process accompanied by differential binding of nuclear proteins 
to this -52/+118 region in vitro. This region does not contain any putative RA or cAMP 
responsive element, however, which suggests that RA and cAMP induce PDGFRA 
expression indirectly via a currently unknown transcription factor (68). 
 A proximal 2.2 kb human PDGFRA promoter fragment appeared to be able to 
faithfully drive expression of a LacZ reporter gene in transgenic mice in a great number 
of tissues in vivo, indicating that it contains most regulatory elements necessary for 
proper PDGFRA transcription (69). However, the LacZ transgene was not expressed in 
OPCs, suggesting that the element driving PDGFRA expression in glia cells is located 
outside this 2.2 kb promoter region. Similar observations have been made for a murine 
6.0 kb promoter fragment, suggesting that this putative glia element is not located in 
the direct upstream promoter region (70). In contrast, a yeast artificial chromosome 
(YAC) containing the entire human PDGFRA gene including 3.6 kb of the proximal 
promoter region was faithfully expressed in OPCs of Ph/Ph mice, indicating that this glia 
element is probably located in intronic or 3’ sequences (58). 
 A number of nuclear proteins are known to influence PDGFRA expression, 
although for most of them a direct DNA target sequence has not been established. 
Joosten et al. (71) previously showed that the homeobox transcription factor PAX1 
can influence PDGFRA promoter activity in human embryonal carcinoma and 
osteosarcoma cells. Moreover, the digenic mouse mutant that is homozygous for 
the Pax1 mutation undulated and heterozygous for the Patch mutation (un/un, Ph/
+), shows severe neural tube defects, whereas the two corresponding single gene 
mutants do not. This indicates that also in vivo Pax1 and Pdgfra act within the same 
or related pathways (72). Mice deficient in the gene for the related transcription 
factor Pax3 showed altered Pdgfra expression, indicating that this transcription factor 
may also act as an upstream regulator of Pdgfra expression (73, 74), although direct 
interaction sites for both Pax1 and Pax3 with the Pdgfra promoter have not been 
identified yet. The transcription factor GATA-4 can upregulate Pdgfra expression in 
F9 murine embryonic carcinoma cell, probably by binding to a sequence element 
located in the -799 to -672 murine promoter region (75), but so far this has only been 
shown in mouse cells. For three transcription factors direct binding site are known, i.e. 
C/EBPs (CCAAT/enhancer-binding proteins), Sp1 and ZNF148. C/EBPδ can upregulate 
Pdgfra expression in vascular smooth muscle cells (VSMCs) by binding to a C/EBP 
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binding site located in the -165 to -138 promoter of the rat Pdgfra gene (76, 77), while 
in humans a conserved C/EBP site at position -162 has been shown to be essential for 
high basal level PDGFRA promoter activity in osteogenic sarcoma MG-63 cells (78). The 
zinc finger transcription factor Sp1 can repress Pdgfra transcription in rat VSMCs when 
phosphorylated in response to FGF2, whereas dephosphorylated Sp1 activates Pdgfra 
transcription, both by binding to an atypical Sp1-binding site at position -61 to -52 in the 
rat promoter (79). Recently, is has been shown that the zinc finger transcription factor 
ZNF148 can bind the human PDGFRA promoter around position -1074 in vitro, but an 
influence on PDGFRA promoter activity has not been established yet (80). 
3.7 PDGFRA and diseases: glial defect 
The mammalian central nervous system is comprised of two cell types: neurons and 
glia cells. The main glia subtypes are oligodendrocytes, i.e. glia cells which produce 
myelin sheaths and support axons, and star-shaped astrocytes, which control the 
extracellular environment of neurons and provide them with support and nutrients. 
Neurons, oligodendrocytes and astrocytes all descend from a neuroepithelial stem 
cell, but there is still controversy regarding the lineage relationship and fate restriction 
of the intermediate precursor cells. There are indications for a common precursor cell 
of both oligodendrocytes and astrocytes (the so-called glial-restricted precursor: GRP), 
but also the existence of a common precursor for oligodendrocytes and motorneurons 
(the motorneuron-oligodendrocyte precursor: MNOP) has been suggested (81). 
Recently a model has been proposed in which motorneuron and oligodendrocyte 
precursors are sequentially generated in vivo from neuroepithelial stem cells, without 
a common lineage-restricted progenitor. In this model neuroepithelial stem cells that 
do not differentiate into motorneuron or oligodendrocyte precursors will eventually 
become astrocytes (82). However, it is as yet unclear which precursors actually exist 
in vivo, since most experiments investigating the potency of precursors are performed 
on explants, whereby the positional cues present in vivo are lost and artificial positional 
cues may be created in vitro (83). 
 In the mouse, Pdgfra is highly expressed by OPCs, which arise in the ventral 
region of the neural tube (46, 84, 85), but recently more dorsally derived OPCs have 
been identified as well (86, 87). Such Pdgfra expressing precursors are sometimes 
referred to as O2A cells, because they can give rise to both oligodendrocytes and 
type 2 astrocytes in vitro (88). In vivo, however, generation of type 2 astrocytes has 
been difficult to establish (89, 90). It has been shown that GRPs, which can generate 
oligodendrocytes as well as astrocytes, may also express Pdgfra, although not in 
an initial stage (91, 92). Mature astrocytes also express Pdgfra (93), which suggests 
that PDGFRA is involved in both oligodendrocyte and astrocyte development. Very 
recently, Pdgfra has been found to be expressed in the adult brain in a population of 
subventricular zone astrocyte-like cells that are the primary precursors of newly formed 
neurons. These so-called B cells have now been shown, like adult OPCs, also to be able 
to generate oligodendrocytes in response to demyelination in vivo (94)), while forming 
tumor-like growths in response to increased PDGF signaling (95). 
PDGFs are known to act as potent mitogens and chemo-attractants for OPCs 
both in vitro and in vivo (62, 96-98). It is therefore not surprising that some Pdgfra-
related mutants suffer from defective oligodendrocyte development. Reduced Pdgfra 
signaling can result in decreased OPC proliferation and premature differentiation, 
leading to decreased OPC as well as oligodendrocyte numbers and ultimately to 
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severe hypomyelination. Since OPCs fail to reach the most dorsal parts of the neural 
tube, these regions most distant from the site of OPC origin show the highest degree of 
hypomyelination (60, 62)(figure 6). 
Overexpression of Pdgfra signaling molecules has been shown to induce 
hyperproliferation of OPCs (46) and is associated with the formation of various 
gliomas, i.e. brain tumors of glial origin, in both mice and humans (99). Gliomas 
comprise more than 70% of all brain tumors and can be divided into tumors that 
are composed predominantly of astrocytes (astrocytomas), oligodendrocytes 
(oligodendrogliomas), mixtures of various glial cells (e.g. oligoastrocytomas) and 
ependymal cells (ependymomas). These tumors can be further classified according 
to the WHO grading system into four clinical grades according to their malignancy. 
Grade I gliomas are benign and can usually be surgically resected, whereas grade II to 
IV are malignant and diffusely infiltrate throughout the brain, making surgical resection 
virtually impossible. With 65 %, glioblastoma multiforme (GBM, also known as grade IV 
astrocytoma) is the most frequent and most malignant type of glioma. The median 
survival of patients diagnosed with GBM is less than a year, and less than 3% survive 
after five years (100, 101). Two types of GBM can be discriminated. Primary GBMs arise 
de novo and are generally associated with amplification and mutation of ERBB1, 
which encodes the receptor for EGF, and mutation or deletion of the tumor suppressor 
gene PTEN. Secondary GBMs have progressed from lower grade astrocytomas and 
are generally characterized by mutations in the tumor suppressor gene TP53 as well as 
overexpression or amplification of PDGFRA. This progression process is often associated 
with additional genetic alteration such as loss of RB or amplification of CDK4 (100). 
Many gliomas and glioma cell lines of various tumor stages do not only 
overexpress PDGFRA but also express PDGFs, indicating that autocrine PDGFRA signaling 
may play an important role in tumorigenesis (102-104). Moreover PDGFRA amplification 
has been found in various glioblastomas and oligodendrogliomas (105-109). In low 
grade astrocytoma, the level of PDGFRA expression is correlated with poor patient 
prognosis (110). In glioblastomas, mutant forms of PDGFRA have been discovered, 
including one with an in-frame deletion in the extracellular domain, as a result of loss 
of exons 8 and 9 (PDGFR-α∆8,9), resulting in an constitutively active, oncogenic isoform 
(111), and another one with a 2 bp deletion in exon 23 resulting in a mutant truncated 
Figure 6: Pdgfra dependent oligodendrocyte development in the mouse neural tube (from (31)) 
Oligodendrocyte precursor cells (OPC/O2A) expressing Pdgfra arise in the ventral periventricular 
zone of the neural tube from where they proliferate and migrate throughout the neural tube in 
response to Pdgfa and Pdgfc. 
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protein (112). Moreover, it has been shown in mice that Pdgf overexpression alone 
is sufficient to induce the formation of gliomas with, depending on the experimental 
model, properties similar to glioblastoma multiforme, primitive neuroectodermal tumor, 
oligodendroglioma or oligoastrocytoma (113-117). These tumor cells displayed OPC-
like characteristics and constitutively activated Pdgfra, whereby the extent of Pdgfra 
signaling correlated with tumor malignancy. Moreover, PDGF receptor inhibiters as well 
as dominant negative mutations of PDGFs could antagonize tumor growth and reverse 
the malignant phenotype (102, 118, 119). Together, this suggests that also in humans 
PDGFRA expression levels, which determine the responsiveness to PDGF, may directly 
influence the risk of tumorigenesis. In conclusion, these data indicate that insufficient 
signaling via PDGFRA in the glial lineage may lead to hypomyelination and a reduction 
in the number of OPCs and mature oligodendrocytes, while excessive signaling may 
result in glioma formation. 
3.8 PDGFRA and diseases: neural tube defects
In mice, defective Pdgfra signaling can lead to defects in vertebral arch fusion and 
neural tube closure (figure 5), commonly referred to as neural tube defects (NTDs) 
(40, 41, 51, 54-57, 60, 67). NTDs can be defined as congenital malformations which 
involve incomplete development of the brain, spinal cord, and/or their protective 
coverings. The most common forms of NTD are anencephaly, a cranial neural tube 
closure defect, encephalocele, a cranial bone defect, and spina bifida, a caudal 
closure defect. Anencephalic children generally die before or shortly after birth, but 
spina bifida is compatible with life. Pdgfra (-/-) and Ph/Ph mice, as well as several other 
mice with Pdgfra-signaling mutations, display spina bifida. Spina bifida can occur in 
two variants, called occulta (“hidden”) and aperta (“open”). Spina bifida occulta is 
characterized by an incomplete fusion of one or more vertebral arches that can lead 
to a damaged spinal chord, but the defective site is overgrown by skin. It has been 
estimated that over 17% of the general population has unrecognized mild forms of 
spina bifida occulta (120, 121). Spina bifida aperta is a more severe form, in which 
either the meninges alone (meningocoel) but in most cases (90%) also the spinal cord 
(myelomeningocoel) can protrude from within the malformed vertebral column in a 
sack-like structure filled with cerebrospinal fluid. Children born with spina bifida aperta 
need to undergo surgery and mostly remain paralyzed from below the site of the 
defect (122). 
 The spina bifida seen in the mouse Pdgfra signaling mutants involves a skeletal 
defect, i.e. failure of neural arch fusion (41, 54, 60, 67), but development and closure 
of the neural tube are also affected (51, 55, 57). In wild-type mice, Pdgfra is expressed 
by the sclerotome of the somites, which will later develop into the various components 
of the axial skeleton. Lack of Pdgfra expression makes the sclerotome cells unable 
to respond to PDGF signals from the surrounding cells. Therefore, proliferation and 
migration of the sclerotomal precursor cells are impaired which results in improper 
positioning of a.o. the vertebral arches (41). The malformation of the neural tube 
itself may involve improper glial and neuronal development due to lack of PDGF 
responsiveness of the respective cell types, as well as reduced support of the vertebral 
arches. In conclusion, insufficient Pdgfra expression and signaling can result in spina 
bifida.  
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4. Aim of the thesis
The data presented indicate that in mice decreased Pdgfra signaling can lead to 
neural tube defects and myelination defects, while on the other hand increased 
Pdgfra signaling can be involved in the initiation as well as the progression of gliomas. 
It is therefore anticipated that in humans factors that influence PDGFRA expression 
may play a role in risk of developing PDGFRA-related diseases. The aim of the research 
presented in this thesis was to identify both cis- and trans-acting factors that influence 
PDGFRA transcription and subsequently to establish how these factors contribute to the 
susceptibility to and pathogenesis of PDGFRA-related diseases, in particular neural tube 
defects and gliomas. Understanding these mechanisms is very important for (prenatal) 
diagnostics, and ultimately for treatment and prevention of these types of diseases. 
We identified cis-acting factors by the use of two strategies, i.e. by investigating the 
effects of natural sequence variation (polymorphisms) in the PDGFRA promoter region 
on reporter gene activity and endogenous mRNA expression levels and by analyzing 
the inducible activity of various truncated promoter constructs in transient transfection 
assays, in various cell types. Subsequent identification of trans-acting factors was 
performed using electrophoretic mobility shift assays. The effects of natural sequence 
variation on disease susceptibility was studied by comparing the distribution of PDGFRA 
promoter haplotypes between groups of healthy control individuals and groups of 
patients suffering from spina bifida and glioblastoma respectively in case-control 
studies. 
 Chapter 2 identifies polymorphisms in the PDGFRA promoter that give rise to 
five different haplotypes and studies how these haplotypes influence reporter gene 
expression and predisposition to neural tube defects. Chapter 3 describes an extended 
study in which also the influence of the interaction of PDGFRA promoter haplotypes 
with environmental factors on NTD risk is investigated. In Chapter 4 we show haplotype 
specific binding of transcription factors to two polymorphic sites in the PDGFRA 
promoter that correspond with differences in promoter activity. Chapter 6 describes 
how endogenous expression of one of the main PDGFRA haplotypes is specifically 
repressed by epigenetic mechanisms in glioblastoma cell lines. Furthermore, we show 
that this particular haplotype is associated with a decreased risk of glioblastomas. In 
Chapter 5 we show that NTD-associated homeobox transcription factors can regulate 
PDGFRA promoter activity during differentiation of undifferentiated human embryonal 
carcinoma cells. Finally, chapter 7 discusses the mechanisms whereby PDGFRA 
promoter haplotypes affect the pathogenesis of the disorders described in this thesis 
as well as other PDGFRA-related diseases. 
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Neural tube defects (NTDs), including anencephaly and spina bifida, are multifactorial 
diseases that occur with an incidence of 1 in 300 births in the United Kingdom (1). 
Mouse models have indicated that deregulated expression of the gene encoding 
the platelet-derived growth factor α-receptor (Pdgfra) causes congenital NTDs (2-4), 
whereas mutant forms of Pax-1 that have been associated with NTDs cause deregulated 
activation of the human PDGFRA promoter (2, 5). There is an increasing awareness that 
genetic polymorphisms may have an important role in the susceptibility for NTDs (6). 
Here we identify five different haplotypes in the human PDGFRA promoter, of which 
the two most abundant ones, designated H1 and H2α, differ in at least six polymorphic 
sites. In a transient transfection assay in human bone cells, the five haplotypes differ 
strongly in their ability to enhance reporter gene activity. In a group of patients with 
sporadic spina bifida, haplotypes with low transcriptional activity, including H1, were 
under-represented, whereas those with high transcriptional activity, including H2α, 
were over-represented. When testing for haplotype combinations, H1 homozygotes 
were fully absent from the group of sporadic patients, whereas H1/H2α heterozygotes 
were over-represented in the groups of both sporadic and familial spina bifida patients, 
but strongly underrepresented in unrelated controls. Our data indicate that specific 
combinations of naturally occurring PDGFRA promoter haplotypes strongly affect NTD 
genesis. 
 
We carried out single-stranded conformation (SSC) analysis on the 2-kb region upstream 
of the transcription initiation site of human PDGFRA (7). In transgenic mice, this region is 
known to be responsible for the spatio-temporal expression pattern of this gene during 
development (8). We performed analysis on 76 patients with sporadic spina bifida, 49 
patients with familial spina bifida and 77 unrelated controls. SSC analysis revealed the 
presence of at least eight polymorphic sites in this promoter region, whereas subsequent 
sequencing of PCR products and cloning of genomic promoter sequences revealed 
the existence of five different haplotypes of the PDGFRA promoter. These haplotypes 
can be divided into two subfamilies, designated H1 and H2, that differ in at least five 
positions, including a two nucleotide deletion/insertion in the noncoding region of 
exon 1 (Fig. 1). Additional polymorphisms may exist further upstream (9). We found four 
H2 variants, designated H2α–δ, of which H2β–δ differ by only a single nucleotide from 
Fig. 1 Promoter haplotypes resulting from polymorphisms in the –1,589/+118 nucleotide sequence 
of PDGFRA (7). Top, the identified eight polymorphic sites are indicated together with their 
corresponding nucleotide position. Bottom, the five identified haplotypes (H1, H2α, H2β, H2γ and 
H2δ) are indicated together with their nucleotide sequence at the polymorphic sites.
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H2α. Analysis of the control individuals revealed that 30.5% of the haplotypes were of 
type H1 and 57.1% of type H2α, with minor contributions of H2β–δ (Fig. 2a). The overall 
haplotype distribution in the group of familial spina bifida patients was not different 
from that of the control group, but the group of sporadic patients showed a 40% 
reduction in H1 haplotypes, combined with an over-representation of H2α and H2β 
haplotypes. We tested these groups for the presence of specific PDGFRA promoter 
haplotype combinations, and found that H1 homozygotes were fully lacking in the 
group of sporadic patients, whereas H2α/H2β heterozygotes were over-represented 
in this group (Fig. 2b). Heterozygotes of the two most abundant haplotypes, H1 and 
H2α, were significantly under-represented in the control group compared with Hardy–
Weinberg equilibrium, whereas such heterozygotes were over-represented in the 
groups of both sporadic and familial patients (Fig. 2). 
Fig. 2 Distribution of the different PDGFRA promoter haplotypes in a group of 49 familial spina 
bifida patients, 76 sporadic spina bifida patients and 77 control individuals. Sporadic patients had 
no first-, second- or third-degree relative with neural tube defects, whereas familial patients had 
at least one known affected relative within the third degree. Controls were unrelated to any of 
these patients. a, The distribution of the various haplotypes over the three groups is indicated in 
both absolute numbers and percentages, assuming diploid chromosome numbers. Based on χ2 
analysis, H1 haplotypes are significantly under-represented in the sporadic patients compared 
with controls (P<0.01; χ2=6.05). b, The distribution of haplotype combinations in the three groups 
is indicated. The total (T) number of individuals identified with a specific haplotype combination 
is indicated in both absolute numbers and percentages, as well as for the group of controls 
(C), sporadic patients (S) and familial patients (F). Note that H1 homozygotes are absent from 
the group of sporadic patients (P<0.01 compared with controls; χ2=11.7), whereas in this group 
H2α/H2β heterozygotes have a tendency towards over-representation (P<0.1 compared with 
controls; χ2=3.34). c, The observed distribution of combinations of the two major haplotypes (H1 
and H2α) in the investigated groups (Obs.) is compared with the expected Hardy-Weinberg 
equilibrium (Exp.). The observed distribution of H1 homozygotes, H1/H2α heterozygotes and H2α 
homozygotes corresponds in all three groups to 77–78% of all haplotype combinations present. 
When considering specific haplotype combinations, H1 homozygotes were significantly higher 
in both controls (P<0.01; χ2=11.7) and familial patients (P<0.02; χ2=6.4) compared with sporadic 
patients. Moreover, H1/H2α heterozygotes were significantly more abundant in familial patients 
compared with controls (P<0.05; χ2=4.3). When testing the various groups for significant deviation 
of genotype frequencies from Hardy–Weinberg equilibrium according to a three-allele χ2 analysis 
(with alleles H1, H2α, and the pooled group H2β+H2γ+H2δ), we observed a significant deviation in 
controls (P<0.05; χ2=7.91 with three degrees of freedom), with a significant deficit of heterozygotes 
(P<0.01; FIS=+0.248) according to the U-test (28). The group of sporadic patients showed significant 
deviation from Hardy–Weinberg equilibrium (P<0.05; χ2=8.34) with a non-significant excess of 
heterozygotes (FIS=–0.089), whereas we observed no significant deviation from equilibrium in the 
group of familial patients.
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Improper proliferation and differentiation of the mesodermal cartilage 
precursor cells that form the neural arches are major events in the genesis of spinal 
NTDs (1-4, 8, 10, 11). We therefore tested the activity of the various promoter haplotypes 
by transient transfection of promoter haplotype–luciferase constructs into human U2-
OS osteosarcoma cells, which are an in vitro model system for bone formation during 
development. We observed strong differences in transcriptional activity between the 
various haplotypes, with an up to six-fold higher activity of haplotypes H2α and H2β 
compared with that of H1, H2γ and H2δ (Fig. 3). The two haplotypes with high activity 
are those that were found to be overrepresented in sporadic spina bifida patients, 
whereas those with low activity were found to be under-represented in these patients 
(Fig. 2a). The frequency of the high-activity haplotypes H2α and H2β, compared with 
that of the low-activity haplotypes H1, H2γ and H2δ, showed a strongly significant 
difference between the sporadic spina bifida patients and the control group (P<0.01). 
These data provide a direct correlation between the distribution of haplotypes in a 
patient population and a functional biochemical parameter of these haplotypes in 
vitro. 
NTDs are multifactorial diseases that occur as a complex interaction between 
environmental and a variety of predisposing genetic factors (12-14). The heritability of 
human NTDs, which can be defined as the relative contribution of genetic factors, has 
been estimated to be approximately 60% (15). In the case of spina bifida, a severe 
form with open lesions exists (spina bifida aperta), as well as a less severe form in 
which the lesion is covered with skin (spina bifida occulta). This latter form is not always 
recognized and it has been suggested that latent lesions exist in at least 15% of the 
total human population (16, 17). Moreover, severe forms of NTDs will lead to embryonic 
lethality without contributing to the patient population. Various mouse models have 
indicated that aberrant expression of Pdgfra may result in spina bifida. Mice with a 
targeted null mutation in Pdgfra and patch mutant mice, with a natural deletion of the 
chromosomal region that includes Pdgfra, both show severe spina bifida combined 
with embryonic lethality in their homozygous form (3, 4). We have previously shown that 
gain-of-function mutations in the gene encoding Pax-1, an upstream transcriptional 
regulator of Pdgfra, are also associated with spina bifida (5, 18). It has been 
Fig. 3 Distribution of promoter activity of transfected 5´ PDGFRA haplotypes in U2-OS cells. Activity 
is presented as the ratio of luciferase and β-galactosidase activities relative to H1 (set to 1), 
including standard deviation. Repeated transfections were carried out in duplicate with different 
batches of DNA. A similar activity pattern of haplotypes was observed in two other human 
osteosarcoma cell-lines: SAOS and HOS (not shown).
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proposed that reduced PDGF signaling during development may lead to premature 
differentiation of the neural glia and cartilage precursor cells, whereas upregulated 
PDGF signaling may result in a prolonged, undifferentiated, proliferative status of these 
cells (19, 20), in both cases resulting in improper closing of the neural tube. Our current 
results show that combinations of naturally occurring PDGFRA promoter haplotypes 
contribute to the adverse factors that eventually determine the manifestation of spina 
bifida in humans. 
The observation that the H2 haplotype shows multiple variants, in contrast 
to H1, may indicate that H1 has only recently been introduced in the population 
investigated. The observation that H1/H2α heterozygotes are under-represented in 
the control population could indicate that H1 and H2 haplotypes are not randomly 
mixed in the population, as has been shown for promoter haplotypes of the β2-
adrenergic receptor (21). This possibility seems unlikely, however, in the light of the 
over-representation of such heterozygotes in the patient population. Our results 
therefore indicate that, most likely in combination with other adverse factors, H1/H2α 
heterozygotes have an increased risk for malformations resulting in either embryonic 
lethality or NTDs. The fact that no H1 homozygotes were found in the group of sporadic 
patients indicates that this haplotype combination selects against the formation of 
spina bifida. No such protective effect was observed in the group of familial patients, 
indicating that in these patients additional adverse factors are involved for which H1 
homozygosity cannot compensate. 
Studies on the human, mouse and rat PDGF α-receptor promoter have 
provided evidence for the involvement of GATA-4 (22), PAX3-FKHR (23), Pax-1 (5) 
and C/EBPs (24) in transcriptional activation of this gene. Further investigations are 
needed to indicate whether these and other transcription factors are expressed in 
the relevant cell types and are able to activate the human PDGFRA promoter in a 
haplotype-specific manner (9). The observed correlation between haplotype variant 
activity in U2-OS cells and their over- or under-representation in spina bifida patients is 
indicative for the relevance of these functional data, but does not explain why H1/H2α 
heterozygosity predisposes to spina bifida. H2α homozygosity seems to be a neutral 
factor in the genesis of NTDs. It is known from embryonic developmental processes 
in lower organisms that promoters on different chromosomes may physically interact 
and can have a combined activity that is different from the average activity of the 
two promoters (25). Little is known about similar processes in mammals (26), particularly 
because in vitro detection assays for such so-called ‘transvection’ phenomena are 
still lacking. It will be worth investigating if such processes may underlie the observed 
improper matching of H1 and H2α haplotypes of the PDGFRA promoter, resulting in 
enhanced embryonic lethality and NTDs. 
Methods
Automated sequencing
We analyzed the DNA sequences of PCR products and DNA constructs using 
the automated ABI310 automated sequencer according to the manufacturer’s 
protocols. 
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Cell culture 
U2-OS was seeded at a density of 5.0×104 cells/cm2 and grown in Dulbecco’s MEM/
nutrient mix F12 (1:1) supplemented with 10% (v/v) fetal calf serum (Gibco) and 
NaHCO3 (44 mM) in a 7.5% CO2 atmosphere at 37 °C.
Haplotype cloning
PCR products of the 5´ flanking sequences of PDGFRA were obtained using Pfu 
polymerase with proofreading (New England Biolabs), and were ligated and cloned 
using a PCR cloning vector (Invitrogen). Clones were analysed and Pst1/Nco1 
(Fermentas) restriction fragments were subsequently ligated into the pSLA4 luciferase 
reporter vector (Promega).
SSC analysis
DNA samples of 76 sporadic patients, 49 familial NTD patients and 77 control people 
were analysed by PCR (Fermentas) and subsequent SSC analysis with the Phast System 
(Promega) according to the manufacturer’s protocols. We carried out SSC at 4 °C 
on native gels with native buffer strips using 0.3 μl PCR reaction mix containing the 
amplified fragment for each sample.
Transfection, luciferase and β-galactosidase assays
The –1589/+118 PDGFRA promoter haplotype constructs were each transiently 
transfected into U2-OS cells using the calcium phosphate coprecipitation method(27), 
in 10 cm2 wells seeded with 3.5×105 U2-OS cells one day before transfection. Luciferase 
activity was detected 48 h post-transfection (Luciferase assay kit, Promega). The activity 
of 1 μg transfected luciferase construct was corrected for transfection efficiency by 
measuring the β-galactosidase activity obtained from co-transfected SV40-driven lacZ 
gene construct PCH110 (50 ng; Promega).
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Note
During following studies, including a case-control study on the interaction of PDGFRA 
promoter haplotypes with environmental risk factors for spina bifida described in 
chapter 3 and a case-control study on the role of PDGFRA promoter haplotypes in 
glioblastoma risk described in chapter 5, it appeared that the haplotype distribution 
of the control population used in this study deviated from that of our as well as other 
subsequent studies on PDGFRA promoter haplotype distributions. Therefore, our 
conclusion that H1/H2α predisposes to NTDs appeared to be biased as a result of 
this improper control population, as will be discussed in detail in chapter 7 (General 
discussion).   
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Summary
Background: Neural tube defects (NTDs), including spina bifida, are multifactorial 
diseases in which environmental factors, such as maternal nutrition, and genetic 
components interact. Aberrant expression of the gene encoding the platelet-derived 
growth factor alpha-receptor (PDGFRA) has been implicated in NTD etiology in both 
mice and humans. We and others have previously shown that the human PDGFRA 
promoter haplotype H1 is overrepresented and H2 is underrepresented in spina bifida 
patients, suggesting that genetically determined differences in PDGFRA expression 
levels affect the risk of NTDs. In the current study we investigated possible interactions 
between PDGFRA promoter haplotypes and periconceptional maternal glucose, 
myo-inositol and zinc levels in relation to the child’s risk of spina bifida. In addition, we 
studied the effects of PDGFRA promoter haplotypes on physiological parameters such 
as maternal length and birth weight of the child.
Materials and methods: We analyzed a Dutch cohort of 88 children with spina bifida 
aperta and 74 control children, as well as 56 case mothers and 72 control mothers for 
their PDGFRA promoter haplotypes. This cohort had previously been analyzed for their 
plasma glucose and myo-inositol concentrations as well as their red blood cell zinc 
levels.   
Results: A significantly higher frequency of the low activity PDGFRA promoter haplotype 
H1 was found in children with spina bifida than in controls (30.1% vs 20.3 %; p=0.043). 
High body-mass index (BMI) and glucose levels of the mother were strongly associated 
with spina bifida, irrespective of the child’s PDGFRA promoter haplotype. Mothers of 
H2 homozygous cases (sbH2) showed a significantly lower myo-inositol concentration 
(median 14.3 μM) than mothers of H1 homozygous or H1/H2 heterozygous patients 
(sbH1; median 16.7 μM; p=0.0094) as well as mothers of H2 homozygous controls (cH2; 
median 16.2 μM; p=0.0081). Zinc levels were significantly higher in cH2 (median 227.7 
μM) than in cH1 (median 210.7 μM; p=0.0062) and sbH2 (median 210.0 μM; p=0.013). 
Logistic regression analysis revealed a significant association with maternal BMI for both 
H1 and H2 cases, but of glucose only for H2 cases. Stepwise multiple logistic regression 
analysis showed that high maternal glucose in combination with low myo-inositol is the 
main risk factor for H2 cases, while a high BMI of the mother appeared the dominant risk 
factor for H1 cases. Finally, we observed that the presence of an H1 allele is associated 
with reduced body growth. 
Conclusion: These data show that periconceptional BMI, glucose and myo-inositol 
status of the mother differentially associate with the child’s PDGFRA promoter 
haplotype in determining the risk of spina bifida.
Introduction 
Spina bifida belongs to the neural tube defects (NTDs), which are common congenital 
malformations that involve defective formation of the brain and/or spinal cord and 
its protective coverings. The birth prevalence rate of spina bifida is highly variable, 
ranging from 0.7 in central France to 11.7 in South America per 10,000 births (1), but the 
reason for the observed variation is not well understood. Spina bifida is a multifactorial 
disease, which implies that both genetic and environmental factors contribute to the 
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etiology. 
Many candidate genes for NTDs, including spina bifida, have been identified 
in studies on mutant and transgenic mice (reviewed in 2, 3), but only few of these 
genes have actually been confirmed in humans (4). Among the genes thus identified 
is that encoding the platelet-derived growth factor alpha-receptor (PDGFRA). From 
mouse studies it is known that Pdgfra plays an important role in the development of 
the neural tube, since Pdgfra-deficient mice are embryonically lethal and show severe 
spina bifida over the entire spine (5-8). We have previously shown that the human 
PDGFRA –3600/+118 proximal promoter region contains a total of 10 polymorphic sites 
which directly affect its transcriptional activity (9, 10). Based on these polymorphisms 
at least five different haplotypes could be discriminated of which H1 and H2α are 
the most abundant, displaying allele frequencies of 21% and 68%, respectively, in 
the Western European population (9, 11, 12). H1 and H2α differ on eight of these ten 
polymorphic positions, and transient transfection assays have indicated that in most 
cell lines tested H1 induces low and H2α high transcriptional activity (9, 10, 13). We 
and others have shown that the H1 allele is overrepresented in cohorts of spina bifida 
patients, suggesting that low PDGFRA activity during human embryonic development 
increases the risk of NTDs (9, 13, 14). 
During embryonic development, the mother can be considered as the 
environment of the child and therefore many maternal factors are known to influence 
NTD risk. It is well established that maternal peri-conceptional supplementation with folic 
acid prevents NTDs, although approximately 30% of the cases appear to be resistant 
to this treatment (15, 16). In the folic acid-resistant curly tail mutant mouse (17), 70% of 
NTDs could be prevented by myo-inositol (18) or D-chiro-inositol (19) supplementation, 
an effect that appears to be mediated by activation of PKC (20). These data suggest 
that myo-inositol supplementation may also reduce NTD risk in humans. Cellular uptake 
of myo-inositol is competitively inhibited by high levels of glucose (21, 22), and therefore 
the higher risk for diabetic women of an NTD-affected pregnancy may be caused by 
the low myo-inositol levels in their cells as a result of hyperglycemia (23, 24). Conversely, 
myo-inositol significantly reduced the NTD incidence in diabetic rats and reversed the 
inhibitory effect of glucose on murine neural tube closure (25, 26).
We previously demonstrated that low myo-inositol, high glucose and low zinc 
status of the mother 2-4 fold increased the risk of a child with spina bifida (27). In the 
present study, we analyzed these cohorts of mothers and children for their PDGFRA 
promoter haplotypes, in order to investigate how PDGFRA promoter haplotypes, 
as a genetic factor involved in NTDs, interplay with these environmental factors in 
determining the child’s risk of developing spina bifida. Our results indicate that the 
effect of maternal risk factors for spina bifida depends on the PDGFRA promoter 
haplotype of the child.
Materials and Methods
Sample population
A case control study comprising spina bifida cases and their mothers as well as healthy 
control children and their mothers has been performed previously by us (27). Briefly, 
between August 1999 and December 2001, mothers and their Caucasian children 
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with spina bifida (non-syndromic meningo(myelo)cele) were recruited in collaboration 
with the Dutch Spina Bifida Teams of various Dutch University Medical Centers 
and hospitals. Control subjects, i.e. children in the same age range without major 
congenital malformations and their mothers, were recruited from midwiferies, nurseries 
and acquaintances from the case mothers to resemble the cases. Exclusion criteria 
were pregnancy or breastfeeding at the moment op blood sampling, consanguinity, 
familiar relationship between case and control subjects, maternal diabetes mellitus 
and blood transfusion within 3 months prior to blood sampling. Ultimately, this resulted 
in 134 spina bifida children with 127 of their mothers and 80 control children with 72 of 
their mothers. The study protocol was approved by the Institutional Review Board of the 
University Medical Center Nijmegen, The Netherlands. 
Blood sampling and DNA isolation
Blood sampling, DNA isolation, and measurement of myo-inositol, glucose and zinc 
levels were performed as described (27, 28). 
PDGFRA haplotyping
PCR and direct DNA sequencing was performed as described (chapter 5, this thesis). 
We were able to perform haplotype analysis on 88 spina bifida and 74 control 
children, from which DNA of sufficiently high quality was available. Subsequently 
haplotype analysis was performed on their corresponding mothers, resulting in 
analysis of 56 spina bifida and 72 control mothers with DNA of sufficiently high quality. 
Statistical analyses
Differences in PDGFRA promoter haplotype distribution between case and control 
children and their mothers were evaluated by odds ratios and 95% confidence 
intervals. The interaction between individual maternal and child parameters with 
PDGFRA promoter haplotypes in relation to spina bifida risk was analyzed using the 
non-parametric one tailed Wilcoxon U-test (http://eatworms.swmed.edu/~leon/ stats/
utest.html). In order to analyze the relative contribution of maternal parameters in the 
child’s risk of developing spina bifida, logistic regression analysis was performed for 
individual haplotypes and their significance was expressed by odds ratios. Stepwise 
multiple logistic regression was subsequently performed in order to test the relative risk 
of becoming a patient as a function of the measured variables. 
For logistic regression analysis, a binomial response variable (patient versus 
non-patient) was tested against the continuous variables (BMI, glucose, zinc and 
myo-inositol) and the categorical variable haplotype (H1 and H2). A general linear 
model with a binomial error distribution and a logit link function was fitted to the data. 
In order to test the independence of the variables, the correlation structure of the 
predictor variables was first investigated for the entire dataset (n=113). Significant 
but low correlations were found between glucose and BMI (0.198, p<0.05) and 
between glucose and zinc (-0.184, p <0.05). A maximum of 4% of the variation in BMI 
could be explained by variation in glucose, and therefore we further treated the 
predictor variables in the multiple logistic regression procedure as being effectively 
independent. 
In order to be able to compare the impact of various predictor variables in a 
stepwise multiple logistic regression analysis, the distribution of the continuous variables 
was standardized to a mean of 0 and a standard deviation of 1, prior to the analysis. 
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In a stepwise selection procedure the best fitting multiple logistic regression model 
was searched for, i.e. the model with maximum fit for the fewest predictor variables. 
Inclusion criterion for deviance was set to 0.05. This procedure was carried out for 
both the H1 and H2 subset of data are expressed in standardized logistic regression 
coefficients for the variables included in the best fitting model, with their significance 
indicated by odds ratio. All analyses were performed with SAS for Windows 9.3.
Results
PDGFRA haplotypes as risk factors for NTDs
After our initial identification and characterization of human PDGFRA promoter 
haplotypes (9), at least two additional studies have confirmed that the H1 haplotype 
is overrepresented in spina bifida patients (13, 14). To strengthen these findings, and 
to subsequently investigate the interaction between PDGFRA promoter haplotypes 
and environmental factors influencing NTD risk, we analyzed the PDGFRA promoter 
haplotype distribution in a cohort of Dutch spina bifida patients and their mothers, of 
which in previous studies body length, body weight, blood myo-inositol and glucose 
concentrations, as well as red blood cell levels of zinc had been determined (27). Only 
patients with sporadic spina bifida aperta were considered, and only those individuals 
were included of which the PDGFRA promoter haplotypes could be determined 
unequivocally. 
Table 1A shows the PDGFRA promoter haplotype distribution of these patients 
and their mothers, in comparison with a cohort of matched controls. Table 1B shows 
that the haplotype distribution of the control mothers and children is very similar, giving 
rise to an H1 frequency (pH1) of 0.201 and 0.203, respectively. These numbers are very 
similar to the value of pH1=0.211 that we have determined recently for a large (n=998) 
combined Western European control group (chapter 5, this thesis). In contrast, a much 
higher frequency of H1 was observed for both the cases (pH1=0.301) and their mothers 
(pH1=0.286). Table 1C shows that the frequency of H1 in the cases was significantly 
enhanced compared to the control children (OR=1.695; p=0.043), particularly 
because of the increased frequency of H1 homozygotes in the case group (OR=3.746; 
p=0.042). The overrepresentation of H1 in the mother group showed a similar odds ratio 
but was not significant (OR=1.586; p=0.116), most likely because of the smaller sample 
size (Table 1D). These data agree with previous studies showing that both spina bifida 
patients and their mothers have an increased frequency of the PDGFRA H1 allele (13, 
14). 
Maternal parameters as risk factors for spina bifida offspring 
In order to analyze the interaction between genetic and environmental factors in the 
risk of spina bifida, we compared maternal BMI, glucose, myo-inositol and zinc values 
between cases and controls for both the H1 and the H2 group of children. The H1 
group consisted of both H1 homozygotes and H1/H2 heterozygotes, while the H2 group 
consisted of H2 homozygotes irrespective of the their specific subtype (α,β,γ,δ). Table 
2A shows medians with 5th-95th percentile of each maternal parameter, as a function 
of the genetic and disease status of their child. Note that the number of mothers in the 
analysis is not necessarily identical to that of Table 1A, since only mothers were included 
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for whom the respective parameter as well as the haplotype of the child could be 
determined. Table 2B shows the corresponding statistical analysis, on the basis of the 
non-parametric Wilcoxon U-test. The data show that case mothers have significantly 
higher BMI (median 25.6 vs 23.2 kg/m2; p=0.0006), higher serum glucose (4.30 vs 4.05 
mM; p=0.0001) and reduced red blood cell zinc (210.3 vs. 220.1 µM; p=0.0414) values 
than control mothers, in agreement with previous data (27).
When H1 and H2 children were analyzed separately, maternal BMI and 
glucose were found to be significantly enhanced in both groups. Myo-inositol was 
significantly reduced in mothers of H2 cases, both when compared to mothers of H1 
cases and to mothers of H2 controls (14.3 vs. 16.7 and 16.2 μM, p=0.0094 and 0.0081 
respectively), indicating that a haplotype specific effect of maternal myo-inositol exists 
for spina bifida. Intriguingly, mothers with a control H2 child had significantly higher zinc 
levels than mothers with a control H1 child (227.7 vs. 210.0 μM, p=0.0062) or with a spina 
bifida H2 child (210.7 μM, p=0.0130), while maternal zinc was also significantly higher 
for pooled H2 than for pooled H1 haplotypes (224.3 vs. 211.4 μM, p=0.0414), indicating 
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that also maternal blood zinc levels may differentially influence children with an H1 and 
H2 genotype. 
Very similar results were obtained when the above data were analyzed with a 
parametric t-test. Median and mean values never differed by more than 5%, indicating 
that the data presented are close to a normal distribution (data not shown).  
Effect of PDGFRA promoter haplotypes on physiological parameters of mother and 
child
PDGFRA deficient mice are smaller than their wild-type littermates (5-7), suggesting a 
role for Pdgfra in body growth. Therefore we investigated the association of PDGFRA 
haplotypes with growth-related parameters such as maternal length and birth weight of 
the child, as is depicted in table 3. We observed that H1 control mothers are significantly 
shorter than H2 control mothers (166.5 vs.169.4 cm, p=0.0211). This difference was even 
more pronounced for pooled case and control mothers (165.5 vs. 169.1 cm, p=0.0029, 
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table 3A and B), which suggests that H1-driven low PDGFRA expression inhibits body 
growth. Also, the haplotype of the mother appeared to affect the child’s birth weight, 
as is depicted in table 3C and D. Control H1 as well as pooled H1 mothers gave birth 
to a significantly lighter child than control and pooled H2 mothers respectively (3255 vs. 
3430 g, p=0.0129 and 3260 vs. 3350 g, p=0.0220), while the lower birth weight for cases 
as observed in the total population (3160 vs.3320 g, p=0.0271) remained statistically 
significant for the H2 mother subset only (3130 vs. 3430 g, p=0.0140). Furthermore, table 
4E and F show that the haplotype of the child itself also affected birth weight. We 
observed a reduced birth weight for cases compared to control children (3160 vs. 3328 
g, p=0.0097), which remained for the H1 subset (3218 vs. 3370, p=0.0293), but not for 
the much larger H2 subset (3160 vs. 3300, p=0.0804), indicating that particularly for H1 
children spina bifida is associated with a low birth weight. Taken together, these data 
indicate that PDGFRA promoter haplotypes differentially affect body growth. 
Logistic regression analysis on maternal risk factors for spina bifida offspring
In order to analyze which maternal parameters show the best prognostic indication for 
spina bifida risk in the child, we carried out logistic regression analyses for both the H1 
and H2 cohorts. Table 4A shows that according to such analysis maternal BMI is the only 
significantly associated parameter for H1 children, while for H2 children both glucose 
and BMI are significantly associated with spina bifida. 
In order to evaluate the relative contribution of the various maternal parameters 
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in the risk of spina bifida, we performed stepwise multiple regression analysis on this 
set of data and determined for each parameter its partial standardized regression 
coefficient. Table 4B shows that for H1 children BMI is by far the most prominent 
predictive parameter. After taking into account the contribution of BMI, none of the 
other three parameters contributed to a better fit of the model to the experimental 
data and were therefore excluded by the analysis. For H2 children glucose showed 
the highest association with spina bifida, with a minor but significant contribution of 
myo-inositol. Introduction of BMI as an additional parameter resulted in only a small 
further improvement of the fit. In conclusion, enhanced BMI of the mother appears the 
best prognostic parameter for the risk of spina bifida of an H1 child, while enhanced 
maternal glucose, particularly in combination with reduced maternal myo-inositol, is 
the best prognostic parameter for an H2 child.   
Discussion
NTDs are common congenital malformations of multifactorial etiology. In the present 
study we searched for interactions between genetic and environmental factors that 
are known to influence the risk of spina bifida. As a genetic factor we studied the 
PDGFRA promoter haplotype of the child, and as environmental factors the BMI and 
periconceptional levels of blood glucose, myo-inositol and red blood cell zinc of the 
mother. First, we confirmed that spina bifida children show an enhanced incidence 
of the PDGFRA promoter haplotype H1. Second, we observed that high maternal 
BMI, high maternal glucose and low maternal zinc each predispose to spina bifida in 
the offspring, irrespective of their PDGFRA promoter haplotype. Third, when analyzing 
the relative risk of developing spina bifida, we observed by stepwise multiple logistic 
regression analysis that high BMI is the most prominent maternal risk factor for H1 
children, and high glucose in combination with low myo-inositol the most prominent 
for H2 children. Fourth, spina bifida appeared to be associated with a low birth 
weight, particularly for H1 children. Finally, when investigating the role of PDGFRA 
promoter haplotypes on maternal and child physiology, we found that H1 mothers are 
significantly shorter than H2 mothers, while also giving birth to lighter children. These 
data show that PDGFRA promoter haplotypes differentially affect both physiological 
and pathological processes.
 Our observation that the frequency of the H1 allele is increased in spina bifida 
patients as well as in their mothers agrees with previous studies by Zhu (13) and Au (14). 
These authors studied particularly Hispanic populations in the USA, who show a very 
high H1 incidence (pH1=0.31) in their control population. Our current data, showing a 
pH1=0.203 for the control children and pH1=0.201 for their mothers, is in agreement with 
values obtained from a very large Western European control population (pH1=0.211). 
In a previous study we concluded that particularly H1/H2 heterozygosity is associated 
with spina bifida (9), but these results were obtained on the basis of much smaller and 
less well defined cohorts, of which the controls clearly deviated from the Western 
European control population.      
PDGFRA is involved in the growth of various, mostly mesenchymal cell types, 
such as fibroblast, osteoblasts, smooth muscle, neural crest and oligodendrocyte 
precursor cells (29). Many Pdgfra signaling mutants in the mouse display a smaller 
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overall body size than their wild type littermates (5-7, 30-32). In line with this observation, 
we now show that the low expressing H1 haplotype negatively influences the body 
length of humans. PDGFRA is thus one of the few genes that can directly be linked to 
general body size in humans, although a relation with the well described hypothalamus-
pituitary-GH axis remains unclear (33). 
Multifactorial diseases such as NTDs have been described in terms of a liability/
threshold model, in which discontinuous phenotypes are explained by assuming that 
the sum of adverse genetic and/or environmental factors must exceed a threshold 
before the abnormal phenotype becomes manifest (34, 35). In terms of this model the 
low activity H1 allele can be considered as an adverse genetic factor for NTDs, and 
consequently for this haplotype less environmental factors (a.o. BMI, glucose, myo-
inositol and zinc) require an aberrant value, before it results in spina bifida. This is in 
agreement with our finding that high BMI alone is already a substantial maternal risk 
factor for H1 children, while for H2 children a combination of high glucose, low myo-
inositol and high BMI is required. It is important to realize that only live-born children 
with spina bifida have been included in our study, and therefore it is likely that in 
combination with multiple adverse environmental parameters H1 children have a 
higher risk of prenatal death than H2 children. Alternatively, the possibility should be 
considered that the genetic and environmental factors discussed in this study have a 
common mechanism of action, e.g. in mediating PDGFRA signaling, this in spite of the 
observation that they behave as independent parameters in the statistical analysis.
Our data indicate that high BMI and glucose are the main maternal risk 
factors for spina bifida. Periconceptional intake of simple sugars and foods with a 
high glycemic index have already been described to influence NTD risk in humans 
(36), while high concentrations of glucose inhibit neural tube closure in mice (26). Also 
obesity, generally defined as a BMI above 29kg/m2, has previously been associated 
with elevated risk of NTDs, as well as with other anomalies in offspring (37-42). Although 
the underlying mechanism for correlation is unknown, several possibilities have been 
suggested. Obese women might suffer from poorer nutrition than non-obese women, 
resulting in higher glucose and lower myo-inositol blood levels. Alternatively, they may 
have metabolic alterations that increase NTD risk, such as hyperglycemia, increased 
insulin or estrogen levels (40).
The role of myo-inositol in the risk of spina bifida is less well documented. Our 
current data indicate that low maternal myo-inositol is a risk factor particularly for H2 
children. Myo-inositol provides the basis for various inositol phospholipids, of which 
phosphatidylinositol (PI) is the most abundant in mammalian cells (~5-20% (21)). The 
PI derivative PIP2 is used as an intracellular signaling molecule by many growth factor 
and hormone receptors, including PDGFRA (21). NTDs are prevented by myo-inositol 
suppletion in the curly tail mouse (18), via a PKC dependent mechanism (20), thus 
providing a possible link between myo-inositol and PDGFRA, which also signals through 
PKC. In the case of low maternal myo-inositol levels and consequently low myo-inositol 
supply to the developing embryo, in combination with the high expressing H2 allele, the 
amount of PIP2 for PDGFRA signaling may become limited in fast growing tissues such as 
the neural tube, resulting in reduced PDGFRA signaling and consequently a higher risk 
of spina bifida. In addition, low myo-inositol supply in combination with low H1 driven 
embryonic PDGFRA expression may result in reduction of PDGFRA signaling capacity 
to such a low level that these embryos die prenatally. In line with this hypothesis, the 
mothers of the live-born H1 cases analyzed in this study have significantly higher myo-
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inositol levels in their blood than do mothers of H2 cases. Since glucose inhibits cellular 
uptake of myo-inositol, high glucose levels may enhance the effect of low maternal 
myo-inositol supply, which in combination may affect PDGFRA signaling. It must be 
noted, however, that is unclear how the myo-inositol levels in serum as measured in this 
study correlate to its intracellular availability. 
Maternal zinc status has also previously been implicated in the etiology of 
neural tube defects (43-46). Zinc is an essential element for the structure and function of 
a large number of macromolecules including 300 enzymes. It plays a role in e.g. insulin 
biosynthesis and is a structural component of many transcription factors (47, 48). In this 
study we observed that maternal zinc levels are higher for H2 than for H1 children, and 
higher in controls than in cases. A number of zinc finger transcription factors have been 
implicated in PDGFRA transcriptional regulation, including GATA4, Sp1 and ZNF148 (12, 
49-52), but it is unclear to what extent zinc concentrations limit the efficiency of their 
action, and thereby of PDGFRA signaling.
  In conclusion, we found that PDGFRA promoter haplotypes are differentially 
involved in the etiology of neural tube defects and interact with different environmental 
factors to influence NTD risk. 
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Abstract
We have previously shown that polymorphisms in the promoter of the human platelet-
derived growth factor α-receptor (PDGFRA) gene can be grouped into five distinct 
haplotypes, designated H1, H2α, H2β, H2γ and H2δ, and that specific combinations 
of these promoter haplotypes predispose to neural tube defects (NTDs). These 
promoter haplotypes differ strongly in their ability to drive reporter gene expression 
in various human cell lines, with highest activity for H2α and H2β. Here we show that 
the haplotype-linked PDGFRA promoter region extends to 3.6 kb upstream from the 
transcription start site, and contains a total of ten polymorphic sites. For two of these 
polymorphic sites, i.e. –909C/A and +68GAins/del, we observed differential binding 
of nuclear proteins from human osteosarcoma (HOS) cells. The protein complex 
binding specifically to –909C, which is present in all haplotypes except the low activity 
haplotype H2γ, contained members of the upstream stimulatory factor (USF) family of 
transcription factors. Furthermore we identified a protein complex of 125 kDa which 
bound specifically to the low activity haplotype H1 at position +68GAdel and may 
represent an H1-specific PDGFRA transcriptional repressor. The current identification 
of cis-acting elements in the PDGFRA promoter and the transcription factors that 
bind them, provides a new strategy for the identification of genes that are potentially 
involved in neural tube defects.
Introduction
With the recent completion of the overall sequence of the human genome, current 
genomic research now focuses on the estimated 0.1% difference in DNA sequences 
between individuals. Emphasis is put particularly on the role of single nucleotide 
polymorphisms (SNPs) and small insertion/deletions (ins/dels) within regulatory DNA 
sequences, since such polymorphisms may directly affect the expression levels of the 
nearby genes. Regulatory polymorphisms in multiple genes may not only determine 
the specific genetic characteristics of an individual, but also his/her predisposition for 
complex diseases.
In a previous study, we have identified seven SNPs and one dinucleotide ins/
del in the 1.6 kb promoter region of the gene encoding the human platelet-derived 
growth factor α-receptor (PDGFRA). These polymorphisms appeared to be linked and 
gave rise to five distinct haplotypes, designated H1, H2α, H2β, H2γ and H2δ (1). H1 and 
H2α are the two most common haplotypes (approximately 22% and 65% of the Western 
European population (1-3) and differ from each other on six positions in this promoter 
region, while H2β, H2γ and H2δ differ each on only a single nucleotide position from 
H2α. Upon transient transfection of these PDGFRA promoter haplotypes into the human 
osteosarcoma cell lines U2OS, HOS and SAOS, we observed an up to six-fold higher 
promoter activity for H2α and H2β when compared to H1, H2γ and H2δ (1). This suggests 
that the corresponding polymorphisms may also influence gene expression in vivo and, 
as a consequence, may contribute to the susceptibility to PDGFRA-related diseases.
Deregulated expression of PDGFRA has been linked to neural tube defects 
(NTDs) in mice (4,5) as well as in humans (1,6). NTDs, including anencephaly and spina 
bifida, are common congenital malformations that involve defective development of 
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the brain and/or spinal cord as a result of incomplete closure of the neural tube. NTDs 
occur with an average frequency of one per thousand births in the Western world and 
are considered to be multifactorial in origin, implying that both environmental and 
genetic factors contribute to their etiology (7). 
In mice, Pdgfra deficiency leads to prenatal lethality and various 
developmental defects including severe spina bifida along the entire spinal column 
(4,5(. Moreover, some PDGFRA upstream regulators have been associated with NTDs, 
such as Pax1 (8-10), Pax3 (11-13) and PRX1/PRX2 (14,15), both in mice and men. 
This suggests that aberrant PDGFRA expression may predispose to NTDs in humans. 
Interestingly, we (1) and others (6) have shown that the H1 promoter haplotype of 
PDGFRA is associated with an increased risk of NTDs. In order to understand the role 
of PDGFRA haplotypes in NTDs at the molecular level, it will be important to identify 
transcription factors that are able to bind the PDGFRA promoter in a SNP dependent 
manner.  Recently, De Bustos et al. (3) have shown that the C to A substitution specific 
for the H2δ haplotype results in a loss of binding capacity of the zinc finger transcription 
factor ZNF148.
The PDGFRA haplotype-linked promoter SNPs identified thus far are located in 
the promoter region between +118 and -1589 relative to the transcription start site 
according to Afink et al. (16), which is the most conserved part of the promoter 
between human, mouse and rat. Studies on transgenic mice containing PDGFRA 
promoter constructs have shown, however, that the promoter region between -1589 
and -3600 may contain additional elements necessary for proper PDGFRA transcription 
(17,18). Analyses by Herrmann et al. (2) have indicated that this region contains at least 
a  five base pairs ins/del at position –1631, which according to Zhu et al. (6) is haplotype 
coupled. In the present study we show that this ins/del and an additional T/C SNP at 
position -2795 are linked to the H1 and H2 haplotypes, thereby extending the length 
of the various promoter haplotypes to at least 3600 bp upstream of the transcription 
initiation site. In order to identify haplotype-specific binding of transcription regulating 
proteins, we subsequently analyzed all eight haplotype-coupled SNPs and the 
two ins/dels present in the –3600/+118 PDGFRA promoter region for allele-specific 
binding of nuclear proteins from human osteosarcoma (HOS) cells. Here we show by 
electrophoretic mobility shift assays (EMSAs) that the –909C/A SNP and the +68GAins/
del show haplotype specific protein binding. Using supershift assays the protein binding 
to the –909C oligonucleotide could be identified as a member of the upstream 
stimulatory factor (USF) family of transcription factors, while the +68del oligonucleotide 
was shown to bind specifically a thus far unidentified protein complex with a molecular 
weight of 125 kDa. These data offer a possible mechanistic explanation for the different 
promoter activities of the various PDGFRA promoter haplotypes, and are discussed 
in terms of the relation between promoter haplotypes and susceptibility to PDGFRA-
related diseases such as NTDs. 
Methods
Automated DNA sequencing
For analysis of the -3600 to -1535  region of the PDGFRA promoter, two overlapping 
fragments were amplified by PCR using the following primer pairs: forward primer F1 5’-
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AGGGAACTTTCACCTCAAGC-3’ with reverse primer R1 5’-CAGGCCACCATATGTACCC-
3’ and forward primer F2 5’-CCCACATTCTTAACCCCTTG-3’ with reverse primer R2 5’-
GGAATGCTAACAGGATACCG-3’. PCR mixtures contained 1x PCR buffer, 1 mM MgCl2, 
1 unit of Biotherm DNA polymerase (GeneCraft), 0.4 mM of each dNTP (Fermentas), 
100 ng of each primer and 15 ng of genomic DNA in a total volume of 25 µl. Cycling 
parameters were 5 min at 95°C, followed by 50 cycles of 30 sec at 95°C, 30 sec at 
60°C and 2 min at 72°C, with a subsequent extension of 10 min at 72°C. PCR products 
were purified using the PCR purification kit (QIAgen). Automated sequencing was 
performed on the ABI310 genetic analyzer using the Big Dye terminator sequencing kit 
(Applied Biosystems). 
Cell culture
Human osteosarcoma cells (MNNG/HOS TE85 Clone F-5, ATCC CRL1547) were 
maintained in bicarbonate-buffered Dulbecco’s MEM/nutrient mix F12 (1:1) medium 
supplemented with 10% fetal calf serum (FCS, Life Technologies) in a 7.5% CO2 
atmosphere at 37°C.
Preparation of nuclear extracts
HOS cells were grown to confluency on 56.7 cm2 culture plates, washed once with ice-
cold phosphate-buffered saline (PBS) and harvested on ice by gentle scraping in 1 ml 
PBS. Cells were centrifuged for 15 sec at maximum speed in an Eppendorf centrifuge 
and the pellet containing the cells was resuspended in 400 µl buffer A (10 mM Hepes 
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF). The lysate was 
subsequently incubated for 15 min on ice after which 25 µl of 10% NP40 were added. 
After vortexing for 15 sec and centrifugation for another 30 sec at maximum speed 
in an Eppendorf centrifuge, the pellet containing the nuclei was resuspended in 40 µl 
buffer B (20 mM Hepes pH 7.9, 10 mM NaCl, 1 mM EDTA, 1mM EGTA, 1 mM DTT, 1 mM 
PMSF) and vortexed for 15 min at 4°C. The lysate was subsequently centrifuged for 5 
min at 4°C at maximum speed in an Eppendorf centrifuge and the pellet discarded. 
Protein concentration of the nuclear extract was determined using the Bio-Rad protein 
assay (Bio-Rad) and fractions were frozen in liquid nitrogen.   
Electrophoretic mobility shift assay (EMSA)
Complementary oligonucleotides were annealed and subsequently end-labeled using 
T4 polynucleotide kinase (Fermentas) and (γ-32P)dATP (ICN). Sequences of the forward 
oligonucleotides used are depicted in Table 1. For the EMSA, 10 µg of nuclear extract 
were incubated with 5.0 fmol of the labeled probe and 2 µg poly(dIdC) (Amersham) 
in 1x binding buffer (10 mM Hepes pH 7.9, 60 mM KCl, 4% Ficoll, 1 mM EDTA), in a final 
volume of 20 µl. Unlabeled competitor DNA was added to the binding reactions at 100-
fold molar excess where indicated. After incubating for 5 min at room temperature, 
protein-DNA complexes were separated on a pre-electrophoresed 4% non-denaturing 
polyacrylamide gel in 0.5x TBE buffer (19) at 180 V. After electrophoresis, gels were 
dried and protein-DNA complexes visualized by autoradiography. For supershift assays, 
2 or 4 µg of specific antibody (sc-229X for USF1 and sc-13842X for HES-1, Santa Cruz 
Biotechnology) were added 5 min prior to addition of the probe.
UV-crosslinking
UV-crosslinking experiments were performed using the same DNA probes as in the gel 
Chapter 4
62
PDGFRA haplotype specific transcription factors
63
shift experiments, except that five of the thymidine residues in the reverse sequence 
were substituted for bromo-deoxyuridine residues (Table 1). Binding reactions were 
performed similarly as in the EMSA except that the reactions were scaled up two-fold. 
Reaction mixtures were exposed to UV light (254 nm) for 30 min (GS Gene Linker UV 
chamber, Bio-Rad) after which samples were split in two. One half was analyzed on 
a 4% non-denaturing polyacrylamide gel and, after addition of Laemni buffer, the 
other half on a 12.5% denaturing SDS-polyacrylamide gel. Gels were dried and proteins 
crosslinked to the radiolabeled probe were visualized by autoradiography.
Results
Analysis of the upstream PDGFRA promoter region
In a Dutch control population we have previously identified five distinct PDGFRA 
promoter haplotypes, based on analysis of polymorphisms in the +118 to –1589 
promoter region (see Fig. 1). We have now analyzed the -1535 to -3600 PDGFRA 
promoter region for additional polymorphisms, and observed a T/C SNP at position 
-2795 (NCBI SNP database rs2114039) which is strictly haplotype-coupled, such that 
the T allele corresponds to all H2 haplotypes and the C allele to H1 (Fig. 1). Also, the 
strict correlation of the -1631AACTTins/del (rs10563643) with the known haplotypes 
was confirmed, such that all H2 haplotypes contained this five-nucleotide insertion, 
while the H1 allele fully lacked this sequence. The NCBI SNP data base contains five 
additional putative polymorphic sites in this region (rs17084067 at –1820; rs13114391 at 
–2563; rs13140747 at –2666; rs17084065 at –3180; rs17084062 at –3433), but we could not 
detect any of these polymorphisms in the set of individuals tested (data not shown). 
These data therefore extend the region in which polymorphisms in the PDGFRA 
promoter are linked to the H1 and H2 haplotypes to at least 3600 nucleotides upstream 
from the transcription start site. In total this region contains eight SNPs and two ins/dels 
that are linked to the five haplotypes identified (see survey Fig. 1)
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Differential protein binding to the -909A/C PDGFRA promoter polymorphism
We have previously shown that the five PDGFRA promoter haplotypes differ in their ability 
to drive luciferase expression after transient transfection into human osteosarcoma 
(HOS) cells. Osteosarcoma cells form a relevant model system, since improper bone 
formation during axial development forms a general characteristic of NTDs. In order 
to investigate if these differences in promoter activity correlate with altered binding of 
nuclear proteins to these haplotypes, we performed electrophoretic mobility shift assays 
(EMSAs) on HOS nuclear extracts using double stranded oligonucleotides of 24-29 bp 
length, each containing one of the ten identified haplotype-coupled polymorphisms 
in the –3600/+118 PDGFRA promoter region. Our data revealed differential binding 
of HOS nuclear proteins on the polymorphisms –909C/A and +68GAins/del only. The 
-909A allele is specific for the low activity H2γ haplotype, whereas the GA deletion is a 
characteristic of the low activity H1 haplotype.
Fig. 2a shows a protein complex that binds the -909C, but not the -909A allele 
(lanes 1 and 4). Addition of 100x molar excess of unlabeled -909C oligonucleotide as 
competitor resulted in an almost complete disappearance of the radiolabeled complex 
(lane 2), whereas addition of a similar excess of unlabeled -909A oligonucleotide failed 
to do so (lane 3). Addition of unlabeled competitor DNA to the -909A allele had no 
effect (lanes 5 and 6). These studies therefore identify a protein (complex) from HOS 
cells that specifically binds the -909C allele.
To identify the protein(s) in this -909C complex, we performed in silico analyses 
on the sequences surrounding the -909A/C polymorphic site with TFSEARCH (http:
//www.cbrc.jp/research/db/TFSEARCH.html).  We identified USF (upstream stimulatory 
factor) and N-MYC as potential binders to the -909C, but not to the -909A allele. When 
considering non-vertebrate transcription factors as well, the –909C but not the –909A 
allele also contains a potential binding site for Hairy, the Drosophila homolog of the 
vertebrate Hes (Hairy and Enhancer of split) family of transcription factors. Interestingly, 
both N-Myc and Hes1 have been associated with NTDs in mice (20,21), while proper 
expression of both members of the Usf family, Usf1 and Usf2, is known to be important 
for normal brain function (22). 
In order to investigate the presence of USF proteins in the -909C complex, 
Fig. 1. Promoter haplotypes resulting from polymorphisms in the -3600 /+118 region of PDGFRA. 
At the top, the nucleotide positions of the polymorphisms are indicated, and at the bottom the 
possible nucleotides at these positions and their corresponding haplotypes. The analysis was 
performed on genomic DNA from at least two individuals of each of the following haplotype 
combinations selected from a previously described control population (1): H1/H1, H1/H2α, H2α/
H2α, H2α/H2β, H2β/H2β, H2α/H2γ and H2α/H2δ.
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a competition EMSA was performed with an oligonucleotide that contains the USF 
consensus binding sequence as competitor. Fig. 2b shows that this oligonucleotide 
was able to fully compete with the radiolabeled -909C probe for binding of the 
HOS protein complex (lane 2), which suggests that the -909C complex may indeed 
contain USF proteins. Also, an EMSA with this labeled USF consensus oligonucleotide 
and HOS nuclear extracts displayed the same competition pattern as the -909C 
oligonucleotide (not shown). In addition to the major -909C binding protein complex 
(large arrow head), two minor DNA-protein complexes of higher mobility were present 
(small arrow heads) that were also specifically competed away by the USF consensus 
oligonucleotide, suggesting that these complexes contain USF proteins as well. The 
appearance of these minor complexes was only visible after a longer exposure time. 
Supershift analysis with a specific antibody against USF1 resulted in a dose-dependent 
disappearance of both the major and the minor radiolabeled complexes. However, 
no supershifts could be detected, most likely because the antibody interferes with DNA 
binding or alternatively because the supershifted complexes are not visible on the 
gel since they comigrate with other, non-specific complexes (lanes 3-4). Antibodies 
directed against the transcription factors HES1 (lanes 5-6) or N-MYC (not shown) did 
not result in a disappearance or supershift of the radiolabeled complexes. These data 
therefore identify USF1 as a component of the -909C complexes.
Differential protein binding tot the +68GAins/del PDGFRA promoter polymorphism 
Fig. 3a shows a protein complex that binds specifically to +68del oligonucleotide but 
not the +68ins oligonucleotide (lanes 1 and 4). This complex could be fully abolished by 
an excess of unlabeled +68del allele, but not or only very poorly by a similar excess of 
Fig. 2. Characterization of differential protein binding at the -909 polymorphic site. [32P]-labeled 
probes containing either -909C or -909A (see Table 1) were incubated with HOS nuclear extracts 
and protein-DNA complexes were resolved by non-denaturing gel electrophoresis. A: Protein-
DNA complexes were competed with 100x molar excess of either unlabeled -909C (C) or -909A 
(A). All samples were run on the same gel. B: Protein-DNA complexes were either competed with 
100x molar excess of an unlabeled oligonucleotide containing a USF-1 consensus binding site (U), 
or alternatively pre-incubated with increasing amounts (2 and 4 µg respectively) of antibodies 
against USF-1 or HES-1. All samples were run on the same gel. A major and two minor -909C 
specific complexes are indicated by the large and small arrow heads, respectively. Free probe is 
indicated by the hash.
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+68ins oligonucleotide (lanes 2 and 3), while addition of competitor DNA to the +68ins 
allele had no effect (lanes 5 and 6). These data indicate that HOS nuclear extracts 
contain a protein (complex) that binds with high affinity to the +68del, but with no or 
only low affinity to the +68ins allele. The eight remaining polymorphisms did not display 
differential protein binding that could be competed in a specific manner.
TFSEARCH analysis of the sequence surrounding the +68 polymorphic site did not 
reveal potential binding sites for known transcription factors. Therefore, we determined 
the molecular weight of the protein complex by a UV-crosslinking experiment in which 
five of the thymidines in the +68del and +68ins oligonucleotides had been replaced by 
bromo-deoxyuridines (BrdUs). To verify the specificity of the UV-crosslinked complex, we 
first carried out EMSAs to confirm that thymidine replacement by bromo-deoxyuridine 
and subsequent UV-crosslinking did not alter the EMSA competition pattern. 
Fig. 3b shows that the +68del complex can still be detected after UV-
crosslinking and that the formation of the radiolabeled complex is prevented if prior to 
crosslinking an excess of unlabeled +68del but not of  +68ins oligonucleotide is added, 
similarly as in the non-crosslinked EMSA (lanes 1-3). Addition of specific competitor DNA 
after crosslinking left most of the +68del complex intact, indicating that crosslinking was 
successful (lane 4). 
Subsequent SDS-PAGE analysis of the crosslinked material showed multiple 
radiolabeled bands (Fig. 3c) of which the one with molecular weight around 140 kDa 
displayed a similar competition pattern as in the EMSA. This suggests that this band 
contains proteins that are also present in the +68del EMSA complex. Since this 140 
Fig. 3. Characterization of differential protein binding at the +68 polymorphic site. 
A: [32P]-labeled probes containing either the +68GAins or +68GAdel (see Table 1) were incubated 
with HOS nuclear extracts. Protein-DNA complexes were competed with 100x molar excess of 
unlabeled +68GAdel (del) or +68GAins (ins) oligonucleotides and resolved by non-denaturing gel 
electrophoresis. All samples were run on the same gel. B, C: HOS nuclear proteins binding to the 
+68GAdel probe containing five bromodeoxyuridine substitutions (see Table 1) were UV-crosslinked 
and resolved by non-denaturing gel electrophoresis (B) and denaturing gel electrophoresis (C) 
as described. The asterisk indicates addition of 100x fold molar excess of unlabeled +68GAdel 
oligonucleotide after crosslinking. The +68GAdel specific complex is indicated by the arrowhead 
and the free probe by the hash. Molecular weights are indicated in kDa. 
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kDa band reflects the weight of the bound protein together with the double stranded 
probe (15 kDa), the molecular weight of the +68del binding protein(s) will most likely 
be around 125 kDa.  UV crosslinking of the -909C interacting proteins was unsuccessful, 
and therefore we were unable to confirm the molecular weight of USF1 complexes.
Discussion
Single nucleotide polymorphisms in regulatory DNA sequences may alter gene 
expression by influencing the binding affinity of transcription factors. Therefore, such 
SNPs could play an important role in an individual’s susceptibility to complex diseases. 
Based on our previous observation that polymorphisms in the promoter of the human 
PDGFRA gene can be correlated with the risk of neural tube defects, we have 
extended the investigated promoter region to –3600 bp relative to the transcription 
start site and shown that it contains a total of eight SNPs and two ins/dels, which 
give rise to five distinct promoter haplotypes. It has been established that stable, 
heritable haplotypes can extend over many centi-Morgans (23). In a recent whole-
genome analysis of common DNA variation patterns, it has been shown that at least in 
Caucasians PDGFRA promoter haplotypes extend from –36 to +8 kb relative to exon 1 
(24). We have confirmed that three SNPs located approximately 7 kb downstream from 
the transcription start site (rs7678144, rs6554163 and rs6836215) are indeed still coupled 
to these promoter haplotypes. 
EMSA analyses revealed that two of the polymorphic sites in the -3600/+118 
PDGFRA promoter region, i.e. -909C/A and +68GAins/del, show differential binding of 
nuclear proteins from the HOS human osteosarcoma cells, an in vitro model system for 
bone formation during axial development. USF1 could be identified as a component 
of the –909C complexes, while the protein complex binding to +68GAdel was 
characterized to have a molecular weight of approximately 125 kDa. The differential 
protein binding at these two sites correlates with the low promoter activities of both the 
H1 and H2γ haplotypes compared to H2α and H2β. Zhu et al. (6) also observed a low 
promoter activity for H2γ relative to H2α upon transfection into U2OS cells, but found a 
similarly high promoter activity for both haplotypes  in MCF-7 and HeLa cells, indicating 
that the activity of PDGFRA promoter haplotypes is clearly cell type dependent (see 
also (3)) . HeLa cells are known to contain functional USF proteins, while on the other 
hand USF proteins obtained from human SAOS osteosarcoma cells, although capable 
of binding to DNA, are not transcriptionally active (25). It is therefore well realized that 
our data do not provide direct functional evidence that USF proteins are involved in 
the different activities of the PDGFRA promoter haplotypes.
USF proteins are ubiquitously expressed transcription factors of the basic-
helix-loop-helix/leucine zipper (bHLH-zip) family and are encoded by two genes, USF1 
and USF2.  Both genes can give rise to two proteins by means of alternative splicing; 
USF1 and USF1/BD are encoded by the USF1 gene, whereas USF2a and USF2b are 
encoded by the USF2 gene (26,27,28). USFs bind DNA as dimers, such that under in vivo 
conditions over 66% of the USF binding activity is present as USF1-USF2a heterodimers, 
whereas homodimers of either USF1 or USF2a contribute for approximately 10% and 7% 
respectively, while USF1-USF2b heterodimers can account for up to 15% in some cells 
(28). Moreover, it is known that USF1-USF2a heterodimers display the lowest mobility on 
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EMSA of all USF1 containing dimers, including USF1-USF1, USF1-USF2b, USF1-USF1/BD and 
USF1/BD-USF1/BD (25,28,27). Most likely, the identified major USF1-containing complex 
that binds the -909C polymorphic site is therefore a USF1-USF2a heterodimer, while the 
two minor complexes may represent two of the higher mobility USF1 dimers.
We have previously postulated that aberrant transcription of PDGFRA can 
enhance the risk of neural tube defects. Aberrant transcription may result from a 
combination of promoter polymorphisms and the proper availability of trans-acting 
factors. As a result, not only PDGFRA itself but also genes encoding upstream regulators 
of PDGFRA can be associated with such diseases. Although a number of nuclear 
transcription factors are known that affect PDGFRA expression, such as PAX1 (10), 
PAX3 (11-13), GATA4 (29) and C/EBPs (30,31), a direct interaction of these factors with 
specific promoter regions has only been shown in a limited number of studies (15,16). 
The present approach differs from these previous studies, in that we have used DNA-
protein complex formation as a starting point of our analysis to identify controlling 
elements in the promoter. In addition to our observation that USF1 can specifically bind 
the PDGFRA promoter at the –909C position, it has recently been shown in PSFK-1 cells 
that the zinc finger protein ZNF148 can differentially bind the -1074C/A SNP, whereby 
it recognizes all haplotypes except H2δ. Interestingly, H2δ has been shown  to be 
overrepresented in patients with PNETs and ependymoma brain tumors (3). 
Loss of one Pdgfra allele in combination with a mutated upstream regulator 
Pax1 results in extensive neural tube defects (8). In the light of the role of both Pdgfra 
and Usf genes in axial and neural development, it would be very interesting to study if 
Pdgfra (+/-)/Usf1 (-/-) and Pdgfra (+/-)/Usf2 (-/-) mice indeed show neural tube defects. 
Since H1 has a low promoter activity compared to H2α, the +68GAdel binding protein 
complex potentially acts as an H1 specific repressor of PDGFRA transcription. Using a 
transcription factor trapping approach (32), we are currently isolating larger amounts 
of this protein(s), to allow its identification by the use of mass spectrometry techniques. 
It will be very interesting to see if the corresponding gene can be associated directly 
with neural tube defects. Deregulated expression of PDGFRA has also been associated 
with various neoplasias, including osteosarcomas (33), chondrosarcomas (34), 
gastrointestinal stromal tumors (35) and glia brain tumors (36-40).  It will be of great 
importance to study if the risk for development of such tumors can also be associated 
with PDGFRA promoter haplotypes and upstream regulators of this gene.
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Abstract 
Aberrant expression of the platelet-derived growth factor α-receptor (PDGFRA) gene 
has been associated with various diseases, including neural tube defects and glioma 
malignancies. We have previously shown that the promoter region of the human 
PDGFRA gene contains several polymorphisms which can be grouped into five distinct 
haplotypes, designated H1, H2α, H2β, H2γ and H2δ, of which H1 and H2α are the most 
common. Transient transfection studies have indicated that H1 mediates low and 
H2α high transcriptional activity. In the present study we have investigated the role 
of these PDGFRA promoter polymorphisms in gliomagenesis, both at the cellular and 
genetic level. Our results show that in three out of four H1/H2α heterozygous human 
glioblastoma cell lines tested, the H1-derived mRNA levels are more than 10-fold lower 
than those from H2α, resulting in near monoallelic expression of the H2α allele. This 
appeared to result at least in part from haplotype-specific differences in epigenetic 
regulation, i.e. DNA methylation and histone acetylation. Furthermore, in a case-control 
study on a panel of 71 glioblastoma patients we observed an underrepresentation of 
H1 alleles which was significant when compared to a combined Western European 
control group (n=998, p<0.05). Together, these results indicate that PDGFRA promoter 
haplotypes may provide a genetic predisposition for gliomagenesis. In combination 
with published data on Pdgfra transgenic mice, we propose a model in which PDGFRA 
promoter polymorphisms control the upregulation of PDGFRA during differentiation of 
neural stem cells into glia cells, and thereby the pool size of cells that can undergo 
gliomagenesis.  
Introduction 
Platelet-derived growth factor α-receptor (PDGFRA) signaling plays an important role 
in normal neural development, as well as in the pathogenesis of various disorders of 
the central nervous system. Platelet-derived growth factors (PDGFs) act as potent 
mitogens and chemo-attractants for oligodendrocyte precursor cells (OPCs/O2A cells) 
both in vitro (1-3) and in vivo (4, 5). Mouse OPCs express Pdgfra at high levels (6, 7) and 
its expression level directly affects OPC proliferation and differentiation in vivo (8, 9). 
Defective Pdgfra signaling in transgenic mice leads to various developmental defects, 
including neural tube defects (NTDs) such as spina bifida, and severe hypomyelination 
as a result of impaired oligodendrocyte development (4, 8, 10-13). On the other hand, 
different types of human gliomas and glioma cell lines co-express PDGFs with PDGFRA 
(14-16). In the mouse, constitutive Pdgfra activation by overexpression of its ligand gene 
Pdgfb results in gliomagenesis, whereby the amount of PDGF signaling correlates with 
glioma grade (17-20), whereas in humans malignant gliomas often show amplification 
of PDGFRA (21-25). This suggests that reduced PDGFRA signaling may lead to neural 
tube defects and hypomyelination, while on the other hand increased PDGFRA 
signaling may be involved in the initiation and progression of gliomas. 
DNA polymorphisms such as small DNA insertion/deletions (ins/del) and single 
nucleotide polymorphisms (SNPs) in regulatory DNA sequences are believed to play an 
important role in the regulation of expression levels of the corresponding genes, and 
as a consequence they may directly affect the susceptibility of individuals for diseases 
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related to those genes. We have previously shown that the –3600/+118 promoter 
region of PDGFRA contains a total of ten polymorphic sites that give rise to five distinct 
haplotypes, designated H1, H2α, H2β, H2γ and H2δ (26, 27). H1 and H2α, which differ 
in eight out of these ten positions (26-29), are the two most common haplotypes, with 
allele frequencies of 21% and 68%, respectively, in the Western European population 
(26, 29-31). Upon transient transfection into human osteosarcoma cells, H2α displayed 
a three- to six-fold higher promoter activity than H1 (26, 28). We ((26); M. Toepoel, 
R.P.M. Steegers-Theunissen and E.J.J. van Zoelen, unpublished) and others (28, 29) have 
found an increased H1 frequency in a population of patients with NTDs, suggesting that 
individuals with the H1 haplotype have an increased risk of developing diseases that 
are characteristic for reduced PDGFRA signaling. 
In the present study we have tested the hypothesis that polymorphisms in the 
PDGFRA promoter region may contribute to the genetic predisposition of individuals 
to develop glioblastoma multiforme, the most common and most aggressive form of 
primary brain tumors (32). In H1/H2 heterozygous glioblastoma cell lines in culture we 
determined the endogenous activity of both promoter alleles by the use of a newly 
developed technique. Our data show that in three out of four cell lines tested the H1 
allele displays very low transcriptional activity compared to the H2α allele, which is 
paralleled by differences in epigenetic regulation. Moreover, in a panel of glioblastoma 
patients, we observed a reduced frequency of the H1 allele, which suggests that the 
low activity H1 allele may protect against gliomagenesis. These results identify PDGFRA 
promoter haplotypes as an important genetic factor in the predisposition for gliomas.   
 
Materials and Methods
 
Cell culture and drug treatment
U-251 MGsp, U-343 MGa 31L, U-343 MGa Cl2:6 and U-410 MG human glioblastoma cells 
(33-35) were maintained in bicarbonate-buffered Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% newborn calf serum (NCS; Invitrogen, Carlsbad, 
CA), penicillin (100 U/ml), and streptomycin (100 µg/ml) in a humidified atmosphere 
containing 7.5% CO2. For treatment of cells with 5-azacytidine (5AC) and trichostatin A 
(TSA), both obtained from Sigma-Aldrich (St-Louis, MO), cells were seeded at a density 
of 2.0 x 105 cells/cm2, with daily medium refreshment. One day after seeding, cells were 
incubated for 48 hours in medium with or without 5AC (1 µM), and subsequently for an 
additional 24 hours with or without 5AC and/or TSA (0.5 µM).
DNA, RNA isolation and cDNA synthesis
Cultured cells were grown to confluency in a 9.6 cm2 dish, genomic DNA (gDNA) 
was isolated using the Wizard Genomic DNA Purification kit (Promega, Madison, WI). 
Total RNA was isolated from cells grown in monolayer using Trizol Reagent (Invitrogen) 
according to the manufacturer’s protocol. DNA and RNA concentrations were 
determined by measuring the absorbance at 260 nm. Total RNA (1 µg) was reverse 
transcribed using random hexamer primers (Amersham–Pharmacia, United Kingdom) 
in a total volume of 50 µl, using the SUPERSCRIPT II reverse transcriptase kit (Invitrogen). 
RNA from glioblastoma tumor samples was extracted, purified and reverse transcribed 
as described elsewhere (36).
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Polymerase Chain Reaction (PCR) for allele specificity
Forward primer exon1F (5’-GGAGCTACAGGGAGAGAAAC-3’) was end-labeled 
using T4 polynucleotide kinase (Fermentas, Burlington, Ontario) and [γ-32P]dATP 
(ICN, Irvine, CA), and subsequently purified over a Sephadex G50 column. PDGFRA 
cDNA and gDNA was amplified using labeled forward primer exon1F and reverse 
primer exon3R (5’-AAAGCTGGCAGAGGATTAGG-3’) or reverse primer intron1R (5’-
GACACACAACTGGAATCCAG-3’) respectively. PCR mixtures contained 1x PCR 
buffer, 1 mM MgCl2, 1 unit of Biotherm DNA polymerase (GeneCraft, Germany), 0.4 mM 
of each dNTP (Fermentas), 100 ng of each primer and 15 ng of genomic DNA or 1-5 µl 
of cDNA in a total volume of 25 µl. Cycling parameters were 5 min at 95°C, followed 
by 30-40 cycles of 30 sec at 95°C, 30 sec at 62°C and 1 min at 72°C, with a subsequent 
extension of 10 min at 72°C. 
Sample preparation and polyacrylamide gel electrophoresis
PCR products were digested for one hour at 37°C with 2 units of BsuRI/HaeIII 
(Fermentas). Subsequently, 5 µl of digested PCR product were precipitated by addition 
of 15 µl H2O (milliQ),  2 µl of 3 M NaAc pH 5.2 and 50 µl of 96% ethanol for at least 30 min 
at -20°C, and subsequently centrifuged for 30 min at maximum speed in an Eppendorf 
centrifuge. The pellet was washed twice with 70% ethanol, dried and dissolved in 3 µl of 
formamide loading buffer (98% deionized formamide, 10 mM EDTA, bromophenolblue 
and xylene cyanole). Just prior to electrophoresis, the samples were incubated for 5 
min at 96°C and immediately chilled in an ice-water bath. Samples were analyzed on 
a pre-electrophoresed 13% acrylamide gel containing 8 M urea (37) at 75W, until the 
xylene cyanole had run to the bottom of the gel. After electrophoresis, the gel was fixed 
for 45 min in 10% methanol/10% HAc and vacuum dried for 30 min at 85°C. Digested 
PCR products were visualized and quantified by analysis on a Personal Molecular 
Imager FX System with Quantity One software (BioRad, Hercules, CA).                     
Real-time quantitative PCR
Real-time quantitative RT-PCR on 2-5 µl cDNA  with primers PDGFRA-F (5’-
AAAGAAGTTCCAGACCATCCC-3’) x PDGFRA-R (5’-AGGTGACCACAATCGTTTCC-
3’) and β-actin-F (5’-GAAGAGCTACGAGCTGCCTGA-3’) x β-actin-R (5’-
GAACCGCTCATTGCCAATG-3’) and calculation of expression values was performed 
as described (38).
Bisulphite sequencing
A total of 1 µg of gDNA was converted with the EZ DNA Methylation kit (Zymo Research, 
Orange, CA) according to the manufacturer’s protocol, after which a PCR reaction 
was performed on 50 ng of the converted DNA with primers F-1064CpG (5’-GTTTAGGTT
TGGTTTTTGGAGTATTAG-3’) and R-732CpG (5’-ACCTTTACTCCCTTAAAATCACTTATC-3’) 
designed to recognize bisulphite-modified DNA only. PCR conditions were the same 
as above. Next, 1-2 µl of PCR product were ligated into pCR2.1 using the TA-cloning 
kit (Invitrogen) and individual clones were sequenced on an ABI310 genetic analyzer 
using the Big Dye terminator sequencing kit (Applied Biosystems, Foster City, CA). 
Population studies and haplotype determination
Tumor and peripheral blood samples from German glioblastoma multiforme (WHO 
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grade IV) patients, as well as from age and sex matched German blood donors were 
obtained as described (23), following the approval of the local institutional review 
board of the Heinrich-Heine-University (Düsseldorf, Germany). DNA was extracted from 
these samples as described (36). Genomic DNA from Dutch and Northern Irish controls 
were obtained as described (30, 39, 40). For haplotype determination, a PCR reaction 
was performed on genomic DNA with primer -1651F (5’-AGCCTAAAAACCCGGTTCTC-
3’) and -727R (5’-TCCCTTGAAGTCACTTATCTG-3’) under similar PCR conditions as 
above. PCR products were purified using the PCR purification kit (QIAgen, Germany). 
Automated sequencing was performed on the ABI310 genetic analyzer using the Big 
Dye terminator sequencing kit (Applied Biosystems).
Results
Haplotype-specific PDGFRA expression and gene amplification in human glioblastoma 
cell lines 
Transient transfection assays are frequently used to study the role of promoter 
polymorphisms in transcriptional activity, but such assays do not take into account 
the epigenetic control of gene expression within its physiological chromatin context. 
We have therefore developed an assay that permits quantification of endogenous 
haplotype-specific PDGFRA expression levels, as well as of haplotype-specific PDGFRA 
gene amplification. This assay is based on the observation that one of the polymorphisms 
that discriminates H1 from all H2 haplotypes, the GA insertion/deletion (ins/del) in non-
coding exon 1, is transcribed and can thus be used to determine the haplotype origin 
of PDGFRA transcripts (26-29). Following a PCR reaction with a radiolabeled forward 
primer that anneals just 5’ of the GA ins/del and an unlabeled reverse primer that 
anneals in exon 3 (for cDNA) or in intron 1 (for genomic DNA, gDNA), and subsequent 
cleavage with BsuRI/HaeIII just 3’ of the ins/del, a blunt product of 49 bp product was 
obtained for H1 and a 51 bp product for all H2 haplotypes (Fig. 1A), of which the 
relative amounts were quantified by molecular imager analysis after separation by 
denaturing gel electrophoresis. Most reliable results were obtained with a polymerase 
that has the ability to add adenosines to the 3’ end of each formed product, and 
consequently we obtained products of both 51 and 52 nt for H2, and of 49 and 50 nt 
for H1, depending on the efficiency of the polymerase after cleavage. To determine 
the relative intensities of H1 and H2, we summed up the intensities of the two bands for 
each haplotype. 
 When applying this technique to primary human fibroblasts obtained from 
healthy individuals of three different PDGFRA genotypes, i.e. H1/H1, H1/H2α and 
H2α/H2α, the two homozygous cell lines showed only expression of their corresponding 
haplotype, whereas in the heterozygous fibroblasts the H1 and H2α promoter allele 
induced equal transcript levels, as shown in Fig. 1B and quantified in Fig. 1C (upper 
panel). At the genomic level, the homo- and heterozygosity of the three cell lines was 
confirmed, with equal amounts of H1 and H2α DNA in the heterozygous cells (Fig. 1B 
and 1C, lower panel). Thus, unlike previous observations with promoter transfection 
studies in human osteosarcoma cells, no difference was observed in endogenous H1 
and H2α activity in primary fibroblasts. 
To study the role of PDGFRA expression in gliomagenesis, we subsequently 
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analyzed H1/H2 heterozygous human glioblastoma cell lines for haplotype-specific 
PDGFRA expression. Three out of the four H1/H2α heterozygous cell lines thus identified, 
designated U-251 MGsp, U-343 MGa 31L  and U-343 MGa Cl2:6 (hereafter referred to 
as U-251, 31L  and Cl2:6 respectively), displayed only very low H1 activity, resulting in 
near monoallelic expression of the H2α allele (see Fig. 2A, upper panel). Only the U-
410 MG cell line (hereafter referred to as U-410) exhibited equal expression levels of 
both alleles. Quantification revealed that only 2, 15 and 13%, respectively, of the total 
PDGFRA mRNA level in U-251, 31L and Cl2:6 cells resulted from H1 activity, compared 
to 52% in U-410 cells (see Fig. 2B, upper panel). Thus, it appears that in three out of 
the four heterozygous glioblastoma cell lines tested the H1 allele is strongly repressed 
compared to H2α.
Since PDGFRA is often amplified in gliomas, we also analyzed these cells for 
haplotype-specific PDGFRA amplification. It is known that these cell lines show aberrant 
karyotypes with amplifications of the 4q12 chromosomal region which includes PDGFRA 
(41). Figure 2A (lower panel) shows that in U-251 and 31L cells, H2α DNA is clearly more 
Figure 1. Haplotype-specific PDGFRA expression and gene amplification. A: Schematic 
representation of the two main PDGFRA haplotypes H1 and H2α and the location of the primers 
for amplification of cDNA and genomic DNA (gDNA). Due to the haplotype coupled GA ins/del 
in exon 1, HaeIII/BsuRI (indicated by the scissors) digested amplicons of H1 are 49/50 bp and of 
H2α 51/52 bp respectively (see arrows in B). B: Denaturing gel electrophoresis of digested PCR 
fragments from cDNA and gDNA isolated from primary fibroblasts with haplotype combinations 
H1/H1, H1/H2α and H2α/H2α. In the first lane (bl) no template was used. C: Quantification of band 
intensities by molecular imager analysis. The sum of the intensities of the H1 and H2α bands was 
set to 100%. The percentage of H1 is represented by the black bars and the percentage of H2α 
by the white bars.
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abundant than H1 (33% and 31% H1, respectively; see Fig. 2B, lower panel), whereas in 
Cl2:6 H1 is more abundant than H2α (60% H1), while equal copy numbers appear to be 
present in U-410 cells (50% H1). It therefore appears that in spite of the H1 amplification 
in Cl2:6 cells, the H2α allele gives rise to higher PDGFRA mRNA levels than the H1 alleles 
combined. On the other hand the relative amplification of the H2α allele in U-251 and 
31L cells does not account for the relatively low activity of H1 in these cells.  
 In order to verify that the different expression levels of H1 and H2α are an intrinsic 
property of the U-251, 31L and Cl2:6 cell lines and do not result from cell heterogeneity 
in culture, we subcloned each of these cell lines by limiting dilution. Twelve clones of 
each cell line were analyzed and all appeared to display the same haplotype-specific 
expression profile as the parental cells (data not shown), indicating that either all cells 
in the original culture behaved similarly in terms of haplotype-specific expression, or 
that the cell populations grown from the individual clones had differentiated again into 
the same heterogeneous population.
 The present assay gives only information about the ratio of H1 and H2 activity, 
and therefore we combined this analysis with real-time quantitative RT-PCR to examine 
total PDGFRA expression levels in these cells. This revealed great differences in basal 
PDGFRA expression levels between the various cell lines, with the highest value relative 
to the β-actin house-keeping gene for U-410 (0.2), followed by 31L (0.02), U-251 (0.001) 
and Cl2:6 (0.0004). It therefore appears that in U-410 cells both the H1 and H2α allele 
are much higher expressed than in each of the other cell lines. These data agree with 
Figure 2. Haplotype-specific PDGFRA expression and gene amplification in four H1/H2α 
heterozygous human glioblastoma cell lines. A: Denaturing gel electrophoresis of digested PCR 
fragments from cDNA and gDNA isolated from Cl2:6, U-251, 31L and U-410 cells; bl: no template 
used. B: Quantification of the relative intensities of the H1 and H2α bands. The percentage of H1 is 
represented by the black bars and the percentage of H2α by the white bars. 
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previous studies on the expression level of PDGFRA in these cells at both the protein 
and mRNA level (42), with the exception of the 31L cell line for which we have used 
another subclone.
Haplotype-specific epigenetic regulation of PDGFRA expression
To investigate whether epigenetic regulation is involved in the observed repression 
of the H1 allele in U-251, 31L and Cl2:6 cells, cultures were treated with the DNA 
demethylating agent 5-azacytidine (5AC) and the histone deacetylase inhibitor 
trichostatin A (TSA). Figure 3A shows that particularly in U-251 and Cl2:6 cells the relative 
Figure 3. Effect of 5-azacytidine (5AC; 1 µM) and trichostatin A (TSA; 0.5 µM) on haplotype-specific 
and total PDGFRA expression. Glioblastoma cells were cultured for 2 days in the presence or 
absence of 5AC followed by an additional day in the presence or absence of 5AC and/or TSA. 
A: Gel electrophoretic separation of expressed PDGFRA haplotypes; bl: no template used. B: 
Quantitative analysis of haplotype-specific PDGFRA expression. Total PDGFRA expression relative 
to β-actin was determined by quantitative RT-PCR, multiplied by the fraction of haplotype-specific 
expression and corrected for the haplotype copy number (with the untreated H1 activity set to 1). 
H1 is represented by the black bars and H2α by the white bars.
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expression of H1 is enhanced by this treatment. 
Figure 3B shows the absolute expression levels of the individual H1 and H2α 
alleles in these glioblastoma cell lines, relative to β-actin, corrected for the observed 
differences in relative haplotype copy number (obtained from Fig. 2B). In the absence 
of 5AC and TSA, an 11-fold enhanced expression of H2α compared to H1 is observed 
in U-251 cells, reaching a 12-fold difference in 31L cells and a 17-fold difference in Cl2:
6 cells. Upon treatment of the cells with 5AC and TSA, not only the expression level of 
both the H1 and H2α allele is increased, particularly in U-251 and Cl2:6 cells, but also 
the relative expression of H1 compared to H2α, resulting in only a two-fold difference 
in expression level in Cl2:6 cells after the combined treatment. TSA appeared toxic for 
the 31L and U-410 cells, and 5AC particularly for 31L cells, as judged from the decrease 
in total PDGFRA expression and the large amount of dead cells after treatment. These 
data indicate that epigenetic regulation controls at least in part the difference in 
activity between the H1 and H2α allele in these glioblastoma cells, although under all 
conditions tested H2α remained more active than H1.
Haplotype-specific PDGFRA promoter methylation 
The observed low activity of H1 as compared to H2α in these heterozygous glioblastoma 
cells may result from differences in CpG methylation of the respective promoter alleles. 
The -3600/+118 PDGFRA promoter contains two putative CpG islands, i.e. regions with 
a relatively high CpG content, ranging from -2482 to -2172 and from -1119 to -722 (http:
//www.ebi.ac.uk/emboss/cpgplot/). Only the latter CpG island contains polymorphic 
sites that discriminate between H1 and H2α (-957G/A and -794G/T), and therefore we 
analyzed this promoter region for haplotype-specific CpG methylation by bisulphite 
sequencing. 
Figure 4 shows the CpG methylation patterns of the H1 and H2α -1020/-748 
promoter region, which contains a total of 23 CpG residues, of the four glioblastoma 
Figure 4. Haplotype-specific CpG methylation in the -1020/-748 PDGFRA promoter region. 
Methylation patterns were determined from at least ten clones for each normal or overrepresented 
allele, and at least four clones for underrepresented alleles. Results have been averaged for each 
CpG position, in which open circles represent less than 25% methylation, gray circles represent 
methylation between 25% and 75%, and black circles represent methylation of 75% and more. 
Nucleotide positions of the CpGs are indicated. 
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cell lines. Haplotype-specific CpG methylation patterns were observed in all three H1 
repressing cell lines U-251, 31L and Cl2:6, whereby H1 was methylated more frequently 
and on more positions than H2α. Differential methylation was particularly evident in 
Cl2:6 cells, where all 23 CpG residues of the H1 allele were mostly methylated, whereas 
H2α showed only frequent methylation on the four most 3’ located CpG residues. 
These data show that in heterozygous cells the two alleles of a specific gene can 
strongly differ in their methylation status. By contrast, none of the 23 CpG residues were 
methylated in U-410 cells on either allele, which corresponds well with the high total 
PDGFRA expression level in these cells, equally distributed over both haplotypes. In 
conclusion, hypermethylation of H1 compared to H2α can explain at least in part the 
differential expression of both haplotypes in the three H1 repressing glioma cell lines.  
H1 frequencies and risk of glioblastoma formation
We subsequently analyzed the PDGFRA promoter haplotype distribution in blood 
samples of a group of 71 patients with glioblastoma multiforme and a group of 44 
matched controls, both from Germany (Düsseldorf). The H1 is a relatively rare allele 
in Caucasian control populations (approximately 21%), and therefore large patient 
and matched control groups are required to establish a significant deviation. We 
therefore used the strategy to show that the present control group is highly similar to a 
large Western European control group, while the patient group significantly deviates 
from this Western European control group. Table I shows the distribution of three new 
control cohorts (146 from Nijmegen, the Netherlands; 98 from Belfast, UK; and 44 from 
Düsseldorf, Germany), that were each selected as matched controls for comparison 
with a specific patient cohort (suffering from spina bifida, coronary heart disease and 
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glioblastoma, respectively). The data show that these three control groups have a very 
similar overall distribution of haplotype combinations, although intriguing differences 
were observed in the frequency of some rare allele combinations, such as H1/H2β in 
the Northern Irish group, and of H2α/H2β and H2α/H2γ in the German control group. 
The frequency of H1 in these control populations ranged from 0.202 to 0.219, which 
is very similar to comparable studies on a Swedish (pH1= 0.197; 91 individuals) (31) 
and French (pH1= 0.214; 619 individuals) (30) control population. It can therefore be 
concluded that the H1 incidence in the Western European population is very constant, 
with an average value of pH1=0.211 based on 998 individuals. 
Table I also shows that the PDGFRA promoter haplotype distribution in 
blood samples of the 71 patients with glioblastoma multiforme corresponds to an H1 
frequency of only 0.141, which is significantly lower (p<0.05; see Table II) than that in the 
Western European control population (pH1=0.211) and also lower than in the matched 
German matched control group (pH1=0.205). These data show that the H1 allele is 
underrepresented in glioblastoma patients. Because of the low incidence of H2γ and 
H2δ, similar statistics were obtained when the frequencies of alleles with high (H2α and 
H2β) and low (H1, H2γ and H2δ) activity were compared (data not shown). Although 
larger groups of patients and matched controls will be required to further optimize 
the statistical analysis, still these data indicate that individuals with an H1 allele show a 
decreased risk of developing glioblastomas. 
Haplotype-specific PDGFRA expression in glioblastoma tumors
Increasing evidence indicates that in addition to a large excess of more differentiated 
glia-like cells, glioblastomas also contain a small fraction of tumor stem cells from which 
these more differentiated cells have been derived. Such glioma stem cells have been 
shown to resemble neural stem cells or early glia progenitor cells in many respects (43). 
To investigate total and haplotype-specific PDGFRA expression in surgically removed 
glioblastoma tissue, we analyzed specifically the H1/H2 heterozygous glioblastoma 
samples from the German patient group (14 out of the above 71 cases). Based on 
histological criteria, the tissue samples contained more than 80% tumor cells (data not 
shown). Proper RNA was available from 12 out of the 14 heterozygous tumors. As shown 
in Figure 5A, all samples expressed both haplotypes with at maximum a 2-fold higher 
expression of H2 compared to H1 (GB26D). Only in the case of GB96D expression of 
H1 appeared to be higher than that of H2. Total PDGFRA expression levels relative to 
β-actin in these tumors varied from 0.02 (GB5D) to 0.4 (GB4D), as shown in Figure 5B. 
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These high expression levels in combination with the observation that both alleles are 
active, indicate that with respect to PDGFRA expression the majority of cells in these 
tumors show more resemblance to the U-410 cells than to the other three cell lines 
studied.
Discussion
In the present study we have shown that in H1/H2α heterozygous primary human 
fibroblasts both PDGFRA alleles show similar transcriptional activity, while in three out 
of four heterozygous human glioblastoma cell lines the H1 allele has more than 10-
fold lower activity than H2α, resulting in near monoallelic expression of the H2α allele. 
Mono-allelic expression is known to occur as a result of genomic imprinting, during 
X-chromosome inactivation and upon allelic exclusion of genes in the immune and 
olfactory system (44). The lower activity of the H1 allele in the glioblastoma cell lines 
cells is associated with allele-specific DNA methylation and histone deacetylation, thus 
providing an epigenetic basis for the transcriptional repression. To our knowledge, the 
present study is the first to show that promoter polymorphisms can result in an almost 
complete silencing of one of the alleles. In combination with our observation of a 
reduced H1 frequency in a group of glioblastoma patients, our results suggest that 
the epigenetic repression of the PDGFRA H1 allele is correlated with a reduced risk of 
Figure 5. Quantitative haplotype-specific PDGFRA expression in H1/H2 heterozygous glioblastoma 
samples. A: Gel electrophoretic separation of expressed PDGFRA haplotypes; bl: no template 
used. B: Quantitative analysis of haplotype-specific PDGFRA expression, relative to β-actin. H1 is 
represented by the black bars and H2 by the white bars.
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glioblastoma development. 
Promoter methylation and gene silencing 
The removal of DNA methylation and inhibition of histone deacetylation in the 
glioblastoma cell lines U-251, 31L and Cl2:6 by treatment with 5AC and TSA resulted 
in a derepression of H1 expression to approximately 50% of the level of H2α. It is 
known that CpG methylation can repress transcription by interfering with binding of 
transcription factors and by recruiting histone deacetylase (HDAC) family members via 
methyl-CpG binding proteins (44). The observation that both PDGFRA promoter alleles 
are fully demethylated in U-410, but partly methylated in U-251, 31L and Cl2:6 cells, 
parallels the observed differences in total PDGFRA expression levels. When comparing 
the methylation status of the H1 and H2α alleles in these various cell lines with their 
transcriptional activity, a clear parallel is observed in Cl2:6 and U-410 cells, but much 
less so in 31L and U-251 cells. However, it has been shown previously that methylation of 
only a few CpGs can significantly downregulate promoter activity (45), and therefore 
even minor differences in the haplotype-specific PDGFRA methylation in 31L cells 
might explain the observed 12-fold lower expression of H1 compared to H2α. The 
observation that treatment with 5AC and TSA results in only a partial derepression of H1, 
when compared to H2α, indicates that besides epigenetic regulation also additional 
mechanisms may be involved in the differential expression of H1 and H2α. Due to the 
polymorphic sites, transcription factors could differentially bind the PDGFRA promoter 
haplotypes, as has been shown for USF-1 in human osteosarcoma cells (27) and ZNF-
148 in PNET cells (31). However, thus far we have not observed qualitative differences in 
nuclear protein binding to any of the polymorphisms in the -3600/+118 promoter region 
based on electrophoretic mobility shift assays with nuclear extracts from U-251, 31L and 
Cl2:6 cells (data not shown). 
H1 frequency and disease incidence
There is increasing evidence that promoter polymorphisms form the genetic basis 
for differences in gene expression patterns between individuals and thereby affect 
their predisposition for various multifactorial diseases. Previous studies have shown 
that patients with NTDs show an enhanced frequency of the PDGFRA H1 allele (26, 
28, 29), while our current case-control study indicates that glioblastoma patients 
have a reduced frequency of the H1 allele. This suggests that low PDGFRA activity 
as a result of promoter polymorphisms may increase the risk of improper neural tube 
development, but at the same time reduce the risk of gliomagenesis later in life. These 
observations agree with data on the incidence of these diseases in various racial 
groups in the USA. From a recent study on genome wide distribution of haplotypes in 
USA control populations, H1 frequencies of 0.30, 0.25 and 0.20 could be calculated 
for African Americans, European Americans and Asian Americans respectively (46). 
Interestingly, African Americans have a significantly lower incidence of brain tumors 
than Caucasians (32, 47, 48). Furthermore, Hispanics have the highest incidence of 
neural tube defects in the USA (49, 50), which is paralleled by a high H1 frequency of 
0.31 in the control population and of 0.36 in spina bifida patients (28). Interestingly, a 
significant overrepresentation of the rare H2δ haplotype has recently been observed 
in patients with primitive neuroectodermal tumors and ependymomas (31). Taken 
together, these observations provide a strong link between PDGFRA expression levels 
and the occurrence of central nervous system diseases.
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PDGFRA expression and tumorigenesis
Our results indicate that PDGFRA expression levels provide a predisposition for 
gliomagenesis in humans. Studies on transgenic mice have shown that constitutive 
autocrine Pdgfra activation is sufficient to induce gliomagenesis, whereby the extent 
of PDGF signaling corresponds with tumor malignancy (17-20). Pdgfra expression 
is strongly upregulated upon differentiation of neural stem cells into OPCs (51, 52), 
which are the precursor cells for both oligodendrocytes and type-2 astrocytes (51). 
Our molecular and pharmacological data indicate that increased PDGFRA expression 
during OPC development may involve activation of the PDGFRA gene by DNA 
demethylation and histone modification, including acetylation. Activation of Pdgfra is 
essential for the subsequent proliferation of these progenitor cells, thereby preventing 
their premature differentiation. Pdgfra (+/-) mice show only 50% Pdgfra protein levels 
compared to wild type mice, and brain explants of such hemizygous mice display 
significantly lower OPC numbers than explants from wild type mice. In addition, Pdgfra 
(+/-) mice display decreased OPC pool expansion and oligodendrocyte numbers as 
a result of accelerated OPC maturation (8, 9). This indicates that Pdgfra gene dosage 
and consequently Pdgfra expression levels directly influence the number of OPCs and 
mature oligodendrocytes.
Based on our results, we propose that in a similar manner in humans the low 
activity H1 allele induces accelerated OPC maturation, resulting in a reduced OPC 
pool size and therefore a smaller risk that one of these cells may eventually transform 
into a tumor cell. In our case-control studies we have not discriminated between 
primary and secondary glioblastomas. In general PDGFRA overexpression is more 
often associated with secondary than with primary glioblastomas (53), but based on 
our model in which the OPC pool size plays a central role, we expect that both types 
of glioblastomas will be equally affected by PDGFRA promoter haplotypes. Recently, it 
has been shown that Pdgfra is already expressed in the astrocyte-like neural stem cells, 
which are present in the subventricular zone of adult murine and human brain. These 
cells can still generate both neurons and oligodendrocytes, are dependent on Pdgfra 
signaling for proliferation and form glioma-like hyperplasias upon continuous activation 
by PDGF (54). It will be interesting to study if in heterozygous human cells of this type 
PDGFRA promoter haplotypes are differentially expressed, since this could indicate 
that PDGFRA levels affect gliomagenesis not only by controlling the pool size of OPCs 
but also of neural stem cells.
Glioblastomas have been shown to contain a small fraction of cells, generally 
referred to as cancer stem cells, which have the capacity to self-renew and are 
essential for the continuous outgrowth of the tumor (18, 55, 56). Isolated human glioma 
stem cells have been shown to be highly tumorigenic in nude mice, while the more 
differentiated glia-like cells that form the majority of cells in glioblastoma tumors are 
only poorly tumorigenic (43).  These glioma stem cells resemble neural stem cells in 
that they express similar markers and have in addition the ability to grow in so-called 
neurospheres Addition of serum induces glioma stem cells in vitro to differentiate into 
more mature glia-like cells. Our preliminary results indicate that at least U-251 and Cl2:
6 cells form highly infiltrative intracranal tumors in nude mice, while U-410 cells are 
unable to do so (A. Claes, P. Wesseling, E.J.J. van Zoelen; unpublished). This agrees with 
previous data showing that astrocytoid and small polygonal-shaped glioma cell lines, 
such as the Cl2:6, readily form tumors when injected into the brain of nude rats, while 
glioma cell lines with a fibroblastic morphology, such as the U-343 MG (57) and U-410, 
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are unable to do so (57). These data suggest that the U-251, 31L and Cl2:6 cells used 
in the present study have maintained important characteristics of glioma stem cells, 
in spite of the fact that they have been cultured in serum-containing medium for a 
prolonged period of time. In contrast, the U-410 cell line with its high expression levels of 
both the PDGFRA H1 and H2α allele, shows all the characteristics of more differentiated 
glia-like tumor cells, similar to the majority of cells in the analyzed glioblastoma tissue 
samples.   
In conclusion, we propose that during differentiation of neural stem cells into 
OPCs, PDGFRA expression is gradually upregulated whereby the H2α allele is more 
readily demethylated than the H1 allele. As a result, it will take longer to fully activate 
H1 than H2α, which will result in a smaller size of the OPC pool due to reduced PDGF 
induced proliferation. The highly tumorigenic U-251, 31L and Cl2:6 cell lines with their 
allele-specific PDGFRA expression would thereby more resemble transformed neural 
stem cells or early glia progenitor cells. Upon subsequent differentiation to proliferating 
glia cells, PDGFRA expression is further upregulated to the high, allele-independent 
expression observed in the non-tumorigenic U-410 cells and the majority of cells in 
the analyzed glioblastoma tissue. Deregulated expression of PDGFRA has also been 
associated with other neoplasias than glioblastomas, in particular osteosarcomas, 
chondrosarcomas, breast cancer and ovarian carcinomas (58-61). It will be of interest 
to study if the risk for development of such tumors is also associated with specific 
PDGFRA promoter haplotypes.       
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Abstract
We have previously shown that deregulated expression of the platelet-derived growth 
factor α-receptor (PDGFRA) can be associated with neural tube defects (NTDs) in both 
men and mice. In the present study we have investigated the transcription factors that 
control the upregulation of PDGFRA expression during differentiation of early embryonic 
human cells in culture. In Tera-2 embryonal carcinoma cells PDGFRA expression is 
strongly enhanced upon differentiation induced by retinoic acid and cAMP treatment. 
Here we show that the corresponding increase in promoter activity is controlled by 
an ATTA-sequence containing element located near the transcription initiation site, 
which is bound by a transcriptional complex that includes PBX and PRX homeobox 
transcription factors. Mutation of the putative binding sites for these transcription 
factors results in strong impairment of PDGFRA promoter activity in differentiated cells. 
Since functional inactivation of Prx genes has been associated with NTDs in mice, these 
data support a model in which improper PDGFRA expression as a result of mutations in 
or altered binding of its upstream regulators may be causally related to NTDs.
Introduction
Neural tube defects (NTDs), including anencephaly and spina bifida, form a major 
group of congenital malformations with an average incidence of 1 per 1,000 
pregnancies in the Western world. NTDs are multifactorial traits with both genetic 
and environmental factors contributing to their etiology. Several candidate genes 
for NTDs have emerged from studies on mouse models, but only few of them have 
actually been associated with related diseases in humans. Mice with a targeted null 
mutation in the gene encoding the platelet-derived growth factor α-receptor (Pdgfra) 
and also Patch mutant mice, which contain a natural deletion of the chromosomal 
region that includes Pdgfra, both show severe spina bifida combined with embryonic 
lethality in their homozygous form (1, 2). We have recently shown that this gene also 
plays a prominent role in the genesis of NTDs in humans. Based on an analysis of 
naturally occurring single nucleotide polymorphisms in the PDGFRA promoter, five 
different promoter haplotypes could be discriminated which strongly differed in their 
transcriptional activity. Specific combinations of such haplotypes correlated directly 
with a predisposition for NTDs in a group of sporadic spina bifida patients (3). Based 
on these observations we have postulated that aberrant transcriptional regulation of 
PDGFRA may also play a central role in the genesis of NTDs in humans. 
The above hypothesis suggests that transcription factors that act as upstream 
regulators of PDGFRA expression may also be associated with NTDs. In line with this 
concept, it has been shown that mice heterozygous for the Patch deletion show 
spina bifida only in combination with the undulated mutation in the Pax1 gene (4). In 
a previous study we have shown that Pax1 indeed acts as an upstream transcriptional 
regulator of PDGFRA (5). Moreover we have shown that  Pax1 carrying the undulated 
mutation, as well as a mutant form of PAX1 found in a patient with spina bifida (6), both 
show a gain of function in their ability to stimulate PDGFRA transcription (5). Also other 
transcription factors that in mouse models have been associated with NTDs, including 
Pax3 (7), Gli2/Gli3 (8), HoxD4 (9, 10) and Mfh1 (11) have been associated directly with 
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Pdgfra transcription or at least coexpress with Pdgfra during development. 
  Expression of the platelet-derived growth factor (PDGF) α-receptor and thus 
responsiveness of cells to the various PDGF isoforms (PDGF-A, -B, -C and -D) is strictly 
regulated during embryonic development. Although present in all cells of the pre-
implantation embryo from the two cell stage onwards (12), Pdgfra expression becomes 
limited to mesodermal and certain neural crest-derived structures after implantation 
(13-17). Human embryonal carcinoma (EC) cells, which represent the undifferentiated 
stem cells of non-seminomatous testicular germ cell tumors, are widely used as an in 
vitro model system for studying differentiation-dependent regulation of gene expression 
during early human development (18). In previous studies we have shown that the 
Tera-2 cell line in its undifferentiated state (Tera-EC) expresses PDGFRA from an internal 
promoter, giving rise a set of alternative transcripts that have been used as a specific 
marker for early detection of testicular germ cell tumors (19, 20). Upon in vitro treatment 
with retinoic acid (RA), differentiated cell populations are obtained with neuronal and 
endodermal characteristics, designated Tera-RA, which abundantly express the 6.4 kb 
PDGFRA transcript that encodes the full length functional PDGF α-receptor. Using the 
cloned 2 kb promoter region of human PDGFRA that drives the formation of this 6.4 kb 
transcript, we have shown (21) in transient transfection assays with a luciferase read-
out, that PDGFRA transcription is strongly upregulated upon treatment of Tera-EC cells 
with RA, particularly in combination with dibutyryl-cAMP (Bt2cAMP) and theophylline, 
this in spite of the fact that the promoter does neither contain a consensus RA-
responsive element nor a consensus cAMP-responsive element.
Based on the hypothesis that aberrant expression of PDGFRA during 
development can be associated with NTDs, we have investigated in the present study 
the transcription factors that are involved in the upregulation of PDGFRA promoter 
activity during RA-induced differentiation of Tera-EC cells. Here we show that an 
ATTA-sequence containing element (parATTA) is essential for PDGFRA transcriptional 
activity by binding a new complex of transcription factors that includes the homeobox 
proteins PBX2 and PRX2. Intriguingly, in mouse models Prx genes have been found to be 
associated directly with NTDs (22). These data underline the hypothesis that improper 
PDGFRA expression during development may be a major cause for the genesis of 
NTDs. 
Materials and methods
Reporter constructs
The construction of the truncated PDGFRA promoter-luciferase (LUC) reporter gene 
vectors -2120/ +118 LUC, -441/+118 LUC, -275/+118 LUC, –197/+118 LUC, -175/+118 
LUC and -52/+118 LUC has been described previously (21). Mutant forms of these 
promoter-luciferase constructs were generated using the Quick Change Site-Directed 
Mutagenesis Kit (Stratagene). 
Cell culture
The human embryonal carcinoma cell line Tera-2 clone 13 (23) was maintained in α-
modification of minimal essential medium lacking nucleosides and deoxynucleosides, 
supplemented with 10% ES-approved fetal calf serum (Gibco BRL). Undifferentiated 
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cells were seeded one day prior to transfection at high density (5.0x104 cells/cm2) in 
a 0.1% gelatin-coated tissue culture dish. Differentiation was induced by the addition 
of 5 mM of retinoic acid (RA), 12h after the cells were seeded at low density (5.0x103/
cm2), and maintained in this medium for 7 days before further use. Transfections were 
carried out using the calcium-phosphate method (24) upon addition of 1 µg/well of 
the promoter-luciferase vector. In addition, 50 ng/well of the lacZ-expressing vector 
pCH110 (Pharmacia) were cotransfected to correct for differences in transfection 
efficiency. After the appropriate incubation times, cells were lysed in reporter lysis buffer 
(Promega). Luciferase activity in the lysate was determined using the luciferase assay 
kit (Promega), according to the manufacturer’s protocol. β-Galactosidase activity was 
assayed as described (25) using Galacton plus (Tropix) as the substrate.
Electrophoretic mobility shift assays 
Nuclear extracts from Tera-2 cells were prepared as described by Schreiber et al. 
(26). Extracts (10-15 µg) were incubated with 3x104 cpm 32P-labelled DNA, 2 µg dI-dC 
and, if necessary, unlabelled competitor DNA in a reaction buffer (20 mM Hepes pH 
7.9, 50 mM NaCl, 1mM EDTA, 0.15 mM EGTA, 1 mM DTT, 0.15 mM PMSF, 4% (w/v) Ficoll 
and 50 mM KCl) for 5 min at room temperature. The resulting protein-DNA complexes 
were separated on a 4% polyacrylamide gel using 0.5xTBE as running buffer (24) and 
visualized on X-ray film (Kodak X-Omat, Fuji RX).
Synthetic oligonucleotides
The following synthetic oligonucleotides were obtained in single-stranded form in both 
the sense and anti-sense direction: parATTA (5’-CTATAACATTGAATCAATTACAA-3’), 
m-PBX (5’-CTATAACAGGGAAGCAATTACAA-3’), m-PRX (5’-
CTATAACATTGAATCTAGAGCAA-3’), DM (5’- CTATAACAGGGAAGCTAGAGCAA-3’), 
consensus CRE (5’-AGAGATTGCCTGACGTCAGAGAGAAG-3’ ), consensus AP1 (5’-
CGGATGACTCAGCCGGAA-3’) and consensus AP2 (5’-GATCGAACTGACCGCCC
GCGGCCGT-3’). Equal amounts of the sense and anti-sense oligonucleotides were 
mixed in distilled water, heated to boiling temperature and slowly cooled to room 
temperature. If necessary, the resulting double stranded product was subsequently 
purified by non-denaturating polyacrylamide gel electrophoresis (24). 
Antibodies
Anti-PBX polyclonal antibodies were directed against the C-terminus of the human 
protein, recombinantly prepared as a GST fusion protein (a generous gift from Dr. C. 
Murre, UCSD). Polyclonal antibodies specific for PRX2 (αPrx2) were directed against a 
synthetic peptide derived from mouse Prx2 (IKSYGQEAAIEQPVAPRPTT), while polyclonal 
antibodies recognizing both PRX1 and PRX2 (αPrx1+2) were generated against the 
E.coli recombinant protein  AGRRAAGPVSGPAEARVGAAREPSGGSSGTEAAPQDGDCP
SPGRGTKRKKKQRRNRTTFNSSQLQALERVFERTHYPDAFVREELARRVNLSEARVQVWFQNRRAK
FRRNERAMLATRSASLLKSYGQEAAIEQPVAPRPTTMSPDYLSWPASSPYSSVPPYSPGGSSPATPG
VNMANSIASLRLKAKEFSLHHSQVPTVN. Both antibodies were a generous gift from Dr. F. 
Meijlink, Hubrecht Laboratory, Utrecht.
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Results
We have previously shown that the activity of the so-called PDGFRA P1-promoter is 
strongly upregulated upon RA treatment of undifferentiated Tera-2 human embryonal 
carcinoma cells. Upregulation was also observed in the presence of Bt2cAMP, such 
that synergy in promoter activation was observed by a combination of RA and this 
cAMP analogue (21). Since the promoter region tested does not contain sequences 
corresponding to consensus RA- or cAMP-responsive elements, a panel of progressive 
5’-deletion mutants of the promoter, cloned into a luciferase reporter gene vector, 
was used to map the cis-element(s) involved in the RA- and cAMP-induced promoter 
activity. Upon transient transfection into undifferentiated Tera-EC cells, the promoter 
activity of the deletion mutants varied in agreement with previous data (21), but for 
each mutant a 9- to 20-fold induction of activity was observed upon treatment of 
the cells for 48 hours with RA alone or with RA in combination with Bt2cAMP and the 
phosphodiesterase inhibitor theophylline (RACT), as shown in figure 1. Interestingly, 
similar results were obtained when the transfections were performed in Tera-2 cells that 
had already been differentiated by RA treatment for 7 days (Tera-RA cells). Since these 
differentiated cells already display a high basal PDGFRA promoter activity (21), RA and 
RACT seem to enhance, rather than induce, promoter activity. The observation that 
also the smallest element tested is still RA and Bt2cAMP responsive, suggests that these 
stimuli mediate their effects through regulating elements within the -52/+118 region of 
the PDGFRA gene.
To characterize the transcription factors that bind to this specific promoter 
region, electrophoretic mobility shift assays (EMSAs) were performed using the -
52/+118 promoter fragment as a probe. As shown in figure 2 (lane 1) at least four 
different complexes were observed upon incubation of this fragment with nuclear 
extracts of Tera-EC cells. Upon 24 hours treatment of these cells with RA, quantitative 
changes were observed in the three low mobility complexes, while the high mobility 
Fig. 1. Retinoic acid (RA) and cAMP-induced activity of PDGFRA promoter deletion mutants.
Indicated 5’ promoter-luciferase (LUC) deletion mutants were transiently transfected into
undifferentiated Tera-EC or differentiated Tera-RA cells. Transfected cells were treated for 48
hours with either 5 µM RA or a combination of 5 µM RA, 1 mM Bt2cAMP and 350 µM
theophylline (RACT). Subsequently, luciferase activity in the cells was determined and
corrected for differences in transfection efficiency. The values represent the fold induction of luciferase 
activity after treatment relative to that of unstimulated cells, including the sample standard deviation 
based on two independent experiments. Unstimulated values were in agreement with Afink et al. (21).
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complex had disappeared in favour of two new complexes with even higher mobility. 
Qualitatively similar differences, although often more pronounced, were observed 24 
hours after treatment with RACT (data no shown; see also ref (21)). These data show 
that RA treatment of Tera-2 cells results in a complex but characteristic change in 
nuclear protein binding to the –52/+118 promoter fragment of PDGFRA.
The PDGFRA promoter does not contain a consensus RA-responsive element, 
but it contains various putative binding sites for RA-inducible transcription factors such 
as AP2 (21), and one such AP2 site (+97GCCGTGGG+104) is located within the -52/+118 
region. In addition, an ATTA-containing sequence (+4ATTGAATCAATTA+16), designated 
here as parATTA, is present which shows some homology to both a cAMP-responsive 
element (TGACGTCA) and to binding sites for the AP1 transcription factor complex 
(TGASTCA) (27, 28). In order to investigate the involvement of these sequences in the the 
-52/+118 promoter region in binding of nuclear proteins, we carried out oligonucleotide 
Fig. 2. Electrophoretic mobility shift assay on nuclear extracts of Tera-EC cells before (control) 
and 48 hours after incubation with 5 µM retinoic acid (RA). Use was made of the 32P-labelled 
–52/+118 PDGFRA promoter fragment, either in the absence of any specific competitor (NO), 
or in the presence of a 500-fold excess of consensus AP1, parATTA, consensus AP2 or consensus 
CRE oligonucleotide (see Materials and Methods for sequences). The five distinct DNA-protein 
complexes that can be competed with unlabelled parATTA are indicated by arrows, specified 
as complexes upregulated by RA (<) and complexes with decreased intensity following RA 
treatment (>).
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competition studies, as shown in figure 2. Competition with the unlabelled parATTA 
oligonucleotide resulted in a complete loss of five of the six earlier mentioned protein-
DNA complexes bound to the -52/+118 probe. This shows that this parATTA element 
is essential for the formation of protein-DNA complexes in both Tera-EC and Tera-RA 
cells. No binding competition was observed with a consensus APl oligonucleotide, an 
AP2 oligonucleotide or an oligonucleotide containing a cAMP-responsive element 
(CRE), which is indicative for the specificity of nuclear protein binding to the parATTA 
sequence in this promoter element (figure 2).
ATTA motifs are known to be involved in the DNA binding of homeobox-
containing transcription factors. A search for transcription factor binding sites in 
the parATTA sequence present in the –52/+118 fragment of the PDGFRA promoter 
(TFSEARCH analysis) revealed the highest correlation with binding sites for members of 
the PBX and PRX families of homeobox proteins (TTGAAT and AATTA respectively). In 
order to identify if such factors indeed bind the parATTA sequence in Tera-2 cells, we 
used specific antibodies directed against PBX and PRX proteins in EMSA studies. Figure 
3 shows that upon incubation of parATTA with nuclear extracts of Tera-EC cells, a small 
increase in gel mobility of the DNA-protein complex was observed in the presence of 
antibodies specific for PBX2. More pronounced, a clear supershift was observed when 
the experiment was carried out in the presence of antibodies specific for PRX2, while 
Fig. 3. Identification of parATTA binding proteins in Tera-EC cells. Electrophoretic mobility shift 
assays were performed on the 32P-labelled PDGFRA promoter-derived parATTA oligonucleotide, 
using nuclear extracts of Tera-EC cells in the presence of anti-PRX and anti-PBX antibodies, as 
follows: ne, control nuclear extracts; αPbx2, antibodies specific for PBX2; αPrx2, antibodies specific 
for PRX2; αPb/rx2, a combination of αPbx2 and αPrx2; serum, control rabbit serum in the absence 
of nuclear extract; αPrx1/2, antibodies recognizing both PRX1 and PRX2. Arrows denote the DNA-
protein complexes that are formed or altered upon antibody binding.
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antibodies that recognise both PRX2 and its transcriptional partner PRX1 (22, 29, 30) 
strongly reduce DNA-protein complex formation. These data suggest that the parATTA 
sequence is bound by PRX2, and possibly also PRX1, most likely in a protein complex 
with PBX2. Similar results were obtained using nuclear extracts from Tera-RA cells (data 
not shown).
In order to analyse the specific function of the bound nuclear proteins, we 
introduced inactivating mutations into the parATTA oligonucleotide on positions that 
are specific for binding of either PBX2 or PRX1/2 (based on TFSEARCH analysis). Figure 
4 shows that mutation of the putative PBX binding site in the parATTA oligonucleotide 
results in a strongly reduced ability to bind Tera-2 nuclear proteins. Similar results were 
obtained upon mutation of the ATTA site involved in PRX1/2 binding, while no detectable 
complex formation was observed when both sites were mutated simultaneously. The 
similarity in effect observed upon mutation of the putative PBX and PRX site suggests 
that inhibition of binding of one of these factors may already block formation of the 
entire complex. It has been described that HOX gene products may modulate the 
DNA binding activity of PBX transcription factors and consequently that removal of 
either PBX itself or of the homeobox-containing transcription factor is sufficient for 
dissociation of the DNA-protein complex (31). In agreement with this observation we 
Fig. 4. Effect of mutations in the parATTA sequence on nuclear protein binding. Electrophoretic 
mobility shift assays were performed with nuclear extracts of Tera-EC cells using 32P-labelled 
oligonucleotides with different mutations. The sequences of the wild-type parATTA oligonucleotide 
and of  the mutant forms aimed at preventing PBX and PRX binding (designated m-PBX, m-PRX, 
and the double mutant DM) are shown in the Materials and Methods. The arrow denotes the 
major specific DNA-protein complex.
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find that PBX2 only forms stable complexes with specific DNA sequences when other 
homeobox-containing transcription factors, such as in this case PRX1/2, are bound in 
addition.
Functional analysis of the wild-type and various mutated parATTA elements 
was subsequently studied within the context of the highly active -441/+118 promoter-
luciferase reporter construct. When transfected into Tera-EC cells the various mutations 
in the parATTA element caused a severe reduction in promoter activity compared to 
the wild-type promoter, as shown in figure 5. Mutation of the putative PBX binding site 
resulted in a more than 5-fold reduction in luciferase activity, both before and after 
RACT treatment. A similar reduction was observed upon mutation of the ATTA site or 
when both sets of mutations were combined. A complete loss of promoter activity 
was observed upon deletion of 11 nucleotides from the palindromic sequence within 
parATTA that is involved in binding of PBX and PRX1/2. Since this deletion leaves the 
transcription initiation intact, these data underline the essential role of the parATTA 
element in the basal transcriptional activity of the PDGFRA promoter.
Fig. 5. Effect of mutations in the parATTA element on PDGFRA promoter activity. In the –441/+118 
PDGFRA promoter construct linked to luciferase, the following mutations were made: P1, no 
mutation; ∆11, P1 carrying a deletion of the 11 nucleotide inverted repeat +4ATTGAATCAAT +14; 
m-Pbx, P1 carrying the PBX sensitive mutation similarly as in the m-PBX oligonucleotide; m-Prx, P1 
carrying the PRX sensitive mutation similarly as in the m-PRX oligonucleotide; Dm, P1 carrying both 
sets of mutations similarly as in the DM oligonucleotide. Constructs were transfected into Tera-EC 
cells and luciferase (luc) activity was measured in control cells (-) and in cells treated for 48 hours 
with RACT (+). Promoter activity values were corrected for differences in transfection efficiency, 
expressed in β-galactosidase (bgal) activity. Error bars represent the standard deviation of 
duplicate independent experiments.
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Discussion
In the present study we have shown that the upregulation of PDGFRA expression 
during differentiation of early embryonic human cells requires a promoter element, 
designated parATTA, which binds a complex of PRX and PBX proteins. Various studies 
have shown that improper expression of the PDGF α-receptor during embryonic 
development can result in NTDs, and therefore both PDGFRA itself and genes encoding 
upstream regulators of its expression may be associated with such malformations. We 
have previously shown that PAX1, as product of a NTD-associated gene, is an upstream 
regulator of PDGFRA expression, while the current study identifies PBX2, PRX2 and 
possibly also PRX1 as regulators of PDGFRA expression that are potentially involved in 
NTDs. These observations are in line with mouse studies, where severe NTDs have been 
observed particular in Prx1(-/-); Prx2(-/-) mice, with similar vertebrae defects as seen in 
the Pdgfra null mutant (22). 
The exact nature of the protein complex that binds the parATTA element in 
Tera-2 cells is unclear, but the observation that five distinct DNA–protein complexes 
have been  identified in this study that are competed in electrophoretic mobility shift 
assays by unlabelled parATTA containing oligonucleotides, indicates that multiple 
complexes are formed. This suggests that in addition to PBX2 and PRX1/2, also other 
proteins may be present in the complexes formed. The EMSAs indicate that PBX2 
and PRX1/2 containing complexes can be formed with nuclear extracts from both 
undifferentiated and differentiated Tera-2 cells, indicating that the increase in PDGFRA 
promoter activity upon RA treatment is most likely not due to the induction of these 
homeotic genes. These observations suggest that PBX-PRX proteins form the core of a 
larger complex that is required for transcriptional activation, in agreement with recent 
data on the binding of such transcription factors to a collagen promoter (32). The 
formation of this complex is at most only partly regulated by the mere availability of the 
transcription factors involved and most likely requires an additional activation step. This 
is confirmed by the observed synergy between Bt2AMP and RA, which in comparison 
with RA alone gives rise to only quantitative, and not to qualitative changes in 
transcription factor binding to the –52/+118 region (21). Also the observation that RACT 
still stimulates PDGFRA transcription in Tera-RA cells, supports this hypothesis.
The present data indicate that the parATTA binding proteins PBX2 and PRX1/2 
are essential for formation of the complex that regulates PDGFRA expression during 
embryonic cell differentiation. Homeobox transcription factors are known to control 
expression of other homeotic genes, but only few examples are available in which they 
control expression of non-homeotic genes such as PDGFRA (32). Amino acid alignment 
reveals that members of the PBX and PRX families are 93-99% conserved between 
mouse and human, while the parATTA element itself is 100% conserved between 
rat, mouse and human. This underlines the importance of this mechanism for normal 
vertebrate development.
Studies on the promoters of the human, mouse and rat PDGF α-receptor 
gene have provided evidence for the involvement of GATA4 (33), PAX3-FKHR (7), 
Pax1 (5), C/EBPs (34) and Gli1 (35) in transcriptional control. Potentially, the genes 
encoding these transcription factors can all be involved in the development of NTDs. 
In mice, Pdgfra itself as well as Pax1, Pax3, Prx1 and Prx2, which all encode upstream 
regulators of Pdgfra expression, have been associated directly with NTDs. In humans, 
specific combinations of PDGFRA promoter haplotypes have been associated with 
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predisposition to NTDs, while also mutations in PAX1 and PAX3 are considered to be 
risk factors for human NTDs. Based on our present results, PBX2, PRX2 and maybe also 
PRX1 should also be considered as candidate genes in the genesis of NTDs in humans. 
Further studies will have to indicate if mutations in these genes or alterations in their 
expression levels are indeed observed in patients suffering from anencephaly and 
spina bifida.
In conclusion, we have shown that PDGFRA promoter activity in human Tera-
2 cells is strongly upregulated upon RA and cAMP treatment. The element involved 
is located in the -52/+118 region of the promoter, and electrophoretic mobililty shift 
assays show that multiple protein complexes that can bind this region which are all 
competed by a 23 bp parATTA oligonucleotide. These protein complexes include PRX 
and PBX, but since these complexes are present in both Tera-EC and Tera-RA cells, RA/
cAMP-induced induction of PDGFRA promoter activity seems to require an additional, 
as yet unknown activation step. Point mutations in parATTA reduce binding affinity for 
PBX en PRX proteins and thereby the induction of promoter activation by RA/cAMP. 
It is therefore concluded that the parATTA sequence is essential for normal PDGFRA 
transcription regulation and for its activation upon RA/cAMP treatment.
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Role of PDGFRA promoter polymorphisms in normal physiology 
and disease
With the recent completion of the human genome sequence, current emphasis in 
molecular research is now on the 0.1% of DNA in which individuals differ from each 
other. These differences in DNA sequences mainly result from the presence of single 
nucleotide polymorphisms (SNPs) and small nucleotide insertions and deletions. It is 
well accepted that human beings differ from each other, not because they make 
different proteins but because they make the same proteins in different amounts. 
Regulatory polymorphisms, such as those in promoter regions, can strongly contribute 
to the transcriptional activity of the corresponding gene and thereby to the amount 
of protein produced. Such variation in gene expression levels can, however, also 
predispose individuals to diseases in which the corresponding gene is involved. In 
studies on transgenic mice, the effects of gene depletion or overexpression can be 
studied relatively easily. Often the phenotypes obtained are very severe, because the 
expression level of the gene of interest is strongly impaired. Under those conditions a 
direct relation between gene defect and disease is observed. However, the promoter 
polymorphisms that occur in the normal human population will induce more subtle 
differences in gene expression levels than those observed in transgenic mice. As a 
result promoter polymorphisms may predispose individuals to diseases in which the 
gene of interest is involved, but generally only in combination with other genetic and 
environmental factors as part of a multifactorial disease. Our current data show that 
polymorphisms in the PDGFRA promoter contribute not only to the normal physiology 
(body length) of individuals but also to their risk of developing such diseases as neural 
tube defects and brain tumors.     
PDGFRA promoter polymorphisms influence disease susceptibility
Studies on transgenic mice have shown that Pdgfra plays a role in various 
diseases, including neural tube defects (NTDs) and glioma tumors. Altered expression of 
this gene may influence cell proliferation, differentiation, survival, migration, chemotaxis 
and extracellular matrix deposition. In the present study we have investigated how 
expression of the human PDGFRA gene is regulated in various cell types and how 
PDGFRA expression levels contribute to the susceptibility of individuals for developing 
NTDs and glioblastomas. We have identified a number of PDGFRA upstream regulators, 
in particular USF, PRX and PBX, some of which are also themselves associated with 
NTDs in mice. In addition we identified 10 polymorphic sites in the human PDGFRA 
promoter, which give rise to five distinct haplotypes, of which the H1 and H2α alleles 
are the most prominent. Our in vitro studies on human osteosarcomas cells as well as 
our in vivo data on intact human glioblastoma cells indicated that these haplotypes 
strongly differ in promoter activity, such that the H1 allele may induce low and the H2α 
allele high PDGFRA mRNA levels. In case-control studies we subsequently observed 
that the low activity H1 allele predisposes individuals to NTDs while protecting them 
against glioblastomas. Figure 1 gives a survey of the PDGFRA promoter haplotype 
combinations and H1 frequency observed in our studies on Western European control 
populations, spina bifida patients and glioblastoma patients. The data show a gradual 
decrease in H1 frequency when going from neural tube patients to the control 
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population to glioblastoma patients, fully in line with the model that H1 is a low activity 
allele that predisposes to NTDs but protects against glioblastomas. 
It generally requires large patient and matched control cohorts to observe 
a statistically significant enrichment for a specific polymorphism. In our studies the 
increased frequency of H1 in spina bifida patients and decreased incidence of H1 in 
glioblastoma patients both have p-values just below 0.05. However, when comparing 
the two patient groups of Fig.1 with each other, a difference with much higher 
significance is observed both when analyzing the number of H1/H1 homozygotes 
(OR=12.4, p<0.009; 95%CI: 2.0 - 77.1) and the frequency of the H1 allele (OR=2.6, 
p<0.001; 95%CI: 1.5 – 4.6). This shows that with respect to PDGFRA promoter haplotypes 
spina bifida and glioblastoma patients are genetically two highly distinct populations. 
To further evaluate a possible inverse correlation between the risk of NTDs and 
glioblastomas, we subsequently studied the incidence of both diseases on a world-
wide scale. From a recent study on genome wide distribution of haplotypes in the USA, 
an H1 frequency of approximately 0.30 could be calculated for African Americans, 
of 0.25 for European Americans and 0.20 for the Chinese population (1), while an 
Figure 1: Distributions of PDGFRA promoter haplotypes. Depicted are percentages of PDGFRA 
haplotype combinations (A) and single haplotypes (B) in Dutch spina bifida cases (1), their 
mothers (2), Dutch controls (3), combined Western European controls (4), German controls (5), 
and German glioblastoma cases (6). Black represents H1/H1 (A) and H1 (B), gray H1/H2 and white 
H2/H2 (A) and H2 (B). 
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H1 frequency as low as 0.172 was reported for a Taiwanese control population (2). 
Other studies have indicated that particularly American Hispanics show a very high 
H1 frequency ranging from 0.32 to 0.47 (3, 4). When comparing these distributions with 
the incidence of PDGFRA-related diseases in these population groups, it has been 
observed that the incidence of NTDs in the USA is highest among Hispanics, followed 
by American Indians, Whites, Blacks, and finally Asians (5, 6). Thus, it appears that 
groups in the population with a high H1 frequency generally also have an increased 
incidence of NTDs. African Americans form an exception to this correlation, since they 
combine a higher H1 frequency with a lower risk of NTDs, when compared to European 
Americans. Interestingly, the length of the PDGFRA promoter haplotype is considerably 
shorter in African Americans (Fig 2), most likely because they represent a more ancient 
race, but it is unclear if that observation is in any way related to their relatively low NTD 
incidence. Alternatively, the African American race may be protected from NTDs by 
other factors.
When considering gliomas, Caucasians/Whites combine a lower H1 frequency 
with a significantly higher brain tumor incidence than African Americans (11.6 vs. 
7.8 cases per 100,000 persons per years respectively (7), which is consistent with 
our hypothesis. Also in line is the observation that the incidence of central nervous 
system (CNS) tumors in most African countries lies below the 2.4 and 1.5 cases per 
100,000 persons per year for males and females respectively (8). Furthermore, if it is 
assumed that Mexicans have a similarly high H1 incidence as determined for American 
Hispanics from Mexican descent in the studies of Zhu and Au, this could explain why the 
incidence of CNS tumors in Mexico is much lower than in the USA (<5.9 vs. <11.1 cases 
per 100.000 persons per year respectively for males, and <4.3 vs. <11.3 cases per 100.000 
persons per year respectively for females, (8)). However, when considering the low H1 
frequency in Asians, the CNS tumor incidence in Asian countries is unexpectedly low 
(<2.8 and <2.1 cases per 100.000 persons per year for males and females respectively, 
(8)). It could therefore be hypothesized that Asians are protected from gliomagenesis 
by other mechanisms. It has indeed been suggested that in the Asian population a 
distinct genetic pathway is involved in the etiology of glioblastoma multiforme (9). 
H1 and glioblastoma risk
In our glioblastoma case-control study, we could only demonstrate a statistically 
significant difference in H1 frequency between the patient group and a combined 
Western European control group consisting of 998 individuals. The matched control 
group showed a similar haplotype distribution as this Western European control group, 
but at least a threefold increase in both cases and controls would have been required 
to obtain a significant difference in H1 frequency (p<0.05) between glioblastoma 
patients and  the matched controls.   
 The most likely explanation for the protective effect of H1 against glioblastomas 
would be that the low H1-driven PDGFRA expression makes the tumor initiating cells 
less sensitive to PDGF-induced proliferation. These cells could be neural stem cells 
(NSCs), glial restricted precursors (GRPs), oligodendrocyte precursor cells (OPCs) or 
the recently identified astrocyte like adult neural stem cells called B cells (10-12). It 
has been shown that overstimulation of this receptor system is sufficient to induce the 
formation of glioma tumors in mice (13-17). However, this would only account for those 
tumors in which high PDGF signaling is indeed the oncogenic event. This may hold 
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true for secondary glioblastomas, which are associated with overexpression of both 
PDGF and PDGFRA, as opposed to primary glioblastomas, which are characterized 
by EGFR activating mutations and gene amplifications (18). Secondary glioblastomas 
often arise relatively early in life, at an average age of 45 years, whereas primary 
glioblastomas generally occur later in life at an average age of 62 years (8). In general, 
primary glioblastomas are the most prevalent type, constituting more than 80% of all 
glioblastomas (19). The glioblastoma patients tested in our study were on the average 
60 years of age (unpublished) and the majority shows EGFR abnormalities (20), which 
suggests that these are mainly primary glioblastomas. This makes it unlikely that high 
PDGF signaling is the primary cause of tumor formation in most of these patients. 
 We therefore prefer an alternative hypothesis, one that can also account 
for the effect of PDGFRA promoter haplotypes on primary glioblastomas. Although 
in rodents Pdgfra expression has been observed in early NSCs (21)), its expression 
expression is strongly upregulated upon differentiation into OPCs (22, 23). Based on 
our data on haplotype specific expression in glioblastoma cell lines, we propose that 
following differentiation of their neural stem cells, H1 individuals display lower PDGFRA 
expression levels on their glial precursors (OPCs/O2As/GRPs) than H2 individuals due 
to differential promoter (de)methylation. This would result in a decreased precursor 
pool size, analogous to what has been observed in Pdgfra (+/-) and (-/-) mice when 
compared to wild-type mice (24). Assuming that each glia precursor cell has a specific 
risk of transforming into a malignant counterpart, lower precursor numbers will reduce 
the total risk of developing glial tumors later in life. In this way, PDGFRA promoter 
haplotypes could influence the risk of all glial precursor-derived tumors, irrespective 
of the PDGF levels at the actual time of tumorigenesis. In this respect, it would be very 
interesting to study haplotype specific expression in the recently identified B cells(10, 
25), to investigate whether these cells also show a reduced H1 expression during their 
initial development.
H1 and NTD risk
Several mouse models have shown that decreased Pdgfra signaling, either by 
ligand or receptor deficiency, can lead to spina bifida, suggesting that low PDGFRA 
expression may be a risk factor for NTDs in humans. Based on our observation that H1 is 
a weak promoter in a number of cell lines, we therefore tested the hypothesis that the 
H1 allele confers a genetic predisposition to NTDs. In our initial study (26) we observed 
an underrepresentation of H1/H2 heterozygotes in the control group in combination 
with an overrepresentation of such heterozygotes in sporadic and familial NTD cases. 
Subsequent studies have indicated, however, that for unknown reasons the control 
group used in that study strongly deviated from the later established Western European 
control group. When compared with this latter control group (pH1=0.211), the patient 
data of Joosten et al. (26) show an increased H1 frequency in the group of familial 
NTD patients (pH1=0.316) but not in that of sporadic patients (pH1=0.184). The reason 
for this latter observation is unknown, but may be related to the less strict definition of 
the cases, since also cases with encephalocele, craniorachischisis and anencephaly 
were incuded (27, 28). Therefore, our initial conclusion that H1/H2 heterzygotes have 
an increased predisposition for NTDs appeared to be biased as a result of this improper 
control group and possibly also deviating case groups. 
In our subsequent analysis we have used a cohort of both spina bifida patients 
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and controls and their respective mothers, in combination with data on their blood 
glucose, myo-inositol and zinc value. Cases consisted only of live-born spina bifida 
apertas, while control mothers and children were carefully selected to match with the 
cases and their mothers on the basis of race, geographical origin, time of birth of the 
child, and the absence of congenital malformations (29). Importantly this control group 
strictly obeyed the distribution that we and others had obtained for other Western 
European control cohorts. From all these data combined we could define a Western 
European control distribution of PDGFRA promoter haplotypes with an H1 frequency 
(pH1) of 0.211. This control cohort strictly obeyed Hardy-Weinberg equilibrium, so 
without any indication for a deficiency of H1/H2 heterozygotes. Moreover, we could 
conclude that children with an H1 allele have an increased risk of developing NTDs. 
These findings are now supported by two independent studies on American Hispanics 
(3, 4), although minor discrepancies in the conclusions remain, particularly as a result of 
differences in the experimental set-up and recruitment of the cases and controls. These 
differences and their accompanying limitations will now be discussed in order to show 
that they support our hypothesis that H1 increases the risk of NTDs.
In the study by Zhu et al. (3) on the association of PDGFRA promoter haplotypes 
with spina bifida in a group of American Hispanics from Mexican descent, the H1 
allele was more abundant in cases (pH1=0.360) than in controls (pH1=0.319), but the 
observed difference was not within the p<0.05 significance level (OR = 1.2, 95% CI = 
0.7-2.0). An increase in H1 frequency was also observed in case mothers (pH1=0.385), 
which was significant compared to the control mother group (pH1=0.319, OR = 1.3, 95% 
CI = 0.9–1.9). Moreover, the authors observed that H1 homozygotes were significantly 
overrepresented in case mothers, which is in agreement with our findings. From the 
observation that a better correlation was observed between spina bifida of the child 
and the haplotype of the mother than of the child itself the authors concluded that 
that homozygosity for low activity alleles in mothers increases the risk of NTD in their 
offspring, possibly by affecting placental growth. We believe that these findings can 
mainly be attributed to the selection criteria of the cases and case mothers. Zhu et 
al. (3) also included NTD mothers of which no child material was available (79 of 122), 
whereas we only included child-mother pairs in our second study. In our opinion, the 
increased risk for H1 homozygote mothers of an NTD-affected pregnancy could also 
be explained by an increased transmission of the H1 risk allele.
 More recently, Au et al. (4) performed a similar study, in which not only 
American Hispanics from Mexican descent but also American Caucasians were 
included. The authors came to the conclusion that PDGFRA haplotypes are differently 
distributed in the two populations, but they found no significant association with spina 
bifida myelomeningocele. Similar to Zhu et al. (3), they made the distinction between 
low and high activity alleles. However it is known that H2γ can also have a high promoter 
activity in cell types where H1 still displays a low promoter activity (3), and therefore we 
prefer the distinction on sequence similarity, i.e. H1 vs. H2 haplotypes. When doing so, 
the data of Au et al. (4) show an overrepresentation of H1 alleles in the Caucasian 
cases compared to the corresponding controls which, very similar to our observation, 
which is on the verge of significance (29.9% H1 in cases vs. 21.9% in controls, OR = 1.523, 
95% CI = 0.997-2.326). This suggests that only a small increase in the sample would be 
required to obtain a statistically significant difference in H1 frequency between the two 
populations. Nevertheless, these data are in support of our hypothesis that H1 increases 
the risk of spina bifida risk in Caucasians.
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In the Hispanic population of the Au study, the H1 frequency in the control 
group appears extremely high (47.3%) when compared to the findings of Zhu et al. 
(31.9%) in a similar population. In cases and case mothers on the other hand, the 
H1 frequency is similar in both studies (cases Zhu=36.0%, Au=42.9%; case mothers 
Zhu=38.5%, Au=39.6%). We therefore doubt the representativeness of the Hispanic 
control group of the Au et al. study. When comparing the Au Hispanic cases with the 
Zhu Hispanic controls, the H1 allele is significantly more abundant in the cases than 
in the controls (OR=1.608 95% CI: 1.166 – 2.219). Furthermore, the authors observed 
an over-transmission of H1 in the Hispanic spina bifida triads, which suggests that H1 
is indeed a risk factor for spina bifida, also in American Hispanics. In addition, in the 
Au study only mothers of cases were included, and it was observed that both in the 
Caucasians and the Hispanic groups the H1 frequency was higher in cases then in their 
mothers, just as in our study. This indicates that H1 is a risk factor for NTDs in the child itself 
and not for NTDs in offspring, as was concluded by Zhu et al. Thus, when considering 
all these data together it appears that the H1 allele contributes to the etiology of spina 
bifida, both in Caucasians and in American Hispanics. 
Spina bifida and glioblastoma as multifactorial diseases
Both spina bifida and gliomagenesis can be considered as a multifactorial disease 
in which a combination of genetic and environmental factors plays a role. Our data 
show that PDGFRA contributes to the genetic factors for both diseases, such that 
high PDGFRA expression levels enhance the risk of glioblastoma formation, while low 
expression levels increase the risk of NTDs. Besides PDGFRA, only very few genes have 
been implicated in human NTD risk, including methylenetetrahydrofolate reductase 
(30). On the other hand, various environmental factors are known that contribute to 
the risk of spina bifida, including low maternal folic acid intake (31), high maternal BMI 
or maternal obesity (32-37), as well as high glucose and low myo-inositol and low zinc 
status of the mother (29) (and references therein). Such multifactorial diseases are best 
described in terms of a liability/threshold model, in which all factors that influence the 
development of a multifactorial disorder, either genetic or environmental, add up to 
the total liability for the disease. If the sum of all adverse genetic and environmental 
factors exceeds a certain threshold, this will result in the disease phenotype (38). 
Assuming that H1 is an adverse genetic factor for NTDs, this would imply that less 
adverse environmental factors would be required for an H1 child than for an H2 child 
to be affected with spina bifida.    
 Interpretation of our results in terms of this model is complicated by the fact 
that our analysis is restricted to live-born children with spina bifida. Most likely a too 
severe combination of adverse factors will result in prenatal death, and these cases 
are not included in our study. Our observation that high maternal glucose and low 
maternal myo-inositol are risk factors particularly for H2 children, but much less so for 
H1 children, most likely results from increased prenatal mortality of H1 children with a 
low myo- inositol or high glucose mother. On the other hand, it has been established 
that some 15% of control individuals show a very mild form of spina bifida occulta, 
indicating that in the case of NTDs an exact patient group is difficult to define (39, 40).
 In the case of glioblastoma the situation is less complex, since the patient 
definition is more clear, while in addition no environmental factors are known that 
unequivocally predispose to gliomagenesis, with the exception of intracranial radiation 
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(8). Other genetic factors may act in concert with PDGFRA promoter haplotypes 
to exceed the threshold necessary for brain tumor formation to occur. These could 
include mutation or homozygous deletion of the tumor suppressor genes PTEN (20, 41) 
or TP53, or allelic variants of the genes encoding the carcinogen-metabolizing enzymes 
cytochrome P-450 (CYP2D6) and glutathione S-transferase (GSTT1 and GSTM1) (8). It 
has already been shown that deletion of the tumor suppressor gene encoding INK4a-
ARF or that encoding p53 cooperates with a retrovirally expressed PDGFRA ligand 
PDGF-B regarding both tumor latency and frequency in a mouse brain tumor model 
for secondary glioblastoma (42). It should be noted however, that in our precursor 
pool size model high PDGFRA expression in itself is not necessarily tumorigenic, but the 
before mentioned factors could be responsible to transform cells out of the enlarged 
pool. 
Future research
In our study we have shown that U251, 31L and Cl2:6 glioblastoma cells display a more 
than 10-fold lower expression of H1 than of H2α, whereas U410 glioblastoma cells 
show high expression of both alleles. Moreover, we have shown that the first three cell 
lines display low total PDGFRA expression, while U401 cells highly express PDGFRA. In 
combination with the observation that in rats Pdgfra expression is upregulated upon 
differentiation from NSC to OPC (22, 23), we hypothesized that the first three cell lines 
have maintained more stem cell characteristics than the fourth. Our recent preliminary 
results indicate that at least U-251 and Cl2:6 cells form highly infiltrative intracranal tumors 
in nude mice, while U-410 cells are unable to do so (A. Claes, P. Wesseling, E.J.J. van 
Zoelen; unpublished). This agrees with previous data showing that astrocytoid and small 
polygonal-shaped glioma cell lines, such as the Cl2:6, readily form tumors when injected 
into the brain of nude rats, while glioma cell lines with a fibroblastic morphology, such as 
the U-343 MG (43) and U-410, are unable to do so. Another possibility would be to study 
these cells for the expression of NSC, OPC and mature glia specific marker genes, such 
as Nestin (NSC (44)), A2B5 (early OPC (45)), NG2 (OPC (46)) and PLP (oligodendrocytes 
(46)) or MBP (oligodendrocytes (24)). It has recently been described that gliomas 
indeed contain stem cells which resemble NSCs in their gene expression profile (47). 
We furthermore hypothesized that PDGFRA transcription is upregulated 
during differentiation of NSCs to OPCs by promoter demethylation, but such that 
H1 is demethylated at a later stage during this differentiation process than H2α. To 
investigate this possibility, homogeneous populations of H1/H2 heterozygous human 
NSCs would be required which could be stimulated to differentiate into OPCs 
and eventually into mature oligodendrocytes, during which haplotype-specific 
PDGFRA expression could be measured. At the moment it is not feasible, however, 
to obtain such NSCs from mature donor tissue. A possibility would be to use H1/H2 
heterozygous human embryonic stem cells, which could first be induced to neural 
differentiation by growing them as neurospheres and subsequently be grown as 
homogeneous monolayes of NSCs. These cells could be studied for haplotype-
specific PDGFRA expression following differentiation into glia cells, according to a 
recently described protocol (48). Alternatively, homogeneous monolayers of cancer 
stem cells can be isolated from glioblastoma tumors. If these cancer stem cells still 
resemble NSCs in that they only express low levels of PDGFRA, they can also be 
triggered to differentiate into glia-like cells by addition of serum or retinoic acid, as 
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recently described (47). A third approach would be to generate transgenic mice in 
which the Pdfgra gene is replaced by the human PDGFRA H1 and/or H2 allele, or 
alternatively to use Pdgfra (-/-) mice which are complemented with human H1 and H2 
PDGFRA YACs. In this way it can be studied whether the low activity H1 allele indeed 
induces premature OPC maturation resulting in lower OPC and oligodendrocyte 
numbers as well as hypomyelination, when compared to H2. In this respect it would 
also be interesting to compare individuals with the various haplotype combinations 
(H1/H1, H1/H2 and H2/H2) for their amount of myelin by MRI based techniques (49). 
Repression of the H1 allele in glioblastoma cells could be mediated by the 
inability of certain transcription factors to bind methylated DNA. This hypothesis could 
be tested by studying differential protein binding to methylated vs. unmethylated 
promoters by EMSA techniques. Furthermore, haplo-ChIP experiments could be 
performed with antibodies against transcription factors that potentially bind the 
promoter region that is differentially methylated between H1 and H2, such as ZBP-89, 
EGR1, GATA-2 and FKHRL1 (identified by MatInspector analysis), as well as against 
factors that have been identified by methylation specific EMSAs to investigate 
haplotype and/or methylation specific promoter binding in vivo. However, it is unlikely 
that this will give insight into the origin of observed differential (de)methylation, since 
the cause of this phenomenon must lie within the sequential differences between H1 
and H2. Unlike in the human osteosarcoma cells, however, we have been unable to 
detect any polymorphism-dependent protein binding in the -3600/+118 promoter 
region of PDGFRA using nuclear extracts from the three H1 repressing glioblastoma 
cell lines. As an alternative for EMSAs oligonucleotide trapping experiments could 
be used, in which nuclear proteins which are bound differentially to H1 and H2 are 
isolated by affinity chromatography (50). Using this method, we have recently shown 
by mass spectrometry analysis on nuclear extracts from osteosarcoma cells, that the 
chromatin remodeling complex SWI/SNF preferentially binds the H1 specific +68GAdel 
Figure 2: PDGFRA haplotype blocks in African Americans, European Americans and Chinese 
(from Perlegen.com). PDGFRA promoter haplotype block ranges from 54973631 to 55017967 bp 
in European Americans and Chinese and from 54995156 to 55017967 bp in African Americans on 
chromosome 4.
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allele. Subsequent chromatin immunoprecipitation (ChIP) analysis on the glioblastoma 
cell lines indicated that this allelic preference is dependent on promoter methylation 
(P. Joosten, unpublished data). This suggests that SWI/SNF may be involved in the 
differential expression and methylation of PDGFRA promoter alleles in glioblastoma 
cells. 
It has been established that PDGFRA promoter haplotypes span approximately 
40 kb of genomic DNA, at least in Caucasian Americans and Chinese (fig. 2), and 
therefore it cannot be excluded that polymorphisms outside the -3600/+118 region 
studied so far are involved in the haplotype-specific expression and methylation in 
these glioblastoma cell lines. In this respect, we could confirm that the haplotype of 
polymorphism rs7678144, which lies just on the 3’ border of the haplotype block at 
approximately 7 kb downstream of the transcription start site, is linked to the PDGFRA 
promoter polymorphisms described in our studies, whereas rs4637467, which is located 
at approximately 29 kb downstream, does not appear to be coupled to these 
promoter polymorphisms (unpublished).
Spina bifida is not only a characteristic of Patch and Pdgfra (-/-) mice, but 
also of  Pdgfc mutants and Pdgfa/Pdgfc double mutant mice (51), indicating that the 
genes for these two ligand genes might also be susceptibility genes for human NTDs. 
Thus, NTD case-control could be performed on these genes in humans, and multiple 
logistic regression analysis could be performed to test whether there is an additional 
or interactive effect of PDGFRA promoter haplotypes and PDGFA (52) and/or PDGFC 
alleles (51).
PDGFRA and other diseases
Airway remodeling by proliferation of lung smooth muscle cells is a mayor cause of the 
chronicity and severity of asthma(53), and PDGFRA signaling plays an important role 
in this process (54, 55). In a case control study on various types of asthma, Wu et al. (2) 
found that the frequency of H1 containing PDGFRA genotypes (H1/H1 + H1/H2) was 
increased nonallergic asthmatics, while the higher expression H2/H2 genotype was 
more frequent in patients with more severe types of childhood asthma, thus providing 
an association between PDGFRA promoter haplotypes with a third PDGFRA related 
disease.
Atherosclerosis is another disease in which PDGFRA signaling plays an important 
role, since PDGFRA regulates chemoattraction and proliferation of vascular smooth 
muscle cells (56). Therefore, Herrmann et al. (52) performed a large case-control study 
on coronary heart disease patients, but found no association with variation in the 
genes encoding PDGFRA, PDGFRB, PDGFA and PDGFB, including the H1/H2 linked 
-1631AACTTins/del PDGFRA polymorphism. Most likely this implies that the level of 
PDGFRA expression in pre-atherosclerotic lesions is not indicative for the disease risk. 
 Besides gliomas, also a number of other malignancies have been associated 
with PDGFRA, such as chondrosarcomas, osteosarcomas, breast cancer, prostate 
cancer and gastrointestinal stromal tumors (GISTs). Chondrosarcomas show a high 
expression of both PDGFA and PDGFRA which increases with tumor grade, whereas in 
healthy cartilage tissue no expression could be detected, except for the hypertrophic 
cartilage of callus which shows high expression. Interestingly, higher PDGFRA expression 
in chondrosarcomas has been associated with a significantly shorter patient survival 
time (57). This suggests that PDGFRA expression is involved in chondrocyte proliferation, 
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as well as in the aggressiveness of chondrosarcoma growth and thus that PDGFRA 
haplotypes may also influence susceptibility to chondrosarcomas. This may imply 
that the high expressing H2α allele may stimulate chondrocyte and chondrosarcoma 
growth whereas the low expressing H1 allele may do so less, or, like we hypothesize for 
glioblastomas, H2 and H1 differentially affect the chondrocyte precursor pool size. This 
would require analyzing haplotype-specific expression in proliferating chondrocytes, 
their precursor cells and in chondrosarcoma cells, as well as determining the haplotype 
distribution in chondrosarcoma patients. 
 The growth factor PDGF-AA stimulates the proliferation of osteoblastic cells by 
activation of PDGFRA. Both ligand and receptor are highly expressed in osteosarcomas 
suggesting that auto- and paracrine mechanisms are involved in osteosarcoma 
growth (58). Prostate carcinomas also overexpress both PDGFA and PDGFRA (59, 60), 
suggesting an involvement of PDGFRA expression in prostate cancer development 
as well. In breast carcinomas, PDGFRA expression correlates with tumor malignancy 
(61), while in ovarian carcinomas, PDGFRA expression is associated with high tumor 
grade, high proliferation index and poor patient outcome (62). Thus, similarly to 
chondrosarcomas, PDGFRA promoter haplotypes could also influence susceptibility to 
these types of tumors. Again, haplotype specific expression in the appropriate cells as 
well as haplotype distribution in patients has to be analyzed. By contrasts, GISTs mainly 
arise as a consequence of activating mutations in either PDGFRA or its neighbouring 
gene c-KIT, but not from overexpression of either gene (63). Therefore PDGFRA promoter 
haplotypes most likely will not affect GIST susceptibility. In the case of mesenchymal 
tumors such as osteosarcomas and chondrosarcomas, PDGFRA is already expressed 
in the normal cells and tends to be upregulated in the tumor cells. In the case of 
epithelial tumors, such as breast and prostate cancer, the normal cells are lined up in a 
continuous monolayer of epithelial cells which do not express PDGFRA. Also the tumor 
cells will not express PDGFRA as long as they show an epithelial morphology, but as 
soon as they undergo epithelial-mesenchymal transition (EMT), which is a prerequisite 
for metastasis, they obtain a mesenchymal morphology characterized by PDGFRA 
expression (64). It remains to be established if the extent of PDGFRA expression as a 
result of promoter polymorphisms will correlate with the metastatic behavior of such 
tumor cells. NSCs upregulate PDGFRA upon differentiation into the glial lineage, and in 
this respect this differentiation process resembles EMT. 
 Insufficient PDGFRA signaling can lead to myelination defects due to improper 
oligodendrocyte development, as is demonstrated by several mouse models (46, 65, 
66). Therefore, PDGFRA expression may also play a role in myelination diseases such as 
multiple sclerosis (MS). MS is characterized by demyelination of the CNS with associated 
neurological deficits. Remyelination can occur but is often incomplete, and requires 
the proliferation and migration of OPC into the lesion from the neighboring areas (67). 
In Pdgfra (+/-) mice, which display a 50% reduced PDGFRA protein expression (68), 
OPC proliferation and oligodendrocyte repopulation after demyelination are impaired 
(46), suggesting that also in recovery from or progression of myelination disorders such 
as MS PDGFRA haplotypes may play a role. 
 In conclusion, in multifactorial diseases such as NTDs and glioblastomas it is 
generally very difficult to establish the contribution of a single factor to the etiology. 
Therefore, the association of PDGFRA promoter haplotypes with both these diseases 
as observed by us provides a significant contribution to our understanding of the 
molecular basis of NTDs and glioblastomas.
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Transcription is one of the first steps in the regulation of gene expression, and therefore 
it contributes greatly in determining how much of a protein is produced in time and 
space, which consequently has a great influence on cell function. Transcription is 
regulated by specific DNA sequences surrounding and within genes, so-called cis-
acting factors. The promoter of a gene is a cis-acting sequence located just 5’ of the 
transcription start site, which determines where RNA polymerase II initiates transcription 
and in addition controls the basal rate of transcription. RNA polymerase II is guided to 
the transcription start site by various proteins, together termed the basal transcriptional 
machinery or preinitiating complex. Basal transcription can be stimulated or inhibited 
by other regulatory sequences, termed enhancer and silencer elements. These 
enhancers and silencers recruit transcription factors, so-called trans-acting factors, 
which communicate with the basal transcriptional machinery by protein-protein 
interactions, resulting in a stimulation or inhibition of RNA polymerase II recruitment 
to the transcription initiation site. Additionally, transcriptional regulation takes place 
at the epigenetic level. DNA methylation and modification of histones, the proteins 
that package DNA into chromatin, act in concert to determine the accessibility of 
transcription factors to the DNA. 
Binding of transcription factors to DNA is dependent upon specific DNA 
sequences. Consequently, variation in sequence of regulatory DNA elements may 
alter protein binding and thus transcription of neighboring genes. Natural variation in 
DNA sequence on a specific position is termed a polymorphism, and mainly occurs 
as the substitution of a single nucleotide, a so-called single nucleotide polymorphism 
(SNP). A specific combination of linked polymorphisms is referred to as haplotype. It 
has been postulated that most phenotypic variation between individuals is caused by 
variation in regulatory sequences, since this mostly leads to relatively subtle, non-lethal 
alterations, whereas variations in coding sequences often causes alterations of protein 
function and generally results in much more severe consequences. In agreement with 
this, many studies have shown that by altering protein-DNA binding, and subsequently 
the rate of transcription, regulatory variation can influence susceptibility to diseases 
such as asthma, diabetes and cancers. 
 The platelet-derived growth factor (PDGF) ligand-receptor system plays an 
important role in vertebrate development. The four PDGF isoforms PDGFA, -B, -C and -
D differentially bind and activate the two receptor isoforms PDGFRA and PDGFRB. Both 
ligands and receptors act as homo- or heterodimers and display specific expression 
patterns and, as a consequence, influence various developmental processes. PDGFRA 
and its two specific ligands PDGFA and PDGFC are involved in development of the axial 
skeleton and central nervous system (CNS) by regulating proliferation, migration and 
survival of sclerotomal cells and oligodendrocyte precursor cells (OPCs). Mice deficient 
in Pdgfra signaling display various developmental defects including hypomyelination of 
the central nervous system and the neural tube defect (NTD) spina bifida. This suggests 
that also in humans reduced PDGFRA signaling may contribute to such conditions. On 
the other hand, overexpression of Pdgfra signaling molecules is associated with various 
types of brain tumors (gliomas) in both mice and humans, indicating that enhanced 
PDGFRA signaling may predispose to gliomas. We thus hypothesized that factors that 
influence PDGFRA transcription may contribute to the risk of PDGFRA-related diseases 
such as NTDs and gliomas. The studies described in this thesis were undertaken to 
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identify both cis- and trans-acting factors that regulate PDGFRA transcription and to 
determine their involvement in gliomas and NTDs (chapter 1). 
 In search of regulatory sequences that may influence NTD risk we performed 
a case-control study in which we identified five haplotypes of the –1,589/+118 
promoter region of the human PDGFRA gene, designated H1, H2α, H2β, H2γ and H2δ. 
Of these haplotypes, H1 and H2α, which differ from each other on six of the eight 
polymorphic sites, are the most abundant. Importantly, in transient transfection assays 
on osteosarcoma cells H2α and H2β displayed a 3-5 fold higher promoter activity 
than H1, H2γ and and H2δ. Moreover, specific combinations of promoter haplotypes 
appeared to correlate with NTDs. Together, this shows that naturally occurring variation 
in regulatory sequences can indeed cause differences in gene expression and 
consequently influence disease susceptibility (chapter 2).
 NTDs are multifactorial diseases that result from a combination of various 
genetic and environmental factors. We therefore investigated the interaction of 
PDGFRA promoter haplotypes as a genetic factor, with maternal nutrient status as 
environmental factor on the risk of spina bifida in a similar case-control study. We found 
that the low activity H1 haplotype was significantly overrepresented in cases and 
mildly in case mothers, suggesting that low PDGFRA expression predisposes to spina 
bifida. Furthermore, we could show that for H2 children high maternal glucose and 
low maternal myo-inositol levels are the main risk factors for spina bifida, while for H1 
children the maternal body mass index (BMI) was the only prominent risk factor. Finally, 
we found that mothers with an H1 allele are significantly shorter than homozygous H2 
mothers, indicative for a role of PDGFRA in body growth (chapter 3). 
 Knowing  that differences in PDGFRA expression can influence the occurrence 
of NTDs, we subsequently analyzed the human PDGFRA promoter for haplotype 
specific differences in protein binding on the previously identified polymorphic sites. 
We also included two additional polymorphisms found by an extension of the promoter 
analysis to -3600. We found differential protein binding for two of these ten sites; -
909C/A and +68GAins/del. The protein complex binding specifically to the C allele of 
the -909C/A SNP, which is present in all haplotypes but the low activity H2γ, could be 
identified as USF family members, most likely a USF1a/USF2a heterodimer. Both USF1 
and USF2 are important for normal brain function, suggesting that USF proteins may 
also play a role in PDGFRA transcriptional regulation during development. Furthermore, 
a protein complex of 125 kDa which bound specifically to the low activity haplotype 
H1 at position +68GAdel was found which may represent an H1-specific PDGFRA 
transcriptional repressor. 
 Gliomas often overexpress PDGFRA, and in this study we investigated whether 
endogenous PDGFRA expression in four H1/H2α heterozygous human glioblastoma 
cell lines is haplotype dependent. With a newly developed technique, we could 
show that in three of these four cell lines H1 expression was more than ten-fold lower 
than H2α, which was accompanied by a low total PDGFRA expression. This difference 
in expression could be greatly reduced by DNA demethylating agents and histone 
deacetylase inhibitors, indicating that epigenetic regulation plays an important role in 
the differential expression of H1 and H2α in glioblastoma cells. The large difference in 
haplotype specific expression also suggested that PDGFRA promoter haplotypes might 
influence susceptibility to gliomas. In a case-control study on 71 glioblastoma patients 
we indeed found a reduced frequency of the H1 allele, which was significant when 
comparing to a combined Western European control group, thus suggesting that the 
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low activity H1 haplotype may protect against gliomas.  
 Human embryonal carcinoma (EC) cells are widely used as an in vitro model 
system for studying differentiation-dependent regulation of gene expression during 
early human development. In Tera-2 human embryonal carcinoma cells PDGFRA 
expression is strongly enhanced upon differentiation induced by retinoic acid and 
cAMP treatment. We could show that this upregulation of PDGFRA expression requires 
a promoter element located near the transcription initiation site, which binds a 
complex of PRX and PBX proteins. Interestingly, Prx-deficient mice show a severe NTD 
phenotype, similar to that observed for Pdgfra null mice, suggesting that also in vivo 
these two genes may interact in axial development and thus may play a role in NTD 
genesis. 
 Taken together, the data presented in this thesis show that PDGFRA expression 
can influence physiological (body growth) as well as pathological processes (genesis 
of NTDs and gliomas). We have provided evidence that low PDGFRA expression driven 
by the H1 promoter haplotype predisposes to spina bifida, while at the same time 
protecting against glioblastomas. This observation is further supported by data on 
geographical and racial incidences of these two disorders, which correlate well with 
haplotype frequencies, such that populations with a high H1 frequency show a high 
incidence of NTDs, while populations with a low H1 frequency show a high brain tumor 
incidence. Based on our data and published data on Pdgfra transgenic mice we 
hypothesize that due to slower promoter demethylation, the H1 promoter haplotype 
reduces the risk of gliomagenesis by limiting the glia precursor pool size, which is 
controlled by PDGFRA signalling. Since PDGFRA overexpression is also associated 
with osteosarcomas, chondrosarcomas and ovarian carcinomas, PDGFRA promoter 
haplotypes may also influence susceptibility to these diseases. Additionally, as PDGFRA 
signaling is essential for (re)myelination, PDGFRA promoter haplotypes may also play a 
role in demyelination diseases such as MS (chapter 7). 
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Transcriptie is een van de eerste stappen in de regulatie van genexpressie en aangezien 
het een grote bijdrage levert aan het bepalen van de hoeveelheid eiwit die in tijd en 
plaats wordt geproduceerd, is dit proces van grote invloed op het functioneren van 
de cel.. Transcriptie wordt gereguleerd door specifieke DNA sequenties rondom en 
binnen genen, de zogenoemde cis-werkende factoren. De promoter van een gen is 
een cis-werkende sequentie die net voor de transcriptiestart ligt, de plaats waar het 
RNA polymerase II het transcriptieproces initieert, en die de basale transcriptiesnelheid 
reguleer. Het RNA polymerase II wordt begeleid door een aantal eiwitten, die tezamen 
de basale transcriptionele machinerie of het preinitiatiecomplex worden genoemd. 
Basale transcriptie kan gestimuleerd of geremd worden door andere regulerende 
sequenties, de zogenoemde enhancer en silencer elementen. Deze enhancers 
en silencers rekruteren transcriptiefactoren, die als trans-werkende eiwitten met de 
basale transcriptionele machinerie communiceren via eiwit-eiwitinteracties, en dit 
resulteert in een stimulatie of remming van rekrutering van het RNA polymerase II aan 
de transcriptiestart. Transcriptieregulatie vindt daarnaast ook plaats op epigenetisch 
niveau, waarbij methylering van het DNA en modificatie van histonen, de eiwitten 
die het DNA inpakken in chromatine, samen de toegankelijheid van het DNA voor 
transcriptiefactoren reguleren.
 Binding van transcriptiefactoren aan DNA is afhankelijk van specifieke DNA 
sequenties. Als gevolg daarvan kan variatie in regulerende DNA sequenties leiden tot 
een veranderde DNA binding van transcriptiefactoren en dus ook tot veranderingen 
in transcriptie van nabijgelegen genen. Natuurlijke variatie in DNA sequentie op 
een bepaalde positie wordt een polymorfisme genoemd, en komt voornamelijk 
voor als een substitutie van één enkel nucleotide, hetgeen bekend staat als een 
single nucleotide polymorphism (SNP). Een specifieke combinatie van aan elkaar 
gekoppelde polymorfismen wordt ook wel een haplotype genoemd. Algemeen wordt 
aangenomen dat de meeste fenotypische verschillen tussen individuen het gevolg 
zijn van variatie in regulerende sequenties, aangezien polymorfismen in deze regio’s 
meestal leiden tot relatief subtiele, niet lethale veranderingen, terwijl daarentegen 
variatie in eiwit-coderende sequenties vaak leidt tot veranderde eiwitfuncties 
hetgeen vaak ernstige gevolgen heeft. In overeenstemming hiermee is in veel studies 
aangetoond dat variatie in regulerende sequenties die resulteren in veranderde eiwit-
DNA binding en als gevolg daarvan in veranderde expressie, het risico op het ontstaan 
van ziekten als als astma, diabetes en kanker sterk kan beïnvloeden. 
 Het platelet-derived growth factor (PDGF) ligand-receptor systeem speelt een 
belangrijke rol in de ontwikkeling van vertebraten. De vier ligand-isovormen PDGFA, 
PDGFB, PDGFC en PDGFD, binden en activeren de twee receptor-isovormen PDGFRA 
en PDGFRB ieder op een specifieke manier. Zowel de liganden als de receptoren 
werken in de vorm van homo- en heterodimeren en vertonen celspecifieke 
expressiepatronen, waardoor zij een grote diversiteit aan ontwikkelingsprocessen 
beïnvloeden. PDGFRA en zijn specifieke liganden PDGFA en PDGFC zijn betrokken 
bij de ontwikkeling van het axiale skelet en het centrale zenuwstelsel door het 
reguleren van de proliferatie, migratie en overleving van cellen van het sclerotoom en 
oligodendrocyt precursor cellen (OPCs). Muizen met een defect in Pdgfra signalisatie 
vertonen allerlei ontwikkelingsstoornissen, waaronder hypomyelinisatie van het 
centrale zenuwstelsel en een vorm van neuraal buisdefect (NBD) die bekend staat als 
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spina bifida (open ruggetje). Dit suggereert dat mogelijk ook in de mens factoren die 
signalering via PDGFRA remmen bij kunnen dragen aan het ontstaan van dergelijke 
afwijkingen. Aan de andere kant wordt overexpressie van PDGFRA en zijn liganden 
vaak aangetroffen in verschillende soorten hersentumoren (glioma’s) bij zowel muizen 
als mensen, hetgeen suggereert dat verhoogde PDGFRA signalering aanleiding kan 
geven tot het ontstaan van glioma’s. Wij hebben daarom de hypothese gesteld dat 
factoren die transcriptie van PDGFRA beïnvloeden, bij kunnen dragen aan het risico 
op het ontstaan van PDGFRA-gerelateerde aandoeningen zoals NBDs en glioma’s. De 
studies beschreven in dit proefschrift zijn uitgevoerd om zowel cis- als trans-werkende 
factoren die PDGFRA transcriptie reguleren te identificeren en hun betrokkenheid bij 
glioma’s en NBD te bepalen (hoofdstuk 1).
 Om regulerende DNA sequenties te identificeren die het risico op NBD 
kunnen beïnvloeden, hebben wij een patiënt-controle studie gedaan waarin wij vijf 
verschillende haplotypes van de –1,589/+118 promoter regio van het humane PDGFRA 
gen hebben geïdentificeerd, die wij H1, H2α, H2β, H2γ en H2δ hebben genoemd. Van 
deze haplotypes komen H1 en H2α, die op zes van de acht polymorfe posities van 
elkaar verschillen, het meest voor en verschillen van elkaar op 6 van de 8 polymorfe 
posities. In een transiënte transfectie assay uitgevoerd op humane osteosarcoma 
cellen vertoonden H2α en H2β een 3-5 voudige hogere promoteractiviteit dan H1, 
H2γ en H2δ. Daarnaast bleken specifieke combinaties van promoterhaplotypes te 
correleren met het vóórkomen van NBD. Deze resultaten tonen aan dat variatie in 
regulerende sequenties inderdaad verschillen in genexpressie kan veroorzaken en 
dat dergelijke natuurlijk expressieverschillen de aanleg voor ziektes als NBDs kunnen 
beïnvloeden (hoofdstuk 2).
 NBD zijn multifactoriële aandoeningen die het gevolg zijn van een 
combinatie van diverse genetische en omgevingsfactoren. Daarom hebben wij in 
een patiënt-controle studie onderzocht of er een interactie bestaat tussen PDGFRA 
promoter haplotypes als genetische factor en het voedingspatroon van de moeder 
als omgevingsfactor in relatie tot het risico op het ontstaan van spina bifida. Wij 
hebben aangetoond dat het H1 haplotype, dat aanleiding geeft tot lage PDGFRA 
expressie, significant oververtegenwoordigd is in spina bifida patiënten en mild 
oververtegenwoordigd is in moeders van deze patiënten, hetgeen suggereert dat 
lage PDGFRA expressie het risico op NBD verhoogt. Bovendien konden wij laten zien 
dat voor H2 kinderen een hoog glucose en een laag myo-inositolgehalte in het bloed 
van de moeder de belangrijkste risicofactoren zijn voor het ontstaan van spina bifida 
zijn, terwijl voor H1 kinderen de body mass index (BMI) van de moeder de meest 
prominente risicofactor is. Bovendien bleken moeders met een H1 allel significant kleiner 
te zijn dan H2 homozygote moeders, wat aangeeft dat PDGFRA expressieniveaus een 
direct effect hebben op de lichaamsgroei (hoofdstuk 3). 
  Wetende dat verschillen in PDGFRA expressie het vóórkomen van NBDs kan 
beïnvloeden, hebben wij de humane PDGFRA promoter onderzocht op haplotype 
specifieke verschillen in binding van transcriptiefactoren op de geïdentificeerde 
polymorfe posities. We hebben hierbij ook twee nieuwe promoter polymorfismen 
betrokken, die geïdentificeerd zijn bij een analyse van promotersequenties tot -3600 
bp. Op twee van deze in totaal tien polymorfe posities, te weten -909A/C en +68GAins/
del, hebben we differentiële eiwitbinding waargenomen. Van het eiwitcomplex 
dat specifiek aan het C-allel van de -909A/C SNP bindt, een nucleotide die in alle 
haplotypes behalve H2γ voorkomt, kon aangetoond worden dat het leden van de 
upstream stimulator factor (USF) familie bevat, hoogstwaarschijnlijk bestaande uit een 
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USF1a-USF2a heterodimeer. Daarnaast is er een eiwitcomplex gevonden dat specifiek 
het laag actieve H1 haplotype bindt op het +68GAdel allel, en potentieel zou dit 
complex een H1 specifieke PDGFRA repressor kunnen zijn (hoofdstuk 4). 
 Glioma’s brengen vaak PDGFRA tot overexpressie, maar onbekend is of 
het expressieniveau afhangt van de aanwezige promoter haplotypen. Derhalve 
hebben wij endogene PDGFRA expressieniveaus bestudeerd in vier humane H1/H2α 
heterozygote glioblastoma cellijnen. Gebaseerd op een speciaal daarvoor door ons 
ontwikkelde techniek, hebben wij aangetoond dat in drie van de vier cellijnen de H1 
expressie meer dan tien keer lager was dan die van H2α, hetgeen ook gepaard ging 
met een lagere totale PDGFRA expressie. Het verschil tussen H1 en H2α kon grotendeels 
opgeheven worden door inductie van DNA demethylatie en inhibitie van histon-
deacetylatie, wat aangeeft dat epigenetische regulatie een belangrijke rol speelt in 
de differentiële expressie van H1 en H2α in glioblastoma cellen. Het grote verschil in 
activiteit van de haplotypen suggereert ook dat PDGFRA promoter haplotypen het 
ontstaan van glioma’s kunnen beïnvloeden. In een patiënt-controle studie onder 71 
glioblastoma patienten vonden we inderdaad een verminderde frequentie van het 
H1 allel, hetgeen significant was vergeleken met een gecombineerde West-Europese 
controlegroep. Dit wijst erop dat het laag actieve H1 haplotype beschermend zou 
kunnen werken tegen het ontstaan van glioma’s.
 Humane embryonale carcinoom (EC) cellen worden algemeen gebruikt als 
een in vitro modelsysteem voor het analyseren van differentiatie-afhankelijke regulatie 
van genexpressie tijdens vroege ontwikkeling. In Tera-2 humane EC cellen wordt de 
PDGFRA expressie sterk verhoogd door differentiatie te induceren via behandeling 
met retinolzuur en cAMP. Wij hebben aangetoond dat voor deze inductie van PDGFRA 
expressie een promoter-element nodig is dat de transcriptiefactoren PRX en PBX bindt 
en dichtbij de transcriptie-initiatie plaats ligt. Muizen zonder functioneel Prx hebben 
een sterk NBD fenotype, wat kan betekenen dat PRX en PDGFRA elkaar ook in vivo 
kunnen beïnvloeden tijdens axiale ontwikkeling en zo een rol kunnen spelen in het 
ontstaan van NBDs.
 Samengevat tonen de resultaten in dit proefschrift aan dat PDGFRA expressie 
zowel fysiologische (lichaamsgroei) als pathologische (ontstaan van NBDs en glioma’s) 
processen kan beïnvloeden. Onze data wijzen er op dat lage PDGFRA expressie gestuurd 
door het H1 promoter haplotype het risico op spina bifida verhoogt, maar tegelijkertijd 
beschermt tegen het ontstaan van glioblastoma’s. Dit idee wordt ondersteund 
door studies aan de incidentie van deze ziektes in bepaalde bevolkingsgroepen en 
geografische locaties: in populaties met een hoge H1 frequentie komen NBDs relatief 
vaak voor, terwijl in populaties met een lage H1 frequentie relatief vaak hersentumoren 
voorkomen. Op basis van onze resultaten, in combinatie met gepubliceerde data 
aan Pdgfra transgene muizen, hebben wij de hypothese gepostuleerd dat, dankzij 
tragere promoter demethylering, het H1 haplotype het risico op het ontstaan van 
glioblastoma’s vermindert doordat het de glia precursor-populatie, waarvan bekend 
is dat die wordt bepaald door PDGFRA signalering, klein houdt. Omdat PDGFRA 
overexpressie ook geassocieerd wordt met osteosarcoma’s, chondrosarcoma’s en 
eierstok-sarcoma’s, is het zeer wel mogelijk dat PDGFRA promoter haplotypen ook 
de gevoeligheid voor dergelijke ziektes beïnvloeden. Aangezien PDGFRA signalering 
essentieel is voor (re)myelinatie, kunnen PDGFRA haplotypes daarnaast ook een 
rol spelen in ziektes die geassocieerd zijn met demyelinering zoals multiple sclerosis 
(hoofdstuk 7).
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En toen was er het dankwoord. Het schrijven van dit proefschrift is niet altijd even 
gemakkelijk geweest, en ook een dankwoord is niet iets dat je zo even uit je mouw 
schudt, want je wilt toch iedereen die de afgelopen periode iets voor je betekend 
heeft op passende manier bedanken, en vooral ook niemand vergeten. Allereerst 
natuurlijk Joop. Ik ben je heel erg dankbaar dat je me ertoe over hebt weten te 
halen om na mijn studie toch het onderzoek in te gaan. Zonder jou was dit boekje 
er dus letterlijk nooit gekomen. Dank je wel ook voor je stimulerende discussies, je 
structureringen in mijn chaos en de prettige samenwerking, die ik in de loop der tijd 
steeds meer ben gaan waarderen.
Een andere onmisbare factor uit mijn AIO-periode, tevens lieftallig nimfje, is 
natuurlijk Paul. Dank je wel dat je me als stagiaire hebt doen inzien dat moleculaire 
biologie helemaal niet zo abstract en ongrijpbaar is als het in eerste instantie lijkt. Met 
jou is het altijd giga-gecellig en je bent altijd een grote steun voor me geweest, zowel 
op het lab als daarbuiten. Wil je nog steeds m’n epje zijn? 
Ook met Bart, mijn ander lieftallig nimfje, heb ik heel veel ups en downs, en ook 
menig drankje gedeeld. Of het nu gaat om het losmaken van grote gelen of het 
irriteren van vierdaagselopers, Bart is altijd van de partij. Super bedankt daarvoor! En 
daarom ben ik ook erg blij dat we nu aan elkaars zijde staan, en alleen wij twee weten 
wat er nu eigenlijk in die waterkan zit...
Dan de rest van de harde kern. Ester, dank je wel dat je er altijd voor me bent! 
Zonder jou zou het op MSN stukken minder gezellig zijn. En Monica’s zijn hard nodig in 
deze wereld, dus ik weet zeker dat je een fijne nieuwe werkplek zult vinden. Bas, ik hoop 
dat het niet lang meer duurt voordat ook jij je boekje kunt verdedigen. Gaan we nog 
eens hakkuh? Laura, dank je wel voor je vrolijkheid en de rode wijntjes die we samen 
hebben gedronken. Leonie, ik bewonder je moed om iets totaal anders te gaan doen, 
heel veel succes! Suzanne, altijd behulpzaam, dank je wel voor je fijne gezelschap 
en erg handig dat je zo’n rijke vent hebt ;-). Sander, nog niet zo lang AIO maar nu al 
genoeg verhalen, nu ook nog een mooi boekje. Allemaal enorm bedankt voor de 
gezellige borrels, etentjes, housewarmings, logeerpartijen en weekendjes weg! 
Wie ook een speciale plaats verdient, is Janny. Altijd klaar voor een babbel en een 
grote steun bij alle niet-wetenschappelijke zaken. Wetende dat ik alles met een gerust 
hart aan je kon overlaten, heb je heel veel stress bij me weggenomen in de laatste 
hectische maanden, duizend maal dank daarvoor.
Ook de rest van de collega’s wil ik natuurlijk heel erg bedanken voor de goede 
werksfeer de afgelopen jaren. Catelijne (ik hoop dat je iets moois kunt opbouwen in 
Gent), Saskia, “grote” Ester, Miriam, Diana, Erik, Robert, Walter, Peter, Dorine, Wilma, 
José, Marc, Wadia, Husam, Frits, Monique, Jeroen, Lex, Koen, Wilbert, Dick en ook 
“mijn” studenten, Bart, Saskia en Maarten, hartstikke bedankt voor de fijne tijd op het 
lab.
Iedereen van de NBD-bespreking, en in het bijzonder Barbara en Regine, heel erg 
bedankt voor jullie hulp en stimulerende discussies. Jullie zijn een geweldige steun voor 
me geweest, vooral toen ik er eventjes alleen voor stond. Waar ik ook altijd terecht kon, 
was bij de mensen van Plantkunde, als er bij ons weer eens iets op of kapot was, voor 
advies over experimenten of voor een gezellige borrel of barbecue. Enorm bedankt 
daarvoor. Titti, ik vind het superleuk dat jij op de grote dag pro-rector bent! Ook wil ik 
graag Jelle en Monique heel erg bedanken voor de eindeloze sequenties die ze voor 
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me gelopen hebben, en Gerald voor de crosslinks die ik daar heb mogen doen. En 
Joop, hartstikke bedankt voor alle lastige maar onmisbare statistiek die je voor ons 
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Dan verlaten we nu de wetenschappelijke sferen. Met groot plezier heb ik me 
de afgelopen jaren gestort in de muziek, spelletjes, pubquizzen, festivals en uitgaan. 
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zitten we zo’n 200 km uit elkaar. Jij en Sandra heel veel geluk de komende spannende 
tijd! Maarten, ik mis onze nachtelijke avonturen in het Nijmeegse uitgaansleven, en ik 
wacht nog altijd op een bepaald feestje ;-). Geert, Henco, allebei heel veel geluk met 
jullie kleine spruiten, jullie zijn vast super-papa’s! Michiel, ik mis ook onze vroege uurtjes 
in de Gonzo en Dio, en ik zal nooit aan jouw onaardse strakheid kunnen tippen. Stefan, 
ik hoop dat we nog veel mooie Tori-concertjes mogen meemaken. Johan, dit jaar 
weer naar Haldern? Supergeil! Imke, ook al ben je vaak ver weg, je bent toch altijd 
heel dichtbij. En ook Jeroen, Tim, Kim, Marian, Rudolf, Janine, Tom, Coco, Renee, Arjan 
en de rest in en rond The Kinky Party, Renegade Ostrich en Holgersson, super bedankt 
voor de geweldige tijd die ik heb gehad in Nijmegen! Lex en Bente, Joachim en Ilse, 
dank je wel voor de fijne feestjes, optredens en spelletjes!
Twee mensen die het een stuk aangenamer hebben gemaakt om een nieuw 
leven op te bouwen in Gent, zijn Tom en Vanessa. Tom, dank je wel voor je gezelligheid, 
je ondernemendheid en je luisterend oor. Vanessa, dank je wel dat je ons alle ins en 
outs van het Gentse leven leert kennen. En voor mijn nieuwe collega’s; ik zal met veel 
plezier nog meer vla en pindakaas voor jullie meenemen. 
Hans en Jeannette, ik weet dat ik altijd bij jullie terecht kan. Michael en Vanessa, 
super dat jullie er nog bij kunnen zijn, en heel veel geluk in Australië, maar dat spat er 
nu al vanaf.  
Mijn “kleine” broertje Rik, je hebt je studie nu gevonden, dus maak er iets moois 
van! Dank je wel dat je me op de hoogte houdt van de nieuwe trends en dat je mijn 
gezeur aanhoort. Pap en mam, dank je wel voor jullie nimmer aflatende betrokkenheid 
bij alles wat me bezig houdt. Weet dat ik aan jullie denk en ik hoop er vanaf nu meer 
voor jullie te kunnen zijn. Ik hou van jullie. 
 Lieve Marc, juist voor degene die de meeste woorden verdient, zijn er geen 
woorden om te beschrijven hoeveel je voor me betekent. Ik hou van je, samen kunnen 
we alles aan!
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